Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 5.6.2.1 - DNA topoisomerase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acquired Immunodeficiency Syndrome
Development of pyridine dicoumarols as potent anti HIV-1 leads, targeting HIV-1 associated topoisomeraseII? kinase.
Human topoisomerase I C-terminal domain fragment containing the active site tyrosine is a molten globule: implication for the formation of competent productive complex.
Random diffusion can account for topA-dependent suppression of partition defects in low-copy-number plasmids.
Acro-Osteolysis
Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
Acute Kidney Injury
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Adenocarcinoma
A Pilot Evaluation of a Novel Immunohistochemical Assay for Topoisomerase II-alpha and Minichromosome Maintenance Protein 2 Expression (ProEx C) in Cervical Adenocarcinoma In Situ, Adenocarcinoma, and Benign Glandular Mimics.
AraC-FdUMP[10] (CF10) is a next generation fluoropyrimidine with potent antitumor activity in PDAC and synergy with PARG inhibition.
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Cell fixation in zinc salt solution is compatible with DNA damage response detection by phospho-specific antibodies.
Cinnamomum verum component 2-methoxycinnamaldehyde: a novel antiproliferative drug inducing cell death through targeting both topoisomerase I and II in human colorectal adenocarcinoma COLO 205 cells.
Comprehensive Biomarkers for Personalized Treatment in Pulmonary Large Cell Neuroendocrine Carcinoma: A Comparative Analysis With Adenocarcinoma.
Cuminaldehyde from Cinnamomum verum Induces Cell Death through Targeting Topoisomerase 1 and 2 in Human Colorectal Adenocarcinoma COLO 205 Cells.
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Epidermal Growth Factor Receptor (EGFR) and its Cross-talks with Topoisomerases: Challenges and Opportunities for Multi-Target Anticancer Drugs.
From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.
Identifying ideal candidates for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
In vivo and in vitro assessment of the action of SN 28049, a benzonaphthyridine derivative targeting topoisomerase II, on the murine Colon 38 carcinoma.
Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Mining topoisomerase isoforms in gastric cancer.
Modulation of DNA topoisomerase I activity by p53.
Neutral and ionic platinum compounds containing a cyclometallated chiral primary amine: synthesis, antitumor activity, DNA interaction and topoisomerase I-cathepsin B inhibition.
Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas.
Synthesis, characterization and biological activity of new cyclometallated platinum(iv) complexes containing a para-tolyl ligand.
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
Thymoquinone from Nigella sativa Seeds Promotes the Antitumor Activity of Noncytotoxic Doses of Topotecan in Human Colorectal Cancer Cells in Vitro.
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Toward G-Quadruplex-Based Anticancer Agents: Biophysical and Biological Studies of Novel AS1411 Derivatives.
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]
Adenocarcinoma in Situ
A Pilot Evaluation of a Novel Immunohistochemical Assay for Topoisomerase II-alpha and Minichromosome Maintenance Protein 2 Expression (ProEx C) in Cervical Adenocarcinoma In Situ, Adenocarcinoma, and Benign Glandular Mimics.
Adenocarcinoma of Lung
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity.
Discovery of a Novel Anti-Cancer Agent Targeting Both Topoisomerase I & II as well as Telomerase Activities in Human Lung Adenocarcinoma A549 Cells In Vitro and In Vivo: Cinnamomum verum Component Cuminaldehyde.
Identification of key differentially expressed mRNAs and microRNAs in non-small cell lung cancer using bioinformatics analysis.
Identification of lung adenocarcinoma biomarkers based on bioinformatic analysis and human samples.
Low level phosphorylation of histone H2AX on serine 139 (?H2AX) is not associated with DNA double-strand breaks.
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Quantitative immunocytochemical assays of topoisomerase II in lung adenocarcinoma cell lines. Correlation to topoisomerase II alpha content and topoisomerase II catalytic activity.
SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells.
The DNA damage inducible lncRNA SCAT7 regulates genomic integrity and topoisomerase 1 turnover in lung adenocarcinoma.
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Adenoma
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Expression of Topoisomerase II-? protein in salivary gland tumors.
Adenoma, Islet Cell
Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.
Adenoviridae Infections
Adenovirus infection elevates levels of cellular topoisomerase I.
Adrenal Cortex Neoplasms
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Adrenocortical Carcinoma
Use of a topoisomerase I inhibitor (irinotecan, CPT-11) in metastatic adrenocortical carcinoma.
Anemia
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs.
The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.
Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.
Topotecan in the treatment of hematologic malignancies.
Anemia, Refractory
Topotecan in the treatment of hematologic malignancies.
Angelman Syndrome
Characterization and structure-activity relationships of indenoisoquinoline-derived topoisomerase I inhibitors in unsilencing the dormant Ube3a gene associated with Angelman syndrome.
Human Cerebral Organoids Reveal Early Spatiotemporal Dynamics and Pharmacological Responses of UBE3A.
Anthrax
Drug interactions with Bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance.
Antiphospholipid Syndrome
Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
Aortic Aneurysm, Abdominal
Aortic Aneurysm Natural Progression Is Not Influenced By Concomitant Malignancy And Chemotherapy.
Apraxias
The novel human gene aprataxin is directly involved in DNA single-strand-break repair.
Arthralgia
Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status.
Mechanical thumb pain in a systemic sclerosis patient: simple first carpometacarpal osteoarthritis?
Arthritis, Rheumatoid
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
[Anti-idiotypic and natural catalytically active antibodies]
Astrocytoma
Characterization of a novel anti-cancer compound for astrocytomas.
Combination value of diffusion-weighted imaging and dynamic susceptibility contrast-enhanced MRI in astrocytoma grading and correlation with GFAP, Topoisomerase II? and MGMT.
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Prognostic value of survivin and DNA topoisomerase II? in diffuse and anaplastic astrocytomas.
Subcellular redistribution of DNA topoisomerase I in anaplastic astrocytoma cells treated with topotecan.
Ataxia
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.
Dual regulation of Cdc25A by Chk1 and p53-ATF3 in DNA replication checkpoint control.
Transcription-dependent activation of ataxia telangiectasia-mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
Ataxia Telangiectasia
A defect in DNA topoisomerase II activity in ataxia-telangiectasia cells.
Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks.
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Cellular consequences of overproduction of DNA topoisomerase II in an ataxia-telangiectasia cell line.
Disruption of Telomere Integrity and DNA Repair Machineries by KML001 Induces T Cell Senescence, Apoptosis, and Cellular Dysfunctions.
DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells.
DNA-dependent protein kinase and Ataxia Telangiectasia Mutated (ATM) promote cell survival in response to NK314, a topoisomerase II? inhibitor.
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Genome instability in ataxia telangiectasia (A-T) families: camptothecin-induced damage to replicating DNA discriminates between obligate A-T heterozygotes, A-T homozygotes and controls.
Inhibition of replicon initiation in human cells following stabilization of topoisomerase-DNA cleavable complexes.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype.
Overproduction of topoisomerase II in an ataxia telangiectasia fibroblast cell line: comparison with a topoisomerase II-overproducing hamster cell mutant.
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Tethering DNA damage checkpoint mediator proteins topoisomerase IIbeta-binding protein 1 (TopBP1) and Claspin to DNA activates ataxia-telangiectasia mutated and RAD3-related (ATR) phosphorylation of checkpoint kinase 1 (Chk1).
The ATM protein is required for sustained activation of NF-kappaB following DNA damage.
The tumor suppressor protein PML controls apoptosis induced by the HIV-1 envelope.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Autoimmune Diseases
An aza-anthrapyrazole negatively regulates Th1 activity and suppresses experimental autoimmune encephalomyelitis.
Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins.
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Fused Aryl-Phenazines: Scaffold for the Development of Bioactive Molecules.
Synthetic peptides: the future of patient management in systemic rheumatic diseases?
[Anti-idiotypic antibodies to topoisomerase I in serum from patients with autoimmune diseases]
[Interactions of sera from patients with autoimmune diseases with cDNA expressed fragment of topoisomerase I and monoclonal antibodies against enzyme]
Bacteremia
Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor.
Bacterial Infections
A New-Class Antibacterial-Almost. Lessons in Drug Discovery and Development: A Critical Analysis of More than 50 Years of Effort toward ATPase Inhibitors of DNA Gyrase and Topoisomerase IV.
Cellular Pharmacokinetics and Intracellular Activity of Gepotidacin against Staphylococcus aureus Isolates with Different Resistance Phenotypes in Models of Cultured Phagocytic Cells.
Chemistry, Biological Properties and Analytical Methods of Levonadifloxacin: A Review.
Design and examination of potent pseudosubstrate-based oligonucleotide inhibitors against bacterial topoisomerase IV.
Dioxane-Linked Amide Derivatives as Novel Bacterial Topoisomerase Inhibitors against Gram-Positive Staphylococcus aureus.
Identification of an ethyl 5,6-dihydropyrazolo[1,5-c]quinazoline-1-carboxylate as a catalytic inhibitor of DNA gyrase.
Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1.
Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 2.
Second-generation antibacterial benzimidazole ureas: discovery of a preclinical candidate with reduced metabolic liability.
The metabolism and disposition of GSK2140944 in healthy human subjects.
Blast Crisis
The diverse effect of topoisomerase I specific inhibitor (camptothecin) on normal and BCR/ABL-dependent hematopoietic cells proliferation: therapeutic implications.
[Killing and proapoptotic effects of topoisomerase I inhibitor on K562 cells]
Bloom Syndrome
Aberrant chromosome morphology in human cells defective for Holliday junction resolution.
Analysis of m6A RNA Methylation-Related Genes in Liver Hepatocellular Carcinoma and Their Correlation with Survival.
Association of the Bloom syndrome protein with topoisomerase IIIalpha in somatic and meiotic cells.
Bloom syndrome complex promotes FANCM recruitment to stalled replication forks and facilitates both repair and traverse of DNA interstrand crosslinks.
Bloom's syndrome and PICH helicases cooperate with topoisomerase II? in centromere disjunction before anaphase.
Cleavage of the Bloom's syndrome gene product during apoptosis by caspase-3 results in an impaired interaction with topoisomerase IIIalpha.
Developing T lymphocytes are uniquely sensitive to a lack of topoisomerase III alpha.
Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis.
RMI, a new OB-fold complex essential for Bloom syndrome protein to maintain genome stability.
RMI1 contributes to DNA repair and to the tolerance to camptothecin.
The Bloom syndrome complex senses RPA-coated single-stranded DNA to restart stalled replication forks.
The Bloom's syndrome gene product interacts with topoisomerase III.
The Bloom's syndrome helicase stimulates the activity of human topoisomerase IIIalpha.
Topo IIIalpha and BLM act within the Fanconi anemia pathway in response to DNA-crosslinking agents.
Brain Neoplasms
Chemopotentiation by PARP inhibitors in cancer therapy.
Chemotherapy for mycosis fungoides and the Sézary syndrome.
Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer.
Complications of chemotherapy in neuro-oncology.
Convection-enhanced delivery of a topoisomerase I inhibitor (nanoliposomal topotecan) and a topoisomerase II inhibitor (pegylated liposomal doxorubicin) in intracranial brain tumor xenografts.
Decreased cyclin B1 expression contributes to G2 delay in human brain tumor cells after treatment with camptothecin.
Expression of DNA topoisomerase I, IIalpha, and IIbeta in human brain tumors.
Expression of topoisomerase II, bcl-2, and p53 in three human brain tumor cell lines and their possible relationship to intrinsic resistance to etoposide.
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Pharmacokinetic considerations in the treatment of CNS tumours.
Phase II evaluation of topotecan for pediatric central nervous system tumors.
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
The role of topotecan in the treatment of brain metastases.
Topoisomerase I inhibitors for the treatment of brain tumors.
Breast Neoplasms
(-)-Xanthatin up-regulation of the GADD45? tumor suppressor gene in MDA-MB-231 breast cancer cells: Role of topoisomerase II? inhibition and reactive oxygen species.
A novel copper(II) complex identified as a potent drug against colorectal and breast cancer cells and as a poison inhibitor for human topoisomerase II?.
A Phase II Study of Irinotecan and Etoposide as Treatment for Refractory Metastatic Breast Cancer.
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer.
Acquired camptothecin resistance of human breast cancer MCF-7/C4 cells with normal topoisomerase I and elevated DNA repair.
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases.
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation.
Analyte-driven self-assembly of graphene oxide sheets onto hydroxycamptothecin-functionalized upconversion nanoparticles for the determination of type I topoisomerases in cell extracts.
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer.
Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells.
Antitumor activity and pharmacokinetics following oral administration of natural product DNA topoisomerase I inhibitors 10-hydroxycamptothecin and camptothecin in SCID mice bearing human breast cancer xenografts.
Apoptotic response to camptothecin and 7-hydroxystaurosporine (UCN-01) in the 8 human breast cancer cell lines of the NCI Anticancer Drug Screen: multifactorial relationships with topoisomerase I, protein kinase C, Bcl-2, p53, MDM-2 and caspase pathways.
Aromatic analogues of DNA minor groove binders--synthesis and biological evaluation.
Assessment of DNA Topoisomerase I Unwinding Activity, Radical Scavenging Capacity, and Inhibition of Breast Cancer Cell Viability of N-alkyl-acridones and N,N'-dialkyl-9,9'-biacridylidenes.
Association between the c.*229C>T polymorphism of the topoisomerase II? binding protein 1 (TopBP1) gene and breast cancer.
Association between Twist and multidrug resistance gene-associated proteins in Taxol
BCL-2, topoisomerase II?, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
Benzo[b]tryptanthrin inhibits MDR1, topoisomerase activity, and reverses adriamycin resistance in breast cancer cells.
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Caspase activation in MCF7 cells responding to etoposide treatment.
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
CD99 correlates with low cyclin D1, high topoisomerase 2? status and triple negative molecular phenotype but is prognostically irrelevant in breast carcinoma.
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Changes of Topoisomerase II{alpha} Expression in Breast Tumors after Neoadjuvant Chemotherapy Predicts Relapse-Free Survival.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Chemotherapeutics and Radiation Stimulate MHC Class I Expression through Elevated Interferon-beta Signaling in Breast Cancer Cells.
Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview.
Chk1 inhibitor synergizes quinacrine mediated apoptosis in breast cancer cells by compromising the base excision repair cascade.
Cholinergic Receptor Nicotinic Alpha 5 (CHRNA5) RNAi is associated with cell cycle inhibition, apoptosis, DNA damage response and drug sensitivity in breast cancer.
Chromosome 17 centromere (CEP17) duplication as a predictor of anthracycline response: evidence from the NCIC Clinical Trials Group (NCIC CTG) MA.5 Trial.
Cinnamaldehyde/chemotherapeutic agents interaction and drug-metabolizing genes in colorectal cancer.
Circulating Bone-related Markers and YKL-40 Versus HER2 and TOPO2a in Bone Metastatic and Nonmetastatic Breast Cancer: Diagnostic Implications.
Clinical significance of the increased multidrug resistance-associated protein (MRP) gene expression in patients with primary breast cancer.
Clinical significance of topoisomerase 2A expression and gene change in operable invasive breast cancer.
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.
Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer.
Correlations of TOP2A gene aberrations and expression of topoisomerase II? protein and TOP2A mRNA expression in primary breast cancer: a retrospective study of 86 cases using fluorescence in situ hybridization and immunohistochemistry.
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Cytotoxic activity of octahydropyrazin[2,1-a:5,4-a']diisoquinoline derivatives in human breast cancer cells.
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II?-Targeted Chemotherapeutic Agents for Breast Cancer.
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
DNA Damage and Pulmonary Hypertension.
DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
DNA-Containing Exosomes Derived from Cancer Cells Treated with Topotecan Activate a STING-Dependent Pathway and Reinforce Antitumor Immunity.
Doxorubicin prevents endoplasmic reticulum stress-induced apoptosis.
Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Enhancement of camptothecin-induced cytotoxicity with UCN-01 in breast cancer cells: abrogation of S/G(2) arrest.
Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer.
ER, PgR, HER-2, Ki-67, topoisomerase II?, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.
Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
Etirinotecan pegol for the treatment of breast cancer.
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Expression and functional analyses of breast cancer resistance protein in lung cancer.
Expression of Topoisomerase II-? in Triple Negative Breast Cancer.
Expressions of Topo II? and Ki67 in breast cancer and its clinicopathologic features and prognosis.
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
EZN-2208 (PEG-SN38) overcomes ABCG2-mediated topotecan resistance in BRCA1-deficient mouse mammary tumors.
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
HDAC2 regulates chromatin plasticity and enhances DNA vulnerability.
Her-2/neu and topoisomerase II? in advanced breast cancer: a comprehensive FISH analysis of 245 cases.
HER2/neu, Topoisomerase 2a, Estrogen and Progesterone Receptors: Discordance between Primary Breast Cancer and Metastatic Axillary Lymph Node in Expression and Amplification Characteristics.
Homocamptothecin-daunorubicin association overcomes multidrug-resistance in breast cancer MCF7 cells.
Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer.
Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Heat Shock Protein 90 Overexpression, Ki67 Proliferative Index, and Topoisomerase II-? Co-amplification as Predictors of Pathologic Complete Response to Neoadjuvant Chemotherapy With Trastuzumab and Docetaxel.
Human neural stem cell tropism to metastatic breast cancer.
Identification of breast cancer resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB-506 and J-107088, topoisomerase I inhibitors with an indolocarbazole structure.
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Implications of Topoisomerase (TOP1 and TOP2?) Expression in Patients With Breast Cancer.
Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Induction of apoptosis in MCF-7:WS8 breast cancer cells by beta-lapachone.
Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells.
Inhibition of DNA topoisomerase I and II, and growth inhibition of MDA-MB-231 human breast cancer cells by bis-benzimidazole derivatives with alkylating moiety.
Inhibition of human topoisomerase I and II and anti-proliferative effects on MCF-7 cells by new titanocene complexes.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
L-proline analogues of anthraquinone-2-carboxylic acid: cytotoxic activity in breast cancer MCF-7 cells and inhibitory activity against topoisomerase I and II.
Loss of O?-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
Mitoxantrone affects topoisomerase activities in human breast cancer cells.
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Multiple molecular targets in breast cancer therapy by betulinic acid.
New approaches in cancer treatment.
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Nonclassic functions of human topoisomerase I: genome-wide and pharmacologic analyses.
Oxocrebanine: A Novel Dual Topoisomerase inhibitor, Suppressed the Proliferation of Breast Cancer Cells MCF-7 by Inducing DNA Damage and Mitotic Arrest.
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Pathological tumor response to neoadjuvant chemotherapy using anthracycline and taxanes in patients with triple-negative breast cancer.
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B.
Phosphorylation and stabilization of topoisomerase II? protein by p38? mitogen-activated protein kinase sensitize breast cancer cells to its poisons.
Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2? Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer.
Prognostic potential of topoisomerase II? and HER2 in a retrospective analysis of early advanced breast cancer patients treated with adjuvant anthracycline chemotherapy.
Quinacrine has anti-cancer activity in breast cancer cells through inhibition of topoisomerase activity.
Quinacrine-mediated autophagy and apoptosis in colon cancer cells is through a p53- and p21-dependent mechanism.
Rapid purification of topoisomerase I from human breast cancer cells by high-performance liquid chromatography.
Rapid screening of active components group with Topoisomerase I inhibitory activity in Sophora alopecuroides L. based on ultrafiltration coupled with UPLC-QTOF-MS.
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer.
Resistance to topoisomerase poisons due to loss of DNA mismatch repair.
RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody-drug conjugates in the breast cancer treatment landscape.
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Sacituzumab Govitecan: First Approval.
Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells.
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Spotlight on Geminin.
Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Synthesis and molecular docking studies of some novel Schiff bases incorporating 6-butylquinolinedione moiety as potential topoisomerase II? inhibitors.
Synthesis and structure-activity relationship of lipo-diterpenoid alkaloids with potential target of topoisomerase II? for breast cancer treatment.
Targeted therapy in breast cancer: the HER-2/neu gene and protein.
TCH-1030 targeting on topoisomerase I induces S-phase arrest, DNA fragmentation, and cell death of breast cancer cells.
The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
The Pathological Response to Anthracycline is Associated with Topoisomerase II? Gene Amplification in the HER2 Breast Cancer Subset.
The potential role of topotecan in the treatment of advanced breast cancer.
The Predictive and Prognostic Role of Topoisomerase II? and Tissue Inhibitor of Metalloproteinases 1 Expression in Locally Advanced Breast Carcinoma of Egyptian Patients Treated With Anthracycline-based Neoadjuvant Chemotherapy.
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
The role of topoisomerase II-? (TOPO IIA) as a predictive factor for response to neoadjuvant anthracycline-based chemotherapy in locally advanced breast cancer.
The role of topoisomerase II? in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase II? and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Therapy-related acute promyelocytic leukaemia.
TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy.
TOP2A Amplification in the Absence of That of HER-2/neu: Toward Individualization of Chemotherapeutic Practice in Breast Cancer.
Topoisomerase 2? status in invasive breast carcinoma - comparison of its clinical value according to immunohistochemical and fluorescence in situ hybridization methods of evaluation.
Topoisomerase 2A gene amplification in breast cancer. Critical evaluation of different FISH probes.
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning?
Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer.
Topoisomerase II-alpha as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.
Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.
Topoisomerase II? levels and G2 radiosensitivity in T-lymphocytes of women presenting with breast cancer.
Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013.
Translocation of Bax to mitochondria during apoptosis measured by laser scanning cytometry.
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Trastuzumab Deruxtecan: First Approval.
TREATMENT WITH GEFITINIB OR LAPATINIB INDUCES DRUG RESISTANCE THROUGH DOWNREGULATION OF TOPOISOMERASE II? EXPRESSION.
Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase II?.
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Ubiquitin-family modifications of topoisomerase I in camptothecin-treated human breast cancer cells.
Upregulation of p21WAF1/CIP1 in human breast cancer cell lines MCF-7 and MDA-MB-468 undergoing apoptosis induced by natural product anticancer drugs 10-hydroxycamptothecin and camptothecin through p53-dependent and independent pathways.
Using a stem cell-based signature to guide therapeutic selection in cancer.
Vinorelbine and the topoisomerase 1 inhibitors: current and potential roles in breast cancer chemotherapy.
[New drugs in metastatic breast cancer--1997]
[Predictive biomarkers for response to irinotecan, platinum drugs, and taxanes].
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
[Therapeutic effect of Jin Long capsule combined with neoadjuvant chemotherapy on invasive breast cancer and the expression change of multidrug resistance proteins].
[Topoisomerase inhibitor upregulates MICA/B expression in breast cancer cells through ATM/ATR and NF-?B pathway].
Burkitt Lymphoma
An MCL1-overexpressing Burkitt lymphoma subline exhibits enhanced survival on exposure to serum deprivation, topoisomerase inhibitors, or staurosporine but remains sensitive to 1-beta-D-arabinofuranosylcytosine.
Elevated DNA topoisomerase II activity in nitrogen mustard-resistant human cells.
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Rapid purification and structural study of DNA topoisomerase I from human Burkitt lymphoma Raji cells.
Carcinogenesis
Cancer preventive mechanisms of the green tea polyphenol (-)-epigallocatechin-3-gallate.
Characterization of the topoisomerase I locus in human colorectal cancer.
Chemotherapy-induced secondary malignancies.
Screening and identification of hub genes in pancreatic cancer by integrated bioinformatics analysis.
Spartan deficiency causes accumulation of Topoisomerase 1 cleavage complexes and tumorigenesis.
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
Topoisomerase II-mediated DNA cleavage and mutagenesis activated by nitric oxide underlie the inflammation-associated tumorigenesis.
[Immunohistochemical evaluation of intracranial recurrent meningiomas: correlation of topoisomerase II alpha expression and cell proliferative potential]
Carcinoid Tumor
DNA topoisomerase II-alpha in pulmonary carcinoid tumors.
Genome-wide gene expression analysis of chemoresistant pulmonary carcinoid cells.
Carcinoma
(S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity.
10,11-Methylenedioxycamptothecin, a topoisomerase I inhibitor of increased potency: DNA damage and correlation to cytotoxicity in human colon carcinoma (HT-29) cells.
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
A Natural Anticancer Agent Thaspine Targets Human Topoisomerase IB.
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.
A type-II DNA topoisomerase and a catenating protein from the transplantable VX2 carcinoma.
Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function.
Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells.
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Adenoid cystic carcinomas of the breast have low Topo II? expression but frequently overexpress EGFR protein without EGFR gene amplification.
All-trans retinoic acid suppresses topoisomerase II? through the proteasomal pathway.
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Anthocyanin-rich blackberry extract suppresses the DNA-damaging properties of topoisomerase I and II poisons in colon carcinoma cells.
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
ATM Activation and H2AX Phosphorylation Induced by Genotoxic Agents Assessed by Flow- and Laser Scanning Cytometry.
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
Camptothecin and its analog SN-38, the active metabolite of irinotecan, inhibit binding of the transcriptional regulator and oncoprotein FUBP1 to its DNA target sequence FUSE.
Carbohydrate linked organotin(IV) complexes as human topoisomerase I? inhibitor and their antiproliferative effects against the human carcinoma cell line.
Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells.
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
Characterization of Oligomeric Proanthocyanidin-Enriched Fractions from Aronia melanocarpa (Michx.) Elliott via High-Resolution Mass Spectrometry and Investigations on Their Inhibitory Potential on Human Topoisomerases.
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells.
Combined effects of hyperthermia and CPT-11 on DNA strand breaks in mouse mammary carcinoma FM3A cells.
Comparative drug screening in NUT midline carcinoma.
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
Contribution of c-erbB-2 and topoisomerase IIalpha to chemoresistance in ovarian cancer.
Conversion of topoisomerase I cleavage complexes on the leading strand of ribosomal DNA into 5'-phosphorylated DNA double-strand breaks by replication runoff.
Copper(II) complexes with highly water-soluble L- and D-proline-thiosemicarbazone conjugates as potential inhibitors of Topoisomerase II?.
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Decreased DNA topoisomerase II alpha expression and cold-sensitive growth in a mouse mammary cancer cell line resistant to etoposide and doxorubicin.
Delphinidin Modulates the DNA-Damaging Properties of Topoisomerase II Poisons.
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Design, synthesis and evaluation of thiohydantoin derivatives as potent topoisomerase I (Top1) inhibitors with anticancer activity.
Design, synthesis, and evaluation of novel 6-chloro-/fluorochromone derivatives as potential topoisomerase inhibitor anticancer agents.
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Effect of DNA topoisomerase I inhibitor, 10-hydroxycamptothecin, on the structure and function of nuclei and nuclear matrix in bladder carcinoma MBT-2 cells.
Effect of non-steroidal anti-inflammatory drugs on colon carcinoma Caco-2 cell responsiveness to topoisomerase inhibitor drugs.
Effect of poly(ADP-ribose)polymerase and DNA topoisomerase I inhibitors on the p53/p63-dependent survival of carcinoma cells.
Effect of topoisomerase modulators on cisplatin cytotoxicity in human ovarian carcinoma cells.
Effect of yerba mate (Ilex paraguariensis) tea on topoisomerase inhibition and oral carcinoma cell proliferation.
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Expression of DNA topoisomerase II-?: Clinical significance in laryngeal carcinoma.
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Expression of Topoisomerase II-? protein in salivary gland tumors.
Extensive analysis of the molecular biomarkers excision repair cross complementing 1, ribonucleotide reductase M1, ?-tubulin III, thymidylate synthetase, and topoisomerase II? in breast cancer: Association with clinicopathological characteristics.
Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit.
Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
H1 histone sub-type distribution and DNA topoisomerase activity in skeletal muscle of tumour-bearing rats.
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Identification and characterization of a deletion mutant of DNA topoisomerase I mRNA in a camptothecin-resistant subline of human colon carcinoma.
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Immunohistochemical staining for DNA topoisomerase II-alpha in benign, premalignant, and malignant lesions of the prostate.
Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
Impact of Oxidative Metabolism on the Cytotoxic and Genotoxic Potential of Genistein in Human Colon Cancer Cells.
Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug.
In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems.
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells.
Influence of G2 arrest on the cytotoxicity of DNA topoisomerase inhibitors toward human carcinoma cells with different p53 status.
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Inhibition of topoisomerase II? sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Inhibitors of topoisomerase II: structure-activity relationships and mechanism of action of podophyllin congeners.
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Lack of cross-resistance to fostriecin in a human small-cell lung carcinoma cell line showing topoisomerase II-related drug resistance.
Lack of mitochondrial topoisomerase I (TOP1mt) impairs liver regeneration.
Lack of prognostic relevance of Her-2/neu, topoisomerase II? and EGFR in advanced ovarian carcinoma.
Lanostanoids from Fungi: A Group of Potential Anticancer Compounds.
Limited small-cell lung cancer: a potentially curable disease.
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Mitoxantrone-associated acute myelogenous leukemia in a patient with high-risk adenocarcinoma of the prostate: a case report and brief review.
Mucronulatol from Caribbean propolis exerts cytotoxic effects on human tumor cell lines.
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
New perspectives in colon cancer chemotherapy.
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Novel 7-alkyl methylenedioxy-camptothecin derivatives exhibit increased cytotoxicity and induce persistent cleavable complexes both with purified mammalian topoisomerase I and in human colon carcinoma SW620 cells.
Novel agents that potentially inhibit irinotecan-induced diarrhea.
Novel antitumor L-arabinose derivative of indolocarbazole with high affinity to DNA.
Novel assay utilizing fluorochrome-tagged physostigmine (Ph-F) to In situ detect active acetylcholinesterase (AChE) induced during apoptosis.
Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
p63 involvement in poly(ADP-ribose) polymerase 1 signaling of topoisomerase I-dependent DNA damage in carcinoma cells.
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Pharmacokinetics and Antitumor Efficacy of XMT-1001, a Novel, Polymeric Topoisomerase I Inhibitor, in Mice Bearing HT-29 Human Colon Carcinoma Xenografts.
Phase II Study of Belotecan (CKD 602) as a Single Agent in Patients with Recurrent or Progressive Carcinoma of Uterine Cervix.
Phosphorylation of histone H2AX and activation of Mre11, Rad50, and Nbs1 in response to replication-dependent DNA double-strand breaks induced by mammalian DNA topoisomerase I cleavage complexes.
Poly(ADP-ribose) polymerase signaling of topoisomerase 1-dependent DNA damage in carcinoma cells.
Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
Preclinical study of treatment response in HCT-116 cells and xenografts with (1) H-decoupled (31) P MRS.
Prognostic importance of survivin, Ki-67, and topoisomerase II? in ovarian carcinoma.
Prognostic significance of cyclooxygenase-2 and DNA topoisomerase IIalpha expression in oral carcinoma.
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis.
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
QSAR analysis of substituted bis[(acridine-4-carboxamide)propyl]methylamines using optimized block-wise variable combination by particle swarm optimization for partial least squares modeling.
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Quantitative Structure-Activity Relationship Studies on Indenoisoquinoline Topoisomerase I Inhibitors as Anticancer Agents in Human Renal Cell Carcinoma Cell Line SN12C.
Rapid purification and characterization of DNA topoisomerase I from cultured mouse mammary carcinoma FM3A cells.
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Relationship between topoisomerase II-DNA cleavable complexes, apoptosis and cytotoxic activity of anthracyclines in human cervix carcinoma cells.
Resveratrol modulates the topoisomerase inhibitory potential of doxorubicin in human colon carcinoma cells.
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Roles of NF-kappaB and 26 S proteasome in apoptotic cell death induced by topoisomerase I and II poisons in human nonsmall cell lung carcinoma.
Schedule-dependent activity of topotecan in OVCAR-3 ovarian carcinoma xenograft: pharmacokinetic and pharmacodynamic evaluation.
Screening for inhibitors of topoisomerase I from Lycoris radiata by combining ultrafiltration with liquid chromatography/mass spectrometry.
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice.
Solid phase synthesis of anthraquinone peptides and their evaluation as topoisomerase I inhibitors.
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines.
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
The c.*229C?>?T gene polymorphism in 3'UTR region of the topoisomerase II? binding protein 1 gene and LOH in BRCA1/2 regions and their effect on the risk and progression of human laryngeal carcinoma.
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
The mammalian DNA replication elongation checkpoint: implication of Chk1 and relationship with origin firing as determined by single DNA molecule and single cell analyses.
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Topoisomerase inhibitors modulate gene expression of B-cell translocation gene 2 and prostate specific antigen in prostate carcinoma cells.
Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers.
Update on the role of topotecan in the treatment of recurrent ovarian cancer.
Wedelolactone induces growth of breast cancer cells by stimulation of estrogen receptor signalling.
[Combination of irinotecan hydrochloride (CPT-11) and cisplatin as a new regimen for patients with advanced ovarian cancer]
[Expression and significance of P-glycoprotein, glutathione S-transferase-pi and Topoisomerase II in gastric carcinomas]
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
[Topoisomerase I inhibitor with potential radiosensitizing effect]
Carcinoma, Acinar Cell
Expression of Topoisomerase II-? protein in salivary gland tumors.
Carcinoma, Adenoid Cystic
Adenoid cystic carcinomas of the breast have low Topo II? expression but frequently overexpress EGFR protein without EGFR gene amplification.
Carcinoma, Ductal
Clinical analysis of 21-gene recurrence score test in hormone receptor-positive early-stage breast cancer.
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Carcinoma, Embryonal
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Induction of in vitro differentiation of mouse embryonal carcinoma (F9) cells by inhibitors of topoisomerases.
Carcinoma, Hepatocellular
3,3'-diindolylmethane is a novel topoisomerase IIalpha catalytic inhibitor that induces S-phase retardation and mitotic delay in human hepatoma HepG2 cells.
Association of DNA topoisomerase I and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription.
Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma.
Differential regulation of P53, c-Myc, Bcl-2, Bax and AFP protein expression, and caspase activity during 10-hydroxycamptothecin-induced apoptosis in Hep G2 cells.
Discovery of a novel anti-cancer agent targeting both topoisomerase I and II in hepatocellular carcinoma Hep 3B cells in vitro and in vivo: Cinnamomum verum component 2-methoxycinnamaldehyde.
DNA topoisomerase II? and Ki67 are prognostic factors in patients with hepatocellular carcinoma.
Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells.
Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.
Inhibition of phosphorylation of histone H1 and H3 induced by 10-hydroxycamptothecin, DNA topoisomerase I inhibitor, in murine ascites hepatoma cells.
MicroRNA-139 suppresses hepatocellular carcinoma cell proliferation and migration by directly targeting Topoisomerase I.
MiR-23a-mediated inhibition of topoisomerase 1 expression potentiates cell response to etoposide in human hepatocellular carcinoma.
Novel mechanism by which histone deacetylase inhibitors facilitate topoisomerase II? degradation in hepatocellular carcinoma cells.
Nuclear topoisomerase I and DNase activities in rat diethylnitrosamine-induced hepatoma, in regenerating and fetal liver.
Nuclear translocation and activation of YAP by hypoxia contributes to the chemoresistance of SN38 in hepatocellular carcinoma cells.
Phenolic-containing organic extracts of mulberry (Morus alba L.) leaves inhibit HepG2 hepatoma cells through G2/M phase arrest, induction of apoptosis, and inhibition of topoisomerase II? activity.
Phosphorylation of DNA topoisomerase I is increased during the response of mammalian cells to mitogenic stimuli.
Pinus kesiya Royle ex Gordon induces apoptotic cell death in hepatocellular carcinoma HepG2 cell via intrinsic pathway by PARP and Topoisomerase I suppression.
Potentiation of radioimmunotherapy by inhibition of topoisomerase I.
Sequences and structures at hepadnaviral integration: recombination sites implicate topoisomerase I in hepadnaviral DNA rearrangements and integration.
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1?.
Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.
[The activity of nuclear endonucleases and topoisomerases in the liver of rats and in diethylnitrosamine-induced tumors]
Carcinoma, Lewis Lung
Cellular responses to methyl-N-[4-9-acridinylamino)-2-methoxyphenyl] carbamate hydrochloride, an analogue of amsacrine active against non-proliferating cells.
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance.
QSAR analysis of substituted bis[(acridine-4-carboxamide)propyl]methylamines using optimized block-wise variable combination by particle swarm optimization for partial least squares modeling.
Carcinoma, Mucoepidermoid
Expression of Topoisomerase II-? protein in salivary gland tumors.
Carcinoma, Non-Small-Cell Lung
A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
DNA-PK Inhibition by NU7441 Enhances Chemosensitivity to Topoisomerase Inhibitor in Non-Small Cell Lung Carcinoma Cells by Blocking DNA Damage Repair.
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.
Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase II? mRNA.
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D.
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
The association of topoisomerase 2? expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.
The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Trastuzumab Deruxtecan: First Approval.
Carcinoma, Ovarian Epithelial
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
Phase I/IIa study of combination chemotherapy with CKD-602 and cisplatin in patients with recurrent epithelial ovarian cancer.
Prognostic importance of survivin, Ki-67, and topoisomerase II? in ovarian carcinoma.
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Rates of topoisomerase II-alpha and HER-2 gene amplification and expression in epithelial ovarian carcinoma.
Targeting of topoisomerases for prognosis and drug resistance in ovarian cancer.
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Carcinoma, Renal Cell
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
A TOP2A-derived cancer panel drives cancer progression in papillary renal cell carcinoma.
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Expression of resistance factors (P-glycoprotein, glutathione S-transferase-pi, and topoisomerase II) and their interrelationship to proto-oncogene products in renal cell carcinomas.
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Quantitative Structure-Activity Relationship Studies on Indenoisoquinoline Topoisomerase I Inhibitors as Anticancer Agents in Human Renal Cell Carcinoma Cell Line SN12C.
The activity of topoisomerases is related to the grade and stage in human renal cell carcinoma.
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Carcinoma, Small Cell
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
Carcinoma, Squamous Cell
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells.
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
Effect of retinoic acid on DNA cleavage and cytotoxicity of topoisomerase II-reactive drugs in a human head and neck squamous carcinoma cell line.
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
From Proteomic Analysis to Potential Therapeutic Targets: Functional Profile of Two Lung Cancer Cell Lines, A549 and SW900, Widely Studied in Pre-Clinical Research.
Induction of ubiquitin conjugating enzyme activity for degradation of topoisomerase II alpha during adenovirus E1A-induced apoptosis.
Inhibition of topoisomerase II? sensitizes FaDu cells to ionizing radiation by diminishing DNA repair.
Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3393).
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Phosphorylation of chk1 at serine-345 affected by topoisomerase I poison SN-38.
Selective modulation of the therapeutic efficacy of anticancer drugs by selenium containing compounds against human tumor xenografts.
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Carcinoma, Transitional Cell
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Carcinosarcoma
Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Cardiomyopathies
Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation.
Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Cardiotoxicity
A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma.
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
Adriamycin-associated cardiomyopathy: where are we now? updates in pathophysiology, dose recommendations, prognosis, and outcomes.
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Anthracycline Chemotherapy and Cardiotoxicity.
Cardiac Damage in Anthracyclines Therapy: Focus on Oxidative Stress and Inflammation.
Comparative effects of doxorubicin and a doxorubicin analog, 13-deoxy, 5-iminodoxorubicin (GPX-150), on human topoisomerase II? activity and cardiac function in a chronic rabbit model.
Creating a Biomarker Panel for Early Detection of Chemotherapy Related Cardiac Dysfunction in Breast Cancer Patients.
Cyclizing-berberine A35 induces G2/M arrest and apoptosis by activating YAP phosphorylation (Ser127).
Development of Orthogonal Linear Separation Analysis (OLSA) to Decompose Drug Effects into Basic Components.
Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase II? inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity.
DNA damage response by single-strand breaks in terminally differentiated muscle cells and the control of muscle integrity.
Docetaxel in the adjuvant therapy of HER-2 positive breast cancer patients.
Doxorubicin Redox Biology: Redox Cycling, Topoisomerase Inhibition, and Oxidative Stress.
Doxorubicin-induced cardiotoxicity is maturation dependent due to the shift from topoisomerase II? to II? in human stem cell derived cardiomyocytes.
Emerging DNA topisomerase inhibitors as anticancer drugs.
HU-331 is a catalytic inhibitor of topoisomerase II?.
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase II? Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Mechanisms of Action and Reduced Cardiotoxicity of Pixantrone; a Topoisomerase II Targeting Agent with Cellular Selectivity for the Topoisomerase II? Isoform.
Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.
Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.
Molecular Mechanisms of the Cardiotoxicity of the Proteasomal-Targeted Drugs Bortezomib and Carfilzomib.
Neonatal murine engineered cardiac tissue toxicology model: Impact of dexrazoxane on doxorubicin induced injury.
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase II?.
The displacement of iron(III) from its complexes with the anticancer drugs piroxantrone and losoxantrone by the hydrolyzed form of the cardioprotective agent dexrazoxane.
Topoisomerase 2?: A Promising Molecular Target for Primary Prevention of Anthracycline-induced Cardiotoxicity.
Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity.
Trastuzumab-mediated cardiotoxicity: current understanding, challenges, and frontiers.
Twisting and ironing: Doxorubicin cardiotoxicity by mitochondrial DNA damage.
Type IIB DNA topoisomerase is downregulated by trastuzumab and doxorubicin to synergize cardiotoxicity.
[?urrent views on predictors and biomarkers of early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer (review of literature).]
Central Nervous System Neoplasms
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Cerebellar Neoplasms
Neural stem cell-mediated CE/CPT-11 enzyme/prodrug therapy in transgenic mouse model of intracerebellar medulloblastoma.
Cervical Intraepithelial Neoplasia
A cocktail of MCM2 and TOP2A, p16INK4a and Ki-67 as biomarkers for the improved diagnosis of cervical intraepithelial lesion.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Chagas Disease
DNA Topoisomerase 3? Is Involved in Homologous Recombination Repair and Replication Stress Response in Trypanosoma cruzi.
Cholangiocarcinoma
Identification of key genes associated with the progression of intrahepatic cholangiocarcinoma using weighted gene co-expression network analysis.
Inhibition of topoisomerase II? and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives.
Cockayne Syndrome
Fine-tuning of the replisome: Mcm10 regulates fork progression and regression.
Mutant Cockayne syndrome group B protein inhibits repair of DNA topoisomerase I-DNA covalent complex.
Collagen Diseases
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Colonic Neoplasms
Altered expression of cell proliferation-related and interferon-stimulated genes in colon cancer cells resistant to SN38.
Anthocyanin-rich extracts suppress the DNA-damaging effects of topoisomerase poisons in human colon cancer cells.
Antitumor Activity of Asperphenin A, a Lipopeptidyl Benzophenone from Marine-Derived Aspergillus sp. Fungus, by Inhibiting Tubulin Polymerization in Colon Cancer Cells.
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model.
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Biodegradable Polymeric Micelle-Mediated Delivery of a pH-Activatable Prodrug of 7-Ethyl-10-Hydroxy-Camptothecin (SN-38) to Enhance Anti-Angiogenesis and Anti-Tumor Activity.
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Camptothecin Induces PD-L1 and Immunomodulatory Cytokines in Colon Cancer Cells.
Catalytic inhibition of human DNA topoisomerase by phenolic compounds in Ardisia compressa extracts and their effect on human colon cancer cells.
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations.
Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
Combined topoisomerase I inhibition for the treatment of metastatic colon cancer.
Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line.
Detection of poly(ADP-ribose) polymerase cleavage in response to treatment with topoisomerase I inhibitors: a potential surrogate end point to assess treatment effectiveness.
Different Camptothecin Sensitivities in Subpopulations of Colon Cancer Cells Correlate with Expression of Different Phospho-Isoforms of Topoisomerase I with Different Activities.
Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
DNA Topoisomerase I Gene Copy Number and mRNA Expression Assessed as Predictive Biomarkers for Adjuvant Irinotecan in Stage II/III Colon Cancer.
DNA topoisomerase I--targeted chemotherapy of human colon cancer in xenografts.
DNA topoisomerase I-targeting drugs as radiation sensitizers.
E-pharmacophore guided discovery of pyrazolo[1,5-c]quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase.
Effect of 2'-O-methyl antisense ORNs on expression of thymidylate synthase in human colon cancer RKO cells.
Effects of Ukrain on the activities of DNA-nicking enzymes.
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Expression of BAX in cell nucleus after experimentally induced apoptosis revealed by immunogold and embedment-free electron microscopy.
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Fluorescein hydrazones: A series of novel non-intercalative topoisomerase II? catalytic inhibitors induce G1 arrest and apoptosis in breast and colon cancer cells.
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Genistein induces apoptosis and topoisomerase II-mediated DNA breakage in colon cancer cells.
Glucose-regulated stresses induce resistance to camptothecin in human cancer cells.
Glucuronidation as a mechanism of intrinsic drug resistance in colon cancer cells: contribution of drug transport proteins.
Glucuronidation as a mechanism of intrinsic drug resistance in human colon cancer: reversal of resistance by food additives.
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Hsp90 inhibitors sensitise human colon cancer cells to topoisomerase I poisons by depletion of key anti-apoptotic and cell cycle checkpoint proteins.
Hydrogel-mediated delivery of celastrol and doxorubicin induces a synergistic effect on tumor regression via upregulation of ceramides.
In vitro basis for schedule-dependent interaction between gemcitabine and topoisomerase-targeted drugs in the treatment of colorectal cancer.
Induction of apoptosis in colon cancer cells by a novel topoisomerase I inhibitor TopIn.
Irinotecan (Campto) in the treatment of pancreatic cancer.
Mad-1 is the exclusive JC virus strain present in the human colon, and its transcriptional control region has a deleted 98-base-pair sequence in colon cancer tissues.
Mapping DNA Breaks by Next-Generation Sequencing.
MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment.
Modulation of IMPDH2, survivin, topoisomerase I and vimentin increases sensitivity to methotrexate in HT29 human colon cancer cells.
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
p53-independent upregulation of KILLER/DR5 TRAIL receptor expression by glucocorticoids and interferon-gamma.
Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Polymorphisms of the UDP-glucuronosyl transferase 1A genes are associated with adverse events in cancer patients receiving irinotecan-based chemotherapy.
Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002.
Regression of human colon cancer xenografts in SCID mice following oral administration of water-insoluble camptothecins.
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Resistance to Irinotecan (CPT-11) activates Epidermal Growth Factor Receptor/Nuclear Factor Kappa B and Increases Cellular Metastasis and Autophagy in LoVo Colon Cancer Cells.
Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Sequence-dependent effect of a cyclooxygenase-2 inhibitor on topoisomerase I inhibitor and 5-fluorouracil-induced cytotoxicity of colon cancer cells.
Simultaneous inhibition of ATR and PARP sensitizes colon cancer cell lines to irinotecan.
Small interfering double-stranded RNAs as therapeutic molecules to restore chemosensitivity to thymidylate synthase inhibitor compounds.
Stromal extracellular matrix reduces chemotherapy-induced apoptosis in colon cancer cell lines.
The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1.
The Role of Autophagic Cell Death and Apoptosis in Irinotecan-Treated P53 Null Colon Cancer Cells.
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Therapy-related acute promyelocytic leukaemia.
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Topoisomerase II? mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.
Topoisomerase-I inhibitors in the management of colon cancer.
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects.
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]
Colorectal Neoplasms
A circadian clock transcription model for the personalization of cancer chronotherapy.
A North Central Cancer Treatment Group Phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma.
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol.
A phase III study of irinotecan (CPT-11) versus best supportive care in patients with metastatic colorectal cancer who have failed 5-fluorouracil therapy. V301 Study Group.
A phase-I study of cpt-11, weekly bolus 5-fu and leucovorin in patients with metastatic cancer.
A Pilot Study of Silymarin as Supplementation to Reduce Toxicities in Metastatic Colorectal Cancer Patients Treated With First-Line FOLFIRI Plus Bevacizumab.
A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.
Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines.
Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
Assessment of cyto/genotoxicity of irinotecan in v79 cells using the comet, micronucleus, and chromosome aberration assay.
Assessment of the topoisomerase I gene copy number as a predictive biomarker of objective response to irinotecan in metastatic colorectal cancer.
Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancer monolayers and xenografts.
Biomodulation by hyperthermia of topoisomerase II-targeting drugs in human colorectal cancer cells.
Blocking of PI3K/Akt pathway enhances apoptosis induced by SN-38, an active form of CPT-11, in human hepatoma cells.
Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line.
Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells.
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Cetuximab in the treatment of patients with colorectal cancer.
Characterisation of a synergistic interaction between a thymidylate synthase inhibitor, ZD1694, and a novel lipophilic topoisomerase I inhibitor karenitecin, BNP1100: mechanisms and clinical implications.
Characterization of CPT-11 converting carboxylesterase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity.
Characterization of p53 wild-type and null isogenic colorectal cancer cell lines resistant to 5-fluorouracil, oxaliplatin, and irinotecan.
Characterization of the topoisomerase I locus in human colorectal cancer.
Chemotherapy of advanced gastrointestinal cancer.
Chemotherapy of colorectal cancer: history and new themes.
Clinical applications of the camptothecins.
Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients.
Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients.
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer.
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Current status of colorectal cancer: CPT-11 (irinotecan), a therapeutic innovation.
DNA damage-induced expression of p53 suppresses mitotic checkpoint kinase hMps1: the lack of this suppression in p53MUT cells contributes to apoptosis.
DNA topoisomerase II alpha: a favorable prognostic factor in colorectal caner.
E2F-1 overexpression sensitizes colorectal cancer cells to camptothecin.
Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
EGCG synergizes the therapeutic effect of irinotecan through enhanced DNA damage in human colorectal cancer cells.
EGFR-targeted therapies in colorectal cancer.
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition.
Enhanced clearance of topoisomerase I inhibitors from human colon cancer cells by glucuronidation.
Enzyme-Based Electrochemical Biosensor for Therapeutic Drug Monitoring of Anticancer Drug Irinotecan.
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines.
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Experience with irinotecan for the treatment of malignant glioma.
Experimental drugs and drug combinations in pancreatic cancer.
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Herbal Medicines for Irinotecan-Induced Diarrhea.
Identification of Circadian Determinants of Cancer Chronotherapy through In Vitro Chronopharmacology and Mathematical Modeling.
Improving the Therapeutic Index in Cancer Therapy by Using Antibody-Drug Conjugates Designed with a Moderately Cytotoxic Drug.
In Vitro and In Silico Mechanistic Insights into miR-21-5p-Mediated Topoisomerase Drug Resistance in Human Colorectal Cancer Cells.
In vitro antitumor effect of topoisomerase-I inhibitor, CPT-11, on freshly isolated human gastric and colorectal cancer.
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activation.
Inhibition of poly(ADP-ribose) polymerase prevents irinotecan-induced intestinal damage and enhances irinotecan/temozolomide efficacy against colon carcinoma.
Inhibition of Stat3 by peptide aptamer rS3-PA enhances growth suppressive effects of irinotecan on colorectal cancer cells.
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Irinotecan in the treatment of colorectal cancer: clinical overview.
Irinotecan induces senescence and apoptosis in colonic cells in vitro.
Irinotecan plus fluorouracil/leucovorin for metastatic colorectal cancer: a new survival standard.
Irinotecan versus infusional 5-fluorouracil: a phase III study in metastatic colorectal cancer following failure on first-line 5-fluorouracil. V302 Study Group.
Irinotecan-Induced Gastrointestinal Dysfunction Is Associated with Enteric Neuropathy, but Increased Numbers of Cholinergic Myenteric Neurons.
Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776.
Long-lasting reduction in clonogenic potential of colorectal cancer cells by sequential treatments with 5-azanucleosides and topoisomerase inhibitors.
Mechanisms of topoisomerase I (TOP1) gene copy number increase in a stage III colorectal cancer patient cohort.
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
New agents for colon and breast cancer.
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
New promising anticancer agents in development: what comes next?
Non-linear pharmacokinetics of irinotecan in mice.
Personalized Drug Efficacy Monitoring Chip.
Pharmacogenomic Profiling and Pathway Analyses Identify MAPK-Dependent Migration as an Acute Response to SN38 in p53 Null and p53-Mutant Colorectal Cancer Cells.
Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
Prediction of irinotecan pharmacokinetics by use of cytochrome P450 3A4 phenotyping probes.
Pregnane x Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation.
Profiling markers of prognosis in colorectal cancer.
Prognostic markers in early-stage colorectal cancer: significance of TYMS mRNA expression.
Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage.
Regulation of Tissue-Specific Carboxylesterase Expression by Pregnane X Receptor and Constitutive Androstane Receptor.
Retrospective analysis of the international standard-dose FOLFIRI (plus bevacizumab) regimen in Japanese patients with unresectable advanced or recurrent colorectal carcinoma.
RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status.
Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Stabilisation in colorectal cancer.
Synergistic Effect of SN-38 in Combination with Cetuximab on Angiogenesis and Cancer Cell Invasion.
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status.
The bromodomain and extra-terminal domain inhibitor JQ1 synergistically sensitizes human colorectal cancer cells to topoisomerase I inhibitors through repression of Mre11-mediated DNA repair pathway.
The development of new chemotherapeutic agents.
The importance of stabilization as an endpoint in the treatment of metastatic colorectal carcinoma: recent quality of life studies.
The role of irinotecan in colorectal cancer.
The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Therapeutic options for the treatment of colorectal cancer following 5-fluorouracil failure.
Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis.
TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells.
Tissue penetration and activity of camptothecins in solid tumor xenografts.
Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
Topoisomerase 1(TOP1) gene copy number in stage III colorectal cancer patients and its relation to prognosis.
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer.
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topotecan in advanced colorectal cancer.
Topotecan in colorectal cancer: a phase II study of the EORTC early clinical trials group.
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial.
Trastuzumab Deruxtecan: First Approval.
Weekly irinotecan plus protracted venous fluorouracil infusion (WI-FI) in advanced colorectal cancer: a phase II study.
[Effect of palliative chemotherapy with topoisomerase inhibitor on the quality of life and survival of patients with advanced colorectal carcinoma]
[Irinotecan plus fuorouracil/leucovorin (FOLFIRI) as a second line chemotherapy for refractory or metastatic colorectal cancer]
[Standard therapy of CPT-11 for colorectal cancer]
[Therapeutic approach for colorectal cancer with topoisomerase as a molecular target]
Communicable Diseases
A patent review of topoisomerase I inhibitors (2016-present).
Inhibitors of DNA Gyrase-GyrB Subunit and/or Topoisomerase IV-ParE Subunit May Treat Infectious Diseases Caused by Antibiotic-Resistant Bacteria.
Community-Acquired Infections
In vitro characterization of the antibacterial spectrum of novel bacterial type II topoisomerase inhibitors of the aminobenzimidazole class.
Quercetin diacylglycoside analogues showing dual inhibition of DNA gyrase and topoisomerase IV as novel antibacterial agents.
Connective Tissue Diseases
Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2.
Contracture
Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients.
Massive pericardial effusion in scleroderma: a review of five cases.
Cryptorchidism
Changes of enzymes involved in DNA synthesis in the testes of cryptorchid rats.
Cystadenoma
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
Cystic Fibrosis
Ivacaftor, a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator, Enhances Ciprofloxacin Activity Against Pseudomonas aeruginosa.
l-Methionine anti-biofilm activity against Pseudomonas aeruginosa is enhanced by the cystic fibrosis transmembrane conductance regulator potentiator, ivacaftor.
Cysts
DNA topoisomerase III? promotes cyst generation by inducing cyst wall protein gene expression in Giardia lamblia.
Decompression Sickness
DNA protection by histone-like protein HU from the hyperthermophilic eubacterium Thermotoga maritima.
The C-terminal domain of DNA gyrase A adopts a DNA-bending beta-pinwheel fold.
Topoisomerase IV bends and overtwists DNA upon binding.
Dengue
Topoisomerase III-? is required for efficient replication of positive-sense RNA viruses.
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses.
Diabetes Complications
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Diabetes Mellitus, Type 1
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Diffuse Intrinsic Pontine Glioma
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
dna topoisomerase (atp-hydrolysing) deficiency
Escherichia coli DNA topoisomerase I mutants have compensatory mutations in DNA gyrase genes.
Topoisomerase I Essentiality, DnaA-Independent Chromosomal Replication, and Transcription-Replication Conflict in Escherichia coli.
dna topoisomerase deficiency
An interplay of NOX1-derived ROS and oxygen determines the spermatogonial stem cell self-renewal efficiency under hypoxia.
Expression of the recA gene is reduced in Escherichia coli topoisomerase I mutants.
gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Topoisomerase deficiencies subtly enhance global genomic repair of ultraviolet-induced DNA damage in Saccharomyces cerevisiae.
Topoisomerase I deficiency causes RNA polymerase II accumulation and increases AID abundance in immunoglobulin variable genes.
Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells.
Topoisomerase I Essentiality, DnaA-Independent Chromosomal Replication, and Transcription-Replication Conflict in Escherichia coli.
Drug-Related Side Effects and Adverse Reactions
Drug toxicity in E. coli cells expressing human topoisomerase I.
In vitro sensitivity of human gastric cancer cells (HGC-27) to Helicobacter pylori cytotoxin.
Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Dysplastic Nevus Syndrome
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Encephalomyelitis
Eliminating encephalitogenic T cells without undermining protective immunity.
Encephalomyelitis, Autoimmune, Experimental
Eliminating encephalitogenic T cells without undermining protective immunity.
Endodermal Sinus Tumor
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Endometrial Hyperplasia
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia.
Endometrial Neoplasms
Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study.
Immunohistochemical detection of human telomerase reverse transcriptase (hTERT), topoisomerase IIalpha expression, and apoptosis in endometrial adenocarcinoma and atypical hyperplasia.
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Topoisomerase II? Binding Protein 1 c.*229C>T (rs115160714) Gene Polymorphism and Endometrial Cancer Risk.
Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93.
Treatment options for endometrial cancer: experience with topotecan.
Weekly topotecan for recurrent endometrial cancer: a case series and review of the literature.
Endometriosis
Deep Invasive Endometriosis Lesions of the Rectosigmoid May Be Related to Alterations in Cell Kinetics.
Epilepsy
DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.
Equine Infectious Anemia
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
The topoisomerase I inhibitor, camptothecin, inhibits equine infectious anemia virus replication in chronically infected CF2Th cells.
Topoisomerase I activity associated with human immunodeficiency virus (HIV) particles and equine infectious anemia virus core.
Esophageal Neoplasms
Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer.
Esophageal Squamous Cell Carcinoma
(S)-10-Hydroxycamptothecin Inhibits Esophageal Squamous Cell Carcinoma Growth In Vitro and In Vivo Via Decreasing Topoisomerase I Enzyme Activity.
Expression of ERCC1, TYMS, TUBB3, RRM1 and TOP2A in patients with esophageal squamous cell carcinoma: A hierarchical clustering analysis.
Esthesioneuroblastoma, Olfactory
Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
Fanconi Anemia
Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
Fanconi anemia cells have a normal gene structure for topoisomerase I.
Fanconi's anemia: anomaly of enzyme passage through the nuclear membrane? Anomalous intracellular distribution of topoisomerase activity in placental extracts in a case of Fanconi's anemia.
Intracellular distribution of DNA topoisomerase I in fibroblasts from patients with Fanconi's anaemia.
Rad18 E3 ubiquitin ligase activity mediates fanconi anemia pathway activation and cell survival following DNA Topoisomerase 1 Inhibition.
Regulation of multiple DNA repair pathways by the Fanconi anemia protein SLX4.
Replication Fork Protection Factors Controlling R-Loop Bypass and Suppression.
Topo IIIalpha and BLM act within the Fanconi anemia pathway in response to DNA-crosslinking agents.
Fibrosarcoma
Altered topoisomerase I and II activities in suramin-resistant lung fibrosarcoma cells.
DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
Interaction of topoisomerase I inhibitors with radiation in cis-diamminedichloroplatinum(II)-sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo.
Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I.
Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Fragile X Syndrome
Top3? is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation.
Ganglioneuroblastoma
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Gastrointestinal Neoplasms
Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.
Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.
Genetic Diseases, Inborn
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
Evolutionary Comparison of the Mechanism of DNA Cleavage with Respect to Immune Diversity and Genomic Instability.
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Gilbert Disease
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Glioblastoma
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment.
Effect of p53 activity on the sensitivity of human glioblastoma cells to PARP-1 inhibitor in combination with topoisomerase I inhibitor or radiation.
Fas/CD95-mediated apoptosis in human glioblastoma cells: a target for sensitisation to topoisomerase I inhibitors.
Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.
Hepatocyte growth factor increases mitochondrial mass in glioblastoma cells.
Higher topoisomerase 2 alpha gene transcript levels predict better prognosis in GBM patients receiving temozolomide chemotherapy: identification of temozolomide as a TOP2A inhibitor.
Karenitecin (bnp1350) and flavopridol as radiosensitizers in malignant glioma.
Long-lasting partial regression of glioblastoma multiforme achieved by edotecarin: case report.
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
NADPH/quinone oxidoreductase is a priority target of glioblastoma chemotherapy.
Overexpression of TIMP-1 and Sensitivity to Topoisomerase Inhibitors in Glioblastoma Cell Lines.
p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition.
Poly(ADPR)polymerase-1 signalling of the DNA damage induced by DNA topoisomerase I poison in D54(p53wt) and U251(p53mut) glioblastoma cell lines.
Quantification of DNase type I ends, DNase type II ends, and modified bases using fluorescently labeled ddUTP, terminal deoxynucleotidyl transferase, and formamidopyrimidine-DNA glycosylase.
Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan.
Relationships between DNA damage and growth inhibition induced by topoisomerase II-interfering drugs in doxorubicin-sensitive and -resistant rat glioblastoma cells.
The effect of iodine-131 beta-particles in combination with A-966492 and Topotecan on radio-sensitization of glioblastoma: An in-vitro study.
Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends.
Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.
Topoisomerase II? mediates the resistance of glioblastoma stem cells to replication stress-inducing drugs.
Treatment of neoplastic meningitis with intrathecal 9-nitro-camptothecin.
Tyrosyl-DNA Phosphodiesterase 1 and Topoisomerase I Activities as Predictive Indicators for Glioblastoma Susceptibility to Genotoxic Agents.
Vorinostat enhances the cytotoxic effects of the topoisomerase I inhibitor SN38 in glioblastoma cell lines.
Glioma
A phase I/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma.
A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models.
Canine spontaneous glioma: a translational model system for convection-enhanced delivery.
Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors.
Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Differential response of human glioblastoma cell lines to combined camptothecin and ionizing radiation treatment.
DNA topoisomerase II-alpha as a proliferation marker in human gliomas: correlation with PCNA expression and patient survival.
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo.
Etoposide improves survival in high-grade glioma: a meta-analysis.
Gene expression time-series analysis of camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines.
Glioma cell sensitivity to topotecan: the role of p53 and topotecan-induced DNA damage.
In vitro effects of topotecan and ionizing radiation on TRAIL/Apo2L-mediated apoptosis in malignant glioma.
Inhibition of DNA-PK potentiates the synergistic effect of NK314 and etoposide combination on human glioblastoma cells.
Inhibitory effect of DNA topoisomerase inhibitor isoliquiritigenin on the growth of glioma cells.
Inhibitory effects of lapachol on rat C6 glioma in vitro and in vivo by targeting DNA topoisomerase I and topoisomerase II.
Long-term exposure to irinotecan reduces cell migration in glioma cells.
Pegylated-liposomal doxorubicin and oral topotecan in eight children with relapsed high-grade malignant brain tumors.
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma.
Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma.
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Pyrrolo[2,3-?]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo.
Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11.
Recurrent brainstem gliomas treated with oral VP-16.
Regression of Recurrent Malignant Gliomas with Convection-Enhanced Delivery of Topotecan.
Resveratrol acts as a topoisomerase II poison in human glioma cells.
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Synergistic cytotoxicity, apoptosis and protein-linked DNA breakage by etoposide and camptothecin in human U87 glioma cells: dependence on tyrosine phosphorylation.
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Temozolomide in combination with other cytotoxic agents.
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
The enhanced antitumor-activity of DNA topoisomerase ii-trapping drugs by natural human tumor-necrosis-factor against human glioma cell-lines in-vitro.
Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
TOP2B Enzymatic Activity on Promoters and Introns Modulates Multiple Oncogenes in Human Gliomas.
Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells.
Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications.
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Topoisomerase-I inhibitors for human malignant glioma: differential modulation of p53, p21, bax and bcl-2 expression and of CD95-mediated apoptosis by camptothecin and beta-lapachone.
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage.
[Quantitative analysis of DNA topoisomerase I activity in human and rat glioma: characterization and mechanism of resistance to antitopoisomerase chemical, camptothecin-11]
Glioma, Subependymal
Therapeutic targets in subependymoma.
Gliosarcoma
Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model.
Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
Glomerulosclerosis, Focal Segmental
Expression of DNA topoisomerases in chronic proliferative kidney disease.
Gonorrhea
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
Inhibition of Neisseria gonorrhoeae Type II Topoisomerases by the Novel Spiropyrimidinetrione AZD0914.
Graft vs Host Disease
Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
Granuloma
Cellular pharmacology studies of shikonin derivatives.
Head and Neck Neoplasms
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
DNA topoisomerase I-targeting drugs as radiation sensitizers.
New cytotoxic and molecular-targeted therapies of head and neck tumors.
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Hearing Loss
Mutations in TOP2B cause autosomal-dominant hereditary hearing loss via inhibition of the PI3K-Akt signalling pathway.
Heart Failure
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
Hemangioma
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.
Hematologic Neoplasms
Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series.
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Future role of topotecan in the treatment of lung cancer.
New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitors. Introduction.
Phase I study of irofulven (MGI 114), an acylfulvene illudin analog, in patients with acute leukemia.
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Proton Radiotherapy for Pediatric Ewing's Sarcoma: Initial Clinical Outcomes.
Secondary myelodysplastic syndrome after small cell lung cancer and esophageal cancer.
The broken genome: genetic and pharmacologic approaches to breaking DNA.
Topoisomerase I inhibitors in the treatment of head and neck cancer.
Hepatitis
Topoisomerase I-mediated integration of hepadnavirus DNA in vitro.
Hepatitis B
Deazaflavin Inhibitors of Tyrosyl-DNA Phosphodiesterase 2 (TDP2) Specific for the Human Enzyme and Active against Cellular TDP2.
Human DNA topoisomerase I-mediated cleavage and recombination of duck hepatitis B virus DNA in vitro.
Hepatitis, Chronic
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Hepatoblastoma
The expression of Bcl-XL, Bcl-XS and p27Kip1 in topotecan-induced apoptosis in hepatoblastoma HepG2 cell line.
Herpes Simplex
A DNA topoisomerase activity copurifies with the DNA polymerase induced by herpes simplex virus.
Association of type I DNA topoisomerase with herpes simplex virus.
Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function.
Identification of KIAA1210 as a novel X-chromosome-linked protein that localizes to the acrosome and associates with the ectoplasmic specialization in testes.
Role of DNA topoisomerase I in the replication of herpes simplex virus type 2.
Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Hodgkin Disease
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Immunohistochemical staining for DNA topoisomerase IIa in Hodgkin's disease.
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Topoisomerase II{alpha} Expression as an Independent Prognostic Factor in Hodgkin's Lymphoma.
Huntington Disease
Topoisomerase 1 inhibitor topotecan delays the disease progression in a mouse model of Huntington's disease.
Hypergammaglobulinemia
Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.
Hyperglycemia
Type 1 diabetes affects topoisomerase I activity and GlcNAcylation in rat organs: kidney liver and pancreas.
Hypersensitivity
Camptothecin hypersensitivity in poly(adenosine diphosphate-ribose) polymerase-deficient cell lines.
Cell cycle effects of the DNA topoisomerase inhibitors camptothecin and m-AMSA in lymphoblastoid cell lines from patients with Fanconi anemia.
Cellular and chromosomal hypersensitivity to DNA crosslinking agents and topoisomerase inhibitors in the radiosensitive Chinese hamster irs mutants: phenotypic similarities to ataxia telangiectasia and Fanconi's anaemia cells.
Collaborative roles of gammaH2AX and the Rad51 paralog Xrcc3 in homologous recombinational repair.
Comparison of the effects of DNA topoisomerase inhibitors on lymphoblasts from normal and Fanconi anemia donors.
Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.
Cutaneous reactions to chemotherapeutic drugs and targeted therapies for cancer: part I. Conventional chemotherapeutic drugs.
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
DNA Ligase IV and Artemis Act Cooperatively to Suppress Homologous Recombination in Human Cells: Implications for DNA Double-Strand Break Repair.
Effects of camptothecin on double-strand break repair by non-homologous end-joining in DNA mismatch repair-deficient human colorectal cancer cell lines.
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
gyrB-225, a mutation of DNA gyrase that compensates for topoisomerase I deficiency: investigation of its low activity and quinolone hypersensitivity.
Hypersensitivity of Cockayne's syndrome cells to camptothecin is associated with the generation of abnormally high levels of double strand breaks in nascent DNA.
Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Identification of the MMS22L-TONSL complex that promotes homologous recombination.
Identification of Tyrosyl-DNA Phosphodiesterase as a Novel DNA Damage Repair Enzyme in Arabidopsis.
Isolation of camptothecin-sensitive chinese hamster cell mutants: phenotypic heterogeneity within the ataxia telangiectasia-like XRCC8 (irs2) complementation group.
Large-scale analysis of genes that alter sensitivity to the anticancer drug tirapazamine in Saccharomyces cerevisiae.
Mitochondrial topoisomerase I (Top1mt) is a novel limiting factor of doxorubicin cardiotoxicity.
Mutations of the bacteriophage T4 type II DNA topoisomerase that alter sensitivity to antitumor agent 4'-(9-acridinylamino)methanesulfon-m-anisidide and an antibacterial quinolone.
Overexpression of human topoisomerase I in baby hamster kidney cells: hypersensitivity of clonal isolates to camptothecin.
Overexpression of type I topoisomerases sensitizes yeast cells to DNA damage.
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Pnk1, a DNA kinase/phosphatase required for normal response to DNA damage by gamma-radiation or camptothecin in Schizosaccharomyces pombe.
Quantification of Etoposide Hypersensitivity: A Sensitive, Functional Method for Assessing Pluripotent Stem Cell Quality.
Sensitivity to camptothecin in Aspergillus nidulans identifies a novel gene, scaA+, related to the cellular DNA damage response.
Tdp1 protects from topoisomerase 1-mediated chromosomal breaks in adult zebrafish but is dispensable during larval development.
The DNA helicase activity of yeast Sgs1p is essential for normal lifespan but not for resistance to topoisomerase inhibitors.
The effect of two topoisomerase inhibitors on low-dose hypersensitivity and increased radioresistance in Chinese hamster V79 cells.
The topoisomerase-related function gene TRF4 affects cellular sensitivity to the antitumor agent camptothecin.
Tyrosyl-DNA phosphodiesterases: rescuing the genome from the risks of relaxation.
[Various novel properties of transcriptionally active mini-chromosomes of the SV40 virus]
Hypertension
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.
Hypertension, Pulmonary
Mechanical thumb pain in a systemic sclerosis patient: simple first carpometacarpal osteoarthritis?
Hyperthyroidism
Poly(ADP-ribose) polymerase is affected early by thyroid state during liver regeneration in rats.
Hypertriglyceridemia
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Infections
55.2, a phage T4 ORFan gene, encodes an inhibitor of Escherichia coli topoisomerase I and increases phage fitness.
A simplified protocol for high-yield expression and purification of bacterial topoisomerase I.
Absorption, distribution, metabolism and elimination of 14C-ETX0914, a novel inhibitor of bacterial type-II topoisomerases in rodents.
Antimicrobial Resistance in Mycoplasma spp.
Antimicrobial Resistance in Neisseria gonorrhoeae: Proceedings of the STAR Sexually Transmitted Infection-Clinical Trial Group Programmatic Meeting.
Autonomous parvovirus DNA replication requires topoisomerase I and its activity is increased during infection.
Cellular DNA Topoisomerases Are Required for the Synthesis of Hepatitis B Virus Covalently Closed Circular DNA.
Chikungunya Virus Infection Alters Expression of MicroRNAs Involved in Cellular Proliferation, Immune Response and Apoptosis.
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan.
Discovery of a novel azaindole class of antibacterial agents targeting the ATPase domains of DNA gyrase and Topoisomerase IV.
DNA damage induced by topoisomerase inhibitors activates SAMHD1 and blocks HIV-1 infection of macrophages.
DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line.
Effect of bacteriophage T4 DNA topoisomerase gene 39 on level of beta chain of ribonucleoside diphosphate reductase in a T4 nrdB mutant.
Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
Efficacy of a Novel Tricyclic Topoisomerase Inhibitor in a Murine Model of Neisseria gonorrhoeae Infection.
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Evaluation of a New Chemotherapeutic: Cethromycin-Mediated Protection Against the Plague Pathogen, Yersinia pestis, in a Rat Model of Infection and its Comparison with Levofloxacin.
Expression of the type I DNA topoisomerase gene in adenovirus-5 infected human cells.
Human TOP1 residues implicated in species specificity of HIV-1 infection are required for interaction with BTBD2, and RNAi of BTBD2 in old world monkey and human cells increases permissiveness to HIV-1 infection.
Human topoisomerase 1 messenger RNA is not destabilized by the herpes simplex virus type 2 virion-associated shut-off function.
Human topoisomerase I promotes HIV-1 proviral DNA synthesis: implications for the species specificity and cellular tropism of HIV-1 infection.
Identification of smut-responsive genes in sugarcane using cDNA-SRAP.
Imidazopyrazinones (IPYs): non-quinolone bacterial topoisomerase inhibitors showing partial cross-resistance with quinolones.
In vitro and in vivo metabolism of 14C-AZ11, a novel inhibitor of bacterial DNA gyrase/type II topoisomerase.
Inhibition of human immunodeficiency virus (HIV-1) replication in vitro by noncytotoxic doses of camptothecin, a topoisomerase I inhibitor.
Involvement of topoisomerases in replication, transcription, and packaging of the linear adenovirus genome.
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor.
New aminocoumarin antibiotics as gyrase inhibitors.
New developments in non-quinolone-based antibiotics for the inhibiton of bacterial gyrase and topoisomerase IV.
Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
Novel berberine derivatives: Design, synthesis, antimicrobial effects, and molecular docking studies.
Pharmacokinetic-Pharmacodynamic Evaluation of Gepotidacin against Gram-Positive Organisms Using Data from Murine Infection Models.
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription.
Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Structural alteration of DNA induced by viral protein R of HIV-1 triggers the DNA damage response.
Studies on DNA topoisomerases I and II in herpes simplex virus type 2-infected cells.
Suppression of BK virus replication and cytopathic effect by inhibitors of prokaryotic DNA gyrase.
Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors.
Temporal Interplay between Efflux Pumps and Target Mutations in Development of Antibiotic Resistance in Escherichia coli.
The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs.
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
The role of topoisomerase I in HIV-1 replication.
Therapeutic targets for the treatment of microsporidiosis in humans.
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.
Topotecan inhibits human immunodeficiency virus type 1 infection through a topoisomerase-independent mechanism in a cell line with altered topoisomerase I.
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
[Mutations of DNA gyrase and topoisomerase IV in clinical isolates of fluoroquinolone-resistant Proteus mirabilis]
Infertility
Development of autoimmunity in mice lacking DNA topoisomerase 3beta.
Infertility and aneuploidy in mice lacking a type IA DNA topoisomerase III beta.
Infertility, Male
Proteomic Analysis Reveals that Topoisomerase 2A is Associated with Defective Sperm Head Morphology.
Influenza, Human
A frame shift mutation in a hot spot region of the nuclear autoantigen La (SS-B).
Host-directed therapies for antimicrobial resistant respiratory tract infections.
Keloid
Effect of camptothecin on collagen synthesis in fibroblasts from patients with keloid.
Kidney Neoplasms
A potential novel combination therapy targeting survivin in renal cancer cells: Inhibition of survivin expression by topotecan and hexamethylene bisacetamide.
Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells.
Klatskin Tumor
Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy.
Leiomyomatosis
Topoisomerase I and II consensus sequences in a 17-kb deletion junction of the COL4A5 and COL4A6 genes and immunohistochemical analysis of esophageal leiomyomatosis associated with Alport syndrome.
Leiomyosarcoma
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
Leishmaniasis
A pentapeptide signature motif plays a pivotal role in Leishmania DNA topoisomerase IB activity and camptothecin sensitivity.
Diospyrin, a bisnaphthoquinone: a novel inhibitor of type I DNA topoisomerase of Leishmania donovani.
Topoisomerase 1B as a Target Against Leishmaniasis.
Leishmaniasis, Cutaneous
Efficacy of a Binuclear Cyclopalladated Compound Therapy for Cutaneous Leishmaniasis in the Murine Model of Infection with Leishmania amazonensis and Its Inhibitory Effect on Topoisomerase 1B.
Leishmaniasis, Visceral
Copper salisylaldoxime (CuSAL) imparts protective efficacy against visceral leishmaniasis by targeting Leishmania donovani topoisomerase IB.
Deletion Study of DNA Topoisomerase IB from Leishmania donovani: Searching for a Minimal Functional Heterodimer.
Structural insights on the small subunit of DNA topoisomerase I from the unicellular parasite Leishmania donovani.
The HIV - 1 protease inhibitor Amprenavir targets Leishmania donovani topoisomerase I and induces oxidative stress-mediated programmed cell death.
Topoisomerase IB poisons induce histone H2A phosphorylation as a response to DNA damage in Leishmania infantum.
Leukemia
2- or 6-(1-azidoalkyl)-5,8-dimethoxy-1,4-naphthoquinone: synthesis, evaluation of cytotoxic activity, antitumor activity and inhibitory effect on DNA topoisomerase-I.
3-O-(E)-p-Coumaroyl Tormentic Acid from Eriobotrya japonica Leaves Induces Caspase-Dependent Apoptotic Cell Death in Human Leukemia Cell Line.
A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. United Kingdom Childhood Cancer Study Investigators.
A phase I and pharmacodynamic study of sequential topotecan and etoposide in patients with relapsed or refractory acute myelogenous and lymphoblastic leukemia.
A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
Abnormalities in the long arm of chromosome 11 (11q) in patients with de novo and secondary acute myelogenous leukemias and myelodysplastic syndromes.
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Activity of a novel camptothecin analogue, homocamptothecin, in camptothecin-resistant cell lines with topoisomerase I alterations.
Activity of oral and intravenous 9-aminocamptothecin in SCID mice engrafted with human leukemia.
ALCAPs induce mitochondrial apoptosis and activate DNA damage response by generating ROS and inhibiting topoisomerase I enzyme activity in K562 leukemia cell line.
Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells.
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Altered topoisomerase I activity and recombination activating gene expression in a human leukemia cell line resistant to doxorubicin.
Altered topoisomerase I expression in two subclones of human CEM leukemia selected for resistance to camptothecin.
Alternative RNA Processing of Topoisomerase II? in Etoposide-Resistant Human Leukemia K562 Cells: Intron Retention Results in a Novel C-Terminal Truncated 90-kDa Isoform.
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.
Anion-dependent modulations of DNA topoisomerase II-mediated reactions in potassium-containing solutions.
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Apoptotic response of HL-60 human leukemia cells to the antitumor drug NB-506, a glycosylated indolocarbazole inhibitor of topoisomerase 1.
Arrest of replication fork progression at sites of topoisomerase II-mediated DNA cleavage in human leukemia CEM cells incubated with VM-26.
Automated Extraction of DNA and RNA from a Single Formalin-Fixed Paraffin-Embedded Tissue Section for Analysis of Both Single-Nucleotide Polymorphisms and mRNA Expression.
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Bufalin reduces the level of topoisomerase II in human leukemia cells and affects the cytotoxicity of anticancer drugs.
c-IAP1 is overexpressed in HL-60 cells selected for doxorubicin resistance: effects on etoposide-induced apoptosis.
Camptothecin induces differentiation and stimulates the expression of differentiation-related genes in U-937 human promonocytic leukemia cells.
Caspase inhibition in camptothecin-treated U-937 cells is coupled with a shift from apoptosis to transient G1 arrest followed by necrotic cell death.
Cell cycle analysis of amount and distribution of nuclear DNA topoisomerase I as determined by fluorescence digital imaging microscopy.
Cell cycle arrest and protein kinase modulating effect of bufalin on human leukemia ML1 cells.
Cell death in leukemia: passenger protein regulation by topoisomerase inhibitors.
Cells lacking DNA topoisomerase II beta are resistant to genistein.
Cellular and biochemical antileukemic mechanisms of the meroterpenoid Oncocalyxone A.
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Changes in topoisomerase I levels and localization during myeloid maturation in vitro and in vivo.
Characterization and mechanisms of chromosomal alterations induced by benzene in mice and humans.
Characterization of a camptothecin-resistant human DNA topoisomerase I.
Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
Characterization of genomic breakpoints in MLL and CBP in leukemia patients with t(11;16).
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Chemotherapy-related secondary leukemias: A role for DNA repair by error-prone non-homologous end joining in topoisomerase II - Induced chromosomal rearrangements.
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Circumvention of resistance by doxorubicin, but not by idarubicin, in a human leukemia cell line containing an intercalator-resistant form of topoisomerase II: evidence for a non-topoisomerase II-mediated mechanism of doxorubicin cytotoxicity.
Comparative QSAR studies on substituted bis-(acridines) and bis-(phenazines)-carboxamides: a new class of anticancer agents.
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Contributions of the D-Ring to the activity of etoposide against human topoisomerase II?: potential interactions with DNA in the ternary enzyme--drug--DNA complex.
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
CRISPR/Cas9 Genome Editing of the Human Topoisomerase II? Intron 19 5' Splice Site Circumvents Etoposide Resistance in Human Leukemia K562 Cells.
Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
Cudraflavanone A purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells, at least in part, through the inhibition of DNA topoisomerase I and protein kinase C activity.
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells.
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Development and characterization of a WEHI-3B D+ monomyelocytic leukemia cell line resistant to novobiocin and cross-resistant to other topoisomerase II-targeted drugs.
Development of a stable camptothecin-resistant subline of P388 leukemia with reduced topoisomerase I content.
Dietary factors and the risk for acute infant leukemia: evaluating the effects of cocoa-derived flavanols on DNA topoisomerase activity.
Dietary polyphenols influence antimetabolite agents: methotrexate, 6-mercaptopurine and 5-fluorouracil in leukemia cell lines.
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
Differential expression of human topoisomerase IIIalpha during the cell cycle progression in HL-60 leukemia cells and human peripheral blood lymphocytes.
Differential induction of apoptosis in undifferentiated and differentiated HL-60 cells by DNA topoisomerase I and II inhibitors.
Differentiation induction of human promyelocytic leukemia cells by 10-hydroxycamptothecin, a DNA topoisomerase I inhibitor.
Distinct steps in DNA fragmentation pathway during camptothecin-induced apoptosis involved caspase-, benzyloxycarbonyl- and N-tosyl-L-phenylalanylchloromethyl ketone-sensitive activities.
DNA binding and topoisomerase I poisoning activities of novel disaccharide indolocarbazoles.
DNA fragmentation induced by protease activation in p53-null human leukemia HL60 cells undergoing apoptosis following treatment with the topoisomerase I inhibitor camptothecin: cell-free system studies.
DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues.
DNA Topology and Topoisomerases: Teaching a "Knotty" Subject.
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Dysregulation of the DNA Damage Response and KMT2A Rearrangement in Fetal Liver Hematopoietic Cells.
Early development of acute myeloid leukemia following treatment of osteosarcoma: a case report and review of the literature.
Effect of 1-beta-D-arabinofuranosylcytosine (ara-C) on nuclear topoisomerase II activity and on the DNA cleavage and cytotoxicity produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) and etoposide in m-AMSA-sensitive and -resistant human leukemia cells.
Effect of bryostatin 1 on drug-induced, topoisomerase II-mediated DNA cleavage and topoisomerase II gene expression in human leukemia cells.
Effect of difluoromethylornithine, an inhibitor of polyamine biosynthesis, on the topoisomerase II-mediated DNA scission produced by 4'-(9-acridinylamino)methanesulfon-m-anisidide in L1210 murine leukemia cells.
Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Enhanced binding to DNA and topoisomerase I inhibition by an analog of the antitumor antibiotic rebeccamycin containing an amino sugar residue.
Etoposide, topoisomerase II and cancer.
Etoposide-induced DNA cleavage in human leukemia cells.
Evidence for BLM and Topoisomerase IIIalpha interaction in genomic stability.
Evidence of DNA topoisomerase II-dependent mechanisms of multidrug resistance in P388 leukemia cells.
Genistein induces topoisomerase IIbeta- and proteasome-mediated DNA sequence rearrangements: Implications in infant leukemia.
Hoechst 33342 induces apoptosis in HL-60 cells and inhibits topoisomerase I in vivo.
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II? in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.
Human LPP gene is fused to MLL in a secondary acute leukemia with a t(3;11) (q28;q23).
Idarubicin and idarubicinol are less affected by topoisomerase II-related multidrug resistance than is daunorubicin.
Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II.
Indole alkaloids and other constituents of Rauwolfia serpentina.
Induction of apoptosis by topotecan: implications for the treatment of leukemia.
Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias.
Inhibition of Moloney murine leukemia virus replication by tyrphostins, tyrosine kinase inhibitors.
Inhibition of murine AIDS (MAIDS) development in C57BL/6J mice by tyrphostin AG-1387.
Inhibition of novel GCN5-ATM axis restricts the onset of acquired drug resistance in leukemia.
Inhibitors of topoisomerases as anticancer drugs: problems and prospects.
Initial testing of topotecan by the pediatric preclinical testing program.
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
Intercalator-induced, topoisomerase II-mediated DNA cleavage and its modification by antineoplastic antimetabolites.
Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11.
Involvement of DNA topoisomerases and DNA topoisomerase inhibitors in the induction of leukemia cell differentiation.
Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells.
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Isolation of a mitochondrial DNA topoisomerase from human leukemia cells.
Isolation of an 11-kDa protein associated with the topoisomerase I activity from equine infectious anemia virus.
Lamellarin D: a novel potent inhibitor of topoisomerase I.
Lamellarin D: a novel pro-apoptotic agent from marine origin insensitive to P-glycoprotein-mediated drug efflux.
Leukemias related to treatment with DNA topoisomerase II inhibitors.
MDR1, MRP, topoisomerase IIalpha/beta, and cyclin A gene expression in acute and chronic leukemias.
Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4-pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7 H- pyridol[1,2,3-de]-[1,4]benzothiazine-6-carboxylic acid (WIN 58161).
Mechanism of action of DNA topoisomerase inhibitors.
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents.
Mechanism of the inhibition of leukemia cell growth and induction of apoptosis through the activation of ATR and PTEN by the topoisomerase inhibitor 3EZ, 20Ac-ingenol.
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Model for MLL translocations in therapy-related leukemia involving topoisomerase II?-mediated DNA strand breaks and gene proximity.
Molecular cloning of a cDNA of a camptothecin-resistant human DNA topoisomerase I and identification of mutation sites.
Molecular docking studies, biological and toxicity evaluation of dihydroisoquinoline derivatives as potential anticancer agents.
Multilocus association of genetic variants in MLL, CREBBP, EP300, and TOP2A with childhood acute lymphoblastic leukemia in Hispanics from Texas.
Mutation at the catalytic site of topoisomerase I in CEM/C2, a human leukemia cell line resistant to camptothecin.
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia.
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
Phorbol ester effects on topoisomerase II activity and gene expression in HL-60 human leukemia cells with different proclivities toward monocytoid differentiation.
Phosphorylation of serine 1106 in the catalytic domain of topoisomerase II alpha regulates enzymatic activity and drug sensitivity.
Plant antitumor agents. 29. Synthesis and biological activity of ring D and ring E modified analogues of camptothecin.
Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Poisoning of topoisomerase I by an antitumor indolocarbazole drug: stabilization of topoisomerase I-DNA covalent complexes and specific inhibition of the protein kinase activity.
Protease inhibitors induce specific changes in protein tyrosine phosphorylation that correlate with inhibition of apoptosis in myeloid cells.
Purification and characterization of a type I DNA topoisomerase from calf thymus mitochondria.
Rapid increase in the activity of DNA topoisomerase I, but not topoisomerase II, in HL-60 promyelocytic leukemia cells treated with a phorbol diester.
Relation between intracellular acidification and camptothecin-induced apoptosis in leukemia cells.
Retroviral expression of a mutant (Gly-533) human DNA topoisomerase I cDNA confers a dominant form of camptothecin resistance.
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Role of Nitric Oxide in the Chemistry and Anticancer Activity of Etoposide (VP-16,213).
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
Silencing and selective methylation of the normal topoisomerase I gene in camptothecin-resistant CEM/C2 human leukemia cells.
Specific inhibition of serine- and arginine-rich splicing factors phosphorylation, spliceosome assembly, and splicing by the antitumor drug NB-506.
Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.
Stimulation of topoisomerase II-mediated DNA cleavage by benzene metabolites.
Structural impact of the leukemia drug 1-beta-D-arabinofuranosylcytosine (Ara-C) on the covalent human topoisomerase I-DNA complex.
Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I: evidence for a specific receptor site and a relation to antitumor activity.
Structure-mutagenicity relationships in series of 11H-indolo[3,2-c]quinoline-1,4-diones, tetrahydro-11H-indolo[3,2-c]quinoline-1,4-diones and 11H-pyrido[3',4':4,5]pyrrolo[3,2-c]quinoline-1,4-diones with leukemia cytotoxic properties. Relations with topoisomerase I inhibiting properties.
Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Syntheses and biological activities of rebeccamycin analogues. Introduction of a halogenoacetyl substituent.
Syntheses and biological evaluation of indolocarbazoles, analogues of rebeccamycin, modified at the imide heterocycle.
Synthesis and biological activity of a photoaffinity etoposide probe.
Synthesis and topoisomerase poisoning activity of A-ring and E-ring substituted luotonin A derivatives.
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
The effect of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 1-beta-D-arabinofuranosylcytosine on the cell cycle phase distribution, topoisomerase II level, mitoxantrone cytotoxicity, and DNA strand break production in K562 human leukemia cells.
The effect of staurosporine on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells.
The effect of topoisomerase inhibitors on the expression of differentiation markers and cell cycle progression in human K-562 leukemia cells.
The production of topoisomerase II-mediated DNA cleavage in human leukemia cells predicts their susceptibility to 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA).
The topoisomerase I-binding RING protein, topors, is associated with promyelocytic leukemia nuclear bodies.
Therapy related leukemias: susceptibility, prevention and treatment.
Therapy-related acute leukemia in breast cancer patients: twelve cases treated with a topoisomerase inhibitor.
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topoisomerase I dissociates human immunodeficiency virus type 1 reverse transcriptase from genomic RNAs.
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topoisomerase I-inhibition enhances vitamin D-responsive expression of the receptor for lipopolysaccharide binding protein CD 14.
Topoisomerase II activities in AML and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topoisomerase II activities in AML blasts and their correlation with cellular sensitivity to anthracyclines and epipodophyllotoxines.
Topoisomerase II and leukemia.
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Topoisomerase inhibitors potentiate the effect of retinoic acid on cell growth inhibition and induction of differentiation of leukemia HL-60 cells.
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Unscheduled activation of cyclin B1/Cdc2 kinase in human promyelocytic leukemia cell line HL60 cells undergoing apoptosis induced by DNA damage.
[Anthracycline antibiotics and their derivatives--inhibitors of topoisomerase I]
[DNA topoisomerase and telomerase activity with relation to multi-drug resistance in leukemia--review]
Leukemia L1210
DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators.
Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage.
Properties of a purified nuclear topoisomerase from L1210 cells.
Thiol dependent inhibition of mouse leukemia L1210 DNA topoisomerase I by nitracrine.
Trifluoperazine modulation of resistance to the topoisomerase II inhibitor etoposide in doxorubicin resistant L1210 murine leukemia cells.
Leukemia, Erythroblastic, Acute
Correlation between the DNA-binding affinity of topoisomerase inhibiting drugs and their capacity to induce hematopoetic cell differentiation.
Protein tyrosine phosphatase-dependent activation of beta-globin and delta-aminolevulinic acid synthase genes in the camptothecin-induced IW32 erythroleukemia cell differentiation.
Synergistic induction of erythroid differentiation of mouse erythroleukemia (MEL) cells by inhibitors of topoisomerases and protein tyrosine kinases.
Leukemia, Lymphocytic, Chronic, B-Cell
Topotecan in chronic lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Is there an entity of chemically induced BCR-ABL-positive chronic myelogenous leukemia?
Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Leukemia, Myeloid
Activation of PKCalpha downstream from caspases during apoptosis induced by 7-hydroxystaurosporine or the topoisomerase inhibitors, camptothecin and etoposide, in human myeloid leukemia HL60 cells.
Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells.
Epicatechin and a cocoa polyphenolic extract modulate gene expression in human Caco-2 cells.
Induction of differentiation of human and mouse myeloid leukemia cells by camptothecin.
Phorbol ester-induced down-regulation of topoisomerase II alpha mRNA in a human erythroleukemia cell line. Evidence for a post-transcriptional mechanism.
The S-phase cytotoxicity of camptothecin.
Topoisomerase inhibitors have potent differentiation-inducing activity for human and mouse myeloid leukemia cells.
Leukemia, Myeloid, Acute
Acute promyelocytic leukemia after mitoxantrone therapy for multiple sclerosis.
Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines.
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Do children have increased susceptibility for developing secondary acute myelogenous leukemia?
Effects of topoisomerase I inhibition on the expression of topoisomerase II alpha measured with fluorescence image cytometry.
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.
Expression of PKC isozyme and MDR-associated genes in primary and relapsed state AML.
Gene expression of hENT1, dCK, CDA, dCMPD and topoisomerase II? as an indicator of chemotherapy response in AML treated with cytarabine and daunorubicin.
In vitro cross-resistance to nucleoside analogues and inhibitors of topoisomerase 1 and 2 in acute myeloid leukemia.
MLL gene rearrangement in acute myelogenous leukemia after exposure to tegafur/uracil.
New drugs in the treatment of acute and chronic leukemia with some emphasis on m-AMSA.
NUP98 is fused to topoisomerase (DNA) IIbeta 180 kDa (TOP2B) in a patient with acute myeloid leukemia with a new t(3;11)(p24;p15).
Overexpression of Mcl-1 confers multidrug resistance, whereas topoisomerase II? downregulation introduces mitoxantrone-specific drug resistance in acute myeloid leukemia.
Paclitaxel Induced MDS and AML: A Case Report and Literature Review.
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Pim kinase inhibition sensitizes FLT3-ITD acute myeloid leukemia cells to topoisomerase 2 inhibitors through increased DNA damage and oxidative stress.
Potential mechanisms of resistance to cytarabine in AML patients.
Secondary acute myelogenous leukemia and myelodysplasia without abnormalities of chromosome 11q23 following treatment of acute leukemia with topoisomerase II-based chemotherapy.
Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia.
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia.
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Thioguanine substitution alters DNA cleavage mediated by topoisomerase II.
Thymineless death in F10-treated AML cells occurs via lipid raft depletion and Fas/FasL co-localization in the plasma membrane with activation of the extrinsic apoptotic pathway.
Topoisomerase activities in undifferentiated acute myeloblastic leukemias and monocytic differentiated leukemias.
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
XPO1 Inhibition Using Selinexor Synergizes With Chemotherapy in Acute Myeloid Leukemia (AML) by Targeting DNA Repair and Restoring Topoisomerase II? to the Nucleus.
Leukemia, Myelomonocytic, Chronic
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Leukemia, Promyelocytic, Acute
Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line.
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy.
Topoisomerase II levels during granulocytic maturation in vitro and in vivo.
Leukemia, T-Cell
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
Leukemia-Lymphoma, Adult T-Cell
Concomitant use of radiotherapy and two topoisomerase inhibitors to treat adult T-cell leukemia with a radiotherapy-resistant bulky disease: a case series.
NK314 potentiates antitumor activity with adult T-cell leukemia-lymphoma cells by inhibition of dual targets on topoisomerase II{alpha} and DNA-dependent protein kinase.
Leukopenia
Circadian rhythm of irinotecan tolerability in mice.
Clinical influences of anticentromere antibody on primary Sjögren's syndrome in a prospective Korean cohort.
Liposarcoma
Doxorubicin resistance in a novel in vitro model of human pleomorphic liposarcoma associated with alternative lengthening of telomeres.
Liver Cirrhosis, Biliary
Autoantibodies to topoisomerase I in primary biliary cirrhosis.
Demographic and clinical features of systemic sclerosis patients with anti-RNA polymerase III antibodies.
Liver Neoplasms
Berberine-10-hydroxy camptothecine-loaded lipid microsphere for the synergistic treatment of liver cancer by inhibiting topoisomerase and HIF-1?.
Combating liver cancer through GO-targeted biomaterials.
DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action.
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
Tirapazamine Sensitizes Hepatocellular Carcinoma Cells to Topoisomerase I Inhibitors via Cooperative Modulation of Hypoxia-Inducible Factor-1?.
Liver Neoplasms, Experimental
Phosphorylation of purified Novikoff hepatoma topoisomerase I.
Phosphorylation sites for type N II protein kinase in DNA-topoisomerase I from calf thymus.
Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.
Topoisomerase I phosphorylation in vitro and in rapidly growing Novikoff hepatoma cells.
Lung Diseases
African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease.
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
Lung Diseases, Interstitial
Definition of naturally processed peptides reveals convergent presentation of autoantigenic topoisomerase-I epitopes in scleroderma.
Frequency of circulating topoisomerase-I-specific CD4 T cells predicts presence and progression of interstitial lung disease in scleroderma.
Lung Neoplasms
A Novel Inhibitor of Topoisomerase I Is Selectively Toxic for a Subset of Non-Small Cell Lung Cancer Cell Lines.
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
A phase I study of irinotecan in combination with amrubicin for advanced lung cancer patients.
A phase I study of sequential intravenous topotecan and etoposide in lung cancer patients.
A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer.
A review of topoisomerase inhibition in lung cancer.
Activity of novel cytotoxic agents in lung cancer: epothilones and topoisomerase I inhibitors.
Activity of topotecan given intravenously for 5 days every three weeks in patients with advanced non-small cell lung cancer pretreated with platinum and taxanes: a phase II study.
Altered MRP is associated with multidrug resistance and reduced drug accumulation in human SW-1573 cells.
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Caspase-mediated cleavage of DNA topoisomerase I at unconventional sites during apoptosis.
Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines.
Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
Chemosensitizing effect of podophyllotoxin acetate on topoisomerase inhibitors leads to synergistic enhancement of lung cancer cell apoptosis.
Cisplatin down-regulates topoisomerase I activity in lung cancer cell lines.
CKD-602, a camptothecin derivative, inhibits proliferation and induces apoptosis in glioma cell lines.
Cleistanthoside A tetraacetate-induced DNA damage leading to cell cycle arrest and apoptosis with the involvement of p53 in lung cancer cells.
Clinical pharmacokinetics of topotecan.
Co-dependency of PKC? and K-Ras: inverse association with cytotoxic drug sensitivity in KRAS mutant lung cancer.
Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Combination of irinotecan and etoposide for treatment of refractory or relapsed small-cell lung cancer.
Combined chemotherapy and radiation in locally advanced non-small-cell lung cancer.
Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer.
Comparison of DNA cleavage induced by etoposide and doxorubicin in two human small-cell lung cancer lines with different sensitivities to topoisomerase II inhibitors.
Comparison of topoisomerase I and II expression in primary brain tumor and lung cancer.
Correlation between BRCA1 and TopBP1 protein expression and clinical outcome of non-small cell lung cancer treated with platinum-based chemotherapy.
Correlation between topoisomerase I and tyrosyl-DNA phosphodiesterase 1 activities in non-small cell lung cancer tissue.
Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer.
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Detection of topoisomerase I gene point mutation in CPT-11 resistant lung cancer cell line.
Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
DNA topoisomerase I drugs and radiotherapy for lung cancer.
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
DNA topoisomerase I-targeting drugs as radiation sensitizers.
Downregulated ABCG2 enhances sensitivity to topoisomerase I inhibitor in epidermal growth factor receptor tyrosine kinase inhibitor-resistant non-small cell lung cancer.
E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer.
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Effects of tumor necrosis factor, alone or in combination with topoisomerase-II-targeted drugs, on human lung cancer cell lines.
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Emerging role of topotecan in first-line therapy of small-cell lung cancer.
Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases.
ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications.
Establishment and characterization of irinotecan-resistant human non-small cell lung cancer A549 cells.
Establishment of the standard regimen for non-small-cell lung cancer in Japan.
Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Expression of P-gp, MRP, LRP, GST-? and TopoII? and intrinsic resistance in human lung cancer cell lines.
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Extended topoisomerase 1 inhibition through liposomal irinotecan results in improved efficacy over topotecan and irinotecan in models of small-cell lung cancer.
Gene-specific damage produced by topoisomerase inhibitors in human lung cancer cells and peripheral mononuclear cells as assayed by polymerase chain reaction-stop assay.
Herbal Medicines for Irinotecan-Induced Diarrhea.
HIF-1alpha modulation by topoisomerase inhibitors in non-small cell lung cancer cell lines.
Higher expression of topoisomerase II in lung cancers than normal lung tissues: different expression pattern from topoisomerase I.
Identification of Natural Products That Inhibit the Catalytic Function of Human Tyrosyl-DNA Phosphodiesterase (TDP1).
IFN-? restores the impaired function of RNase L and induces mitochondria-mediated apoptosis in lung cancer.
In vitro schedule dependency in the treatment of topoisomerase I and II inhibitor.
Increased expression and activity of repair genes TDP1 and XPF in non-small cell lung cancer.
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA.
Investigation of the mechanism and apoptotic pathway induced by 4? cinnamido linked podophyllotoxins against human lung cancer cells A549.
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Irinotecan and platinums in the treatment of non small-cell lung cancer.
Irinotecan in small-cell lung cancer: current data.
Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer.
Irinotecan plus cisplatin in small-cell lung cancer.
Irinotecan therapy for small-cell lung cancer.
Long non-coding RNA LALTOP promotes non-small cell lung cancer progression by stabilizing topoisomerase II? mRNA.
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
Mechanism of action of an imidopiperidine inhibitor of human polynucleotide kinase/phosphatase.
Mining expression and prognosis of topoisomerase isoforms in non-small-cell lung cancer by using Oncomine and Kaplan-Meier plotter.
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Molecular Insight into the Interaction between Camptothecin and Acyclic Cucurbit[4]urils as Efficient Nanocontainers in Comparison with Cucurbit[7]uril: Molecular Docking and Molecular Dynamics Simulation.
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
New state of the art in small-cell lung cancer.
NF-kappa B activation in topoisomerase I inhibitor-induced apoptotic cell death in human non-small cell lung cancer.
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Nuclear Transglutaminase 2 interacts with topoisomerase II? to promote DNA damage repair in lung cancer cells.
p16INK4 expression is associated with the increased sensitivity of human non-small cell lung cancer cells to DNA topoisomerase I inhibitors.
Phase I and pharmacologic study of weekly bolus topotecan for advanced non-small-cell lung cancer.
Phase I study of sequentially administered topoisomerase I inhibitor (irinotecan) and topoisomerase II inhibitor (etoposide) for metastatic non-small-cell lung cancer.
Phase II and pharmacokinetic/pharmacodynamic trial of sequential topoisomerase I and II inhibition with topotecan and etoposide in advanced non-small-cell lung cancer.
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Phase II study of topotecan in metastatic non-small-cell lung cancer.
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer.
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
Phytochemical naphtho[1,2-b] furan-4,5?dione induced topoisomerase II-mediated DNA damage response in human non-small-cell lung cancer.
Point mutations in the topoisomerase I gene in patients with non-small cell lung cancer treated with irinotecan.
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Preliminary results of combined therapy with topotecan and carboplatin in advanced non-small-cell lung cancer.
Prevention of phosphatidylinositol 3'-kinase-Akt survival signaling pathway during topotecan-induced apoptosis.
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.
Reduced Smad4 expression and DNA topoisomerase inhibitor chemosensitivity in non-small cell lung cancer.
Removal of uracil by uracil DNA glycosylase limits pemetrexed cytotoxicity: overriding the limit with methoxyamine to inhibit base excision repair.
Reponses to topoisomerase-I inhibitors in extensive small-cell lung cancer: chance or chromosomes?
RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
Role of topoisomerase I inhibitors in small-cell lung cancer.
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked "nanosponge" network for lung cancer chemotherapy.
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Smad4 loss promotes lung cancer formation but increases sensitivity to DNA topoisomerase inhibitors.
SULF2 methylation is prognostic for lung cancer survival and increases sensitivity to topoisomerase-I inhibitors via induction of ISG15.
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Synthesis and topoisomerase I inhibitory activity of a novel diazaindeno[2,1-b]phenanthrene analogue of Lamellarin D.
Targeted therapy in non-small-cell lung cancer.
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
The association of topoisomerase 2? expression with prognosis in surgically resected non-small cell lung cancer (NSCLC) patients.
The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells.
The significance of the sequence of administration of topotecan and etoposide.
The Topoisomerase 1 Inhibitor Austrobailignan-1 Isolated from Koelreuteria henryi Induces a G2/M-Phase Arrest and Cell Death Independently of p53 in Non-Small Cell Lung Cancer Cells.
Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.
Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
Topoisomerase I inhibitors in small-cell lung cancer. The Japanese experience.
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Topoisomerase I inhibitors in the combined-modality therapy of lung cancer.
Topoisomerase I targeting agents in small-cell lung cancer.
Topoisomerase I-based nonplatinum combinations in non-small-cell lung cancer.
Topoisomerase inhibitor-induced apoptosis accompanied by down-regulation of Bcl-2 in human lung cancer cells.
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.
Transcriptional profiling of targets for combination therapy of lung carcinoma with paclitaxel and mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor.
Trastuzumab Deruxtecan: First Approval.
Treatment of non-small-cell lung cancer in North America: the emerging role of irinotecan.
Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Update on the role of topotecan in the treatment of non-small cell lung cancer.
Upregulation of Stat1-HDAC4 confers resistance to etoposide through enhanced multidrug resistance 1 expression in human A549 lung cancer cells.
[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
[Phase II clinical trials in patients with lung cancer]
[Preclinical trials from the standpoint of clinical trials]
Lupus Erythematosus, Systemic
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Autoantibodies in the diagnosis of systemic rheumatic diseases.
Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma.
Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
DNA-specific antiidiotypic antibodies in the sera of patients with autoimmune diseases.
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
Scleroderma-specific autoantibodies embedded in immune complexes mediate endothelial damage: an early event in the pathogenesis of systemic sclerosis.
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
[Anti-idiotypic and natural catalytically active antibodies]
Lupus Nephritis
Camptothecin and Topotecan, Inhibitors of Transcription Factor Fli-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells.
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan.
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Lymphatic Metastasis
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Lymphohistiocytosis, Hemophagocytic
Host-directed therapies for antimicrobial resistant respiratory tract infections.
Lymphoma
3EZ, 20Ac-ingenol-induced Apoptosis in Chemoresistant Cancers With Cyclin D1 Accumulation.
Activation of multidomain and BH3-only pro-apoptotic Bcl-2 family members in p53-defective cells.
An early phase II study of CPT-11: a new derivative of camptothecin, for the treatment of leukemia and lymphoma.
Cloning of the TIS gene suppressed by topoisomerase inhibitors.
Contribution of gene-specific lesions, DNA-replication-associated damage, and subsequent transcriptional inhibition in topoisomerase inhibitor-mediated apoptosis in lymphoma cells.
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Discrepancy between the initial DNA damage and cell survival after camptothecin treatment in two murine lymphoma L5178Y sublines.
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Effects of topoisomerase I-targeted drugs on radiation response of L5178Y sublines differentially radiation and drug sensitive.
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Evaluation of DNA topoisomerase IIalpha expression provides independent prognostic information in non-Hodgkin's lymphomas.
Herbal Medicines for Irinotecan-Induced Diarrhea.
Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial.
Molecular cloning of the genes suppressed in RVC lymphoma cells by topoisomerase inhibitors.
NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma.
Novel deazaflavin tyrosyl-DNA phosphodiesterase 2 (TDP2) inhibitors.
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas.
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
Phosphorylation of topoisomerase I in L5178Y-S cells is associated with poly(ADP-ribose) metabolism.
PKA controls a level of topoisomerase I mRNA in mouse L5178Y lymphoma cells treated with db-cAMP.
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Reduced sensitivity to camptothecin of topoisomerase I from a L5178Y mouse lymphoma subline sensitive to X-radiation.
Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L.
Study of DNA topoisomerase II? expression in canine lymphomas and its potential role as a marker of sensitivity to anthracycline-based chemotherapy in dogs.
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
The sensitivity to camptothecin of DNA topoisomerase I in L5178Y-S lymphoma cells.
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.
The water-insoluble camptothecin analogues: promising drugs for the effective treatment of haematological malignancies.
Topoisomerase I is differently phosphorylated in two sublines of L5178Y mouse lymphoma cells.
Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents.
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
Lymphoma, B-Cell
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Molecular docking and dynamics simulation study of bioactive compounds from Ficus carica L. with important anticancer drug targets.
New approaches in cancer treatment.
The expression and significance of MRP1, LRP, TOPOII?, and BCL2 in tongue squamous cell carcinoma.
Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review.
Lymphoma, B-Cell, Marginal Zone
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
Lymphoma, Large B-Cell, Diffuse
A glass fiber/diethylaminoethyl double filter binding assay that measures apoptotic internucleosomal DNA fragmentation.
Acquisition of cellular resistance to 9-nitro-camptothecin correlates with suppression of transcription factor NF-kappa B activation and potentiation of cytotoxicity by tumor necrosis factor in human histiocytic lymphoma U-937 cells.
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models.
Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
Lymphoma, Non-Hodgkin
A phase II study of topotecan in non-Hodgkin's lymphoma: an Ohio State University phase II research consortium study.
Action of topoisomerase targeting drugs on non-Hodgkin's lymphoma and leukemia. Correlation of clinical and cell culture studies.
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Phase II study of sequential topotecan and etoposide in patients with intermediate grade non-Hodgkin's lymphoma: a National Cancer Institute of Canada Clinical Trials Group study.
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Response of DNA repair enzymes in murine fibrosarcoma, lymphosarcoma and ascites cells following gamma irradiation.
The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma.
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Lymphoma, T-Cell
Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.
Malabsorption Syndromes
Bone density in Moroccan women with systemic scleroderma and its relationships with disease-related parameters and vitamin D status.
Malaria
Detection of the Malaria causing Plasmodium Parasite in Saliva from Infected Patients using Topoisomerase I Activity as a Biomarker.
Effects of camptothecin, a topoisomerase I inhibitor, on Plasmodium falciparum.
In Vitro and In Silico Characterization of an Antimalarial Compound with Antitumor Activity Targeting Human DNA Topoisomerase IB.
Optimized Detection of Plasmodium falciparum Topoisomerase I Enzyme Activity in a Complex Biological Sample by the Use of Molecular Beacons.
Radicicol-Mediated Inhibition of Topoisomerase VIB-VIA Activity of the Human Malaria Parasite Plasmodium falciparum.
Specific detection of topoisomerase I from the malaria causing P. falciparum parasite using isothermal rolling circle amplification.
The gene encoding topoisomerase I from the human malaria parasite Plasmodium falciparum.
Theoretical and Experimental Studies of New Modified Isoflavonoids as Potential Inhibitors of Topoisomerase I from Plasmodium falciparum.
Mastocytoma
A protein factor that enhances amsacrine-mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
Evidence that a protein kinase enhances amsacrine mediated formation of topoisomerase II-DNA complexes in murine mastocytoma cell nuclei.
Evidence that mAMSA induces topoisomerase action.
Regulation of topoisomerase II by murine mastocytoma cells.
Medulloblastoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Camptothecin and Fas receptor agonists synergistically induce medulloblastoma cell death: ROS-dependent mechanisms.
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.
Intermittent exposure of medulloblastoma cells to topotecan produces growth inhibition equivalent to continuous exposure.
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Topoisomerase II? immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group.
Melanoma
3-O-(E)-p-Coumaroyl Tormentic Acid from Eriobotrya japonica Leaves Induces Caspase-Dependent Apoptotic Cell Death in Human Leukemia Cell Line.
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents.
Camptothecin induces p53-dependent and -independent apoptogenic signaling in melanoma cells.
Cell cycle analysis can differentiate thin melanomas from dysplastic nevi and reveals accelerated replication in thick melanomas.
Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
DNA topoisomerase I content of a pair of human melanoma cell lines with very different radiosensitivities correlates with their in vitro sensitivities to camptothecin.
Dual inhibition of topoisomerases enhances apoptosis in melanoma cells.
Ex vivo activity of XR5000 against solid tumors.
Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes.
Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Inhibition of potentially lethal and sublethal damage repair by camptothecin and etoposide in human melanoma cell lines.
Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
Interaction of Deubiquitinase 2A-DUB/MYSM1 with DNA Repair and Replication Factors.
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells.
Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I/II clinical trial.
Preclinical and clinical activity of the topoisomerase I inhibitor, karenitecin, in melanoma.
RJT-101, a novel camptothecin derivative, is highly effective in the treatment of melanoma through DNA damage by targeting topoisomerase 1.
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma.
Meningioma
Array expression meta-analysis of cancer stem cell genes identifies upregulation of PODXL especially in DCC low expression meningiomas.
DNA topoisomerase II-alpha and cyclin A immunoexpression in meningiomas and its prognostic significance: an analysis of 263 cases.
DNA topoisomerase II? and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
Identification of gene markers associated with aggressive meningioma by filtering across multiple sets of gene expression arrays.
Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas.
Meningitis, Cryptococcal
Topoisomerase I is essential in Cryptococcus neoformans: role In pathobiology and as an antifungal target.
Mesothelioma
Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase II?, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
Microsporidiosis
Therapeutic targets for the treatment of microsporidiosis in humans.
Mitochondrial Diseases
Controlling the topology of mammalian mitochondrial DNA.
Molluscum Contagiosum
DNA contacts by protein domains of the molluscum contagiosum virus type-1B topoisomerase.
DNA contacts stimulate catalysis by a poxvirus topoisomerase.
Lamellarins, from A to Z: a family of anticancer marine pyrrole alkaloids.
Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors.
Pyrrolo[2,1-alpha]isoquinoline as a skeleton for the synthesis of bioactive lamellarin H.
Mouth Neoplasms
Comparative and Mechanistic Study on the Anticancer Activity of Quinacrine-Based Silver and Gold Hybrid Nanoparticles in Head and Neck Cancer.
Dichloromethane fraction from Gardenia jasminoides: DNA topoisomerase 1 inhibition and oral cancer cell death induction.
Optimized combinations of bortezomib, camptothecin, and doxorubicin show increased efficacy and reduced toxicity in treating oral cancer.
PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade.
Mucositis
Circadian variation of topoisomerase II-alpha in human rectal crypt epithelium: implications for reduction of toxicity of chemotherapy.
Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Multiple Myeloma
Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Effects of topoisomerase inhibitors that induce DNA damage response on glucose metabolism and PI3K/Akt/mTOR signaling in multiple myeloma cells.
Expressions of DNA topoisomerase I and II gene and the genes possibly related to drug resistance in human myeloma cells.
Monoclonal gammopathy of undetermined significance (MGUS) in patients with solid tumors: effects of chemotherapy on the monoclonal protein.
nm23, TOP2A and VEGF expression: Potential prognostic biologic factors in peripheral T-cell lymphoma, not otherwise specified.
Overexpression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma.
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Psorospermin structural requirements for P-glycoprotein resistance reversal.
The use of topoisomerase I inhibitors in multiple myeloma.
Myelodysplastic Syndromes
Activity of 9-nitro-camptothecin, an oral topoisomerase I inhibitor, in myelodysplastic syndrome and chronic myelomonocytic leukemia.
Combination of topotecan with cytarabine or etoposide in patients with refractory or relapsed acute myeloid leukemia: results of a randomized phase I/II study.
Cyclophosphamide, ara-C and topotecan (CAT) for patients with refractory or relapsed acute leukemia.
Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy.
Paclitaxel Induced MDS and AML: A Case Report and Literature Review.
Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation in patients with refractory or relapsed acute leukemia.
Possible role of edotecarin, a novel topoisomerase I inhibitor, in therapy-related myelodysplastic syndrome.
The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficient mouse model of human acute myelogenous leukemia.
Topoisomerase I inhibitors in the treatment of myelodysplastic syndromes and chronic myelomonocytic leukemia.
Topotecan, a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Myositis
Antinuclear antibodies (ANAs): diagnostically specific immune markers and clues toward the understanding of systemic autoimmunity.
Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.
Nasopharyngeal Carcinoma
[Apoptosis of nasopharyngeal carcinoma cells induced by topoisomerase I inhibitor]
[Experimental studies on treatment of nasopharyngeal carcinoma with combination regimen of hydroxycamptothecin and etoposide]
[The effect of EB virus bhrfl gene expressing on the topoisomerase I expression in nasopharyngeal carcinoma cell line]
Nasopharyngeal Neoplasms
[Zn(phen)(O,N,O)(H(2)O)] and [Zn(phen)(O,N)(H(2)O)] with O,N,O is 2,6-dipicolinate and N,O is L-threoninate: synthesis, characterization, and biomedical properties.
Neoplasm Metastasis
A model of Primary Culture of Colorectal Cancer and Liver Metastasis to Predict Chemosensitivity.
Cerebral metastases--a therapeutic update.
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Perspectives on new chemotherapeutic agents in the treatment of colorectal cancer.
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Shiquandabutangjiaweibang inhibits tumor metastasis and angiogenesis via regulation of topoisomerase-1.
Significance of topoisomerase III? expression in breast ductal carcinomas: strong associations with disease-specific survival and metastasis.
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
The novel highly lipophilic topoisomerase I inhibitor DB67 is effective in the treatment of liver metastases of murine CT-26 colon carcinoma.
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
[New drugs in metastatic breast cancer--1997]
Neoplasm, Residual
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
Neoplasms
(-)-Xanthatin up-regulation of the GADD45? tumor suppressor gene in MDA-MB-231 breast cancer cells: Role of topoisomerase II? inhibition and reactive oxygen species.
10th Conference on DNA Topoisomerases in therapy.
2"-Substituted 5-phenylterbenzimidazoles as topoisomerase I poisons.
2',5,7-Trihydroxy-4',5'-(2,2-dimethylchromeno)-8-(3-hydroxy-3-methylbutyl) flavanone purified from Cudrania tricuspidata induces apoptotic cell death of human leukemia U937 cells.
2,2'-Methylenebis (6-tert-butyl 4-methylphenol) enhances the antitumor efficacy of belotecan, a derivative of camptothecin, by inducing autophagy.
2,3-Dimethoxybenzo[i]phenanthridines: topoisomerase I-targeting anticancer agents.
2,4,6-Trisubstituted pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
2,4-Diaryl-5,6-dihydro-1,10-phenanthroline and 2,4-diaryl-5,6-dihydrothieno[2,3-h] quinoline derivatives for topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
2,6-Dithienyl-4-furyl pyridines: Synthesis, topoisomerase I and II inhibition, cytotoxicity, structure-activity relationship, and docking study.
2-deoxy-D-glucose enhances the cytotoxicity of topoisomerase inhibitors in human tumor cell lines.
2-Thienyl-4-furyl-6-aryl pyridine derivatives: synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]-propionic acid (XK469) inhibition of topoisomerase IIbeta is not sufficient for therapeutic response in human Waldenstrom's macroglobulinemia xenograft model.
2-[4-(7-chloro-2-quinoxalinyloxyphenoxy]-propionic acid (XK469), an inhibitor of topoisomerase (Topo) IIbeta, up-regulates Topo IIalpha and enhances Topo IIalpha-mediated cytotoxicity.
3-Arylisoquinolines as novel topoisomerase I inhibitors.
9-Nitrocamptothecin inhibits tumor recrosis factor-mediated activation of human immunodeficiency virus type 1 and enhances apoptosis in a latently infected T cell clone.
90-kDa heat shock protein inhibition abrogates the topoisomerase I poison-induced G2/M checkpoint in p53-null tumor cells by depleting Chk1 and Wee1.
?-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and II? in Human Hepatocarcinoma HepG-2 Cells.
?V?3-Targeted Delivery of Camptothecin-Encapsulated Carbon Nanotube-Cyclic RGD in 2D and 3D Cancer Cell Culture.
A Bioactive l-Phenylalanine-Derived Arene in Multitargeted Organoruthenium Compounds: Impact on the Antiproliferative Activity and Mode of Action.
A cocktail of MCM2 and TOP2A, p16INK4a and Ki-67 as biomarkers for the improved diagnosis of cervical intraepithelial lesion.
A comprehensive review on anticancer mechanisms of the main carotenoid of saffron, crocin.
A cysteine-reactive alkyl hydroquinone modifies topoisomerase II?, enhances DNA breakage, and induces apoptosis in cancer cells.
A Dual Topoisomerase Inhibitor of Intense Pro-Apoptotic and Antileukemic Nature for Cancer Treatment.
A dual topoisomerase inhibitor, TAS-103, induces apoptosis in human cancer cells.
A meta-analysis approach for characterizing pan-cancer mechanisms of drug sensitivity in cell lines.
A model for tumor cell killing by topoisomerase poisons.
A new mechanism of acquisition of drug resistance by partial duplication of topoisomerase I.
A new phenolic series of indenopyridinone as topoisomerase inhibitors: Design, synthesis, and structure-activity relationships.
A new series of 2-phenol-4-aryl-6-chlorophenyl pyridine derivatives as dual topoisomerase I/II inhibitors: Synthesis, biological evaluation and 3D-QSAR study.
A new topoisomerase II inhibitor, BE-22179, produced by a streptomycete. I. Producing strain, fermentation, isolation and biological activity.
A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
A novel chromatin tether domain controls topoisomerase II? dynamics and mitotic chromosome formation.
A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines.
A novel polypyrimidine antitumor agent FdUMP[10] induces thymineless death with topoisomerase I-DNA complexes.
A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
A novel topoisomerase 2a inhibitor, cryptotanshinone, suppresses the growth of PC3 cells without apparent cytotoxicity.
A novel topoisomerase I inhibitor DIA-001 induces DNA damage mediated cell cycle arrest and apoptosis in cancer cell.
A patent review of topoisomerase I inhibitors (2016-present).
A PCR-aided transcript titration assay (PATTY) to measure topoisomerase I gene expression in human tumor specimens.
A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
A phase I study of pegylated liposomal doxorubicin and irinotecan in patients with solid tumors.
A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.
A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies.
A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer.
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours.
A phase II trial of irinotecan in hormone-refractory prostate cancer.
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
A phase II trial of topotecan in esophageal carcinoma: a Southwest Oncology Group study (SWOG 9339).
A pilot study of topotecan in the treatment of serous carcinoma of the uterus.
A prospective randomized phase II trial of GM-CSF priming to prevent topotecan-induced neutropenia in chemotherapy-naive patients with malignant melanoma or renal cell carcinoma.
A protein factor from Xenopus oocytes with simian virus 40 large tumor antigen-like DNA supercoiling activity.
A quantitative RT-PCR method to determine topoisomerase I mRNA levels in human tissue samples.
A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
A study of topoisomerase activity in human testicular cancers.
A supramolecular vesicle of camptothecin for its water dispersion and controllable releasing.
A switch in mechanism of action prevents doxorubicin-mediated cardiac damage.
A tale of two tumor targets: topoisomerase I and tubulin. The Wall and Wani contribution to cancer chemotherapy.
A terbenzimidazole that preferentially binds and conformationally alters structurally distinct DNA duplex domains: a potential mechanism for topoisomerase I poisoning.
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Abrogation of the S phase DNA damage checkpoint results in S phase progression or premature mitosis depending on the concentration of 7-hydroxystaurosporine and the kinetics of Cdc25C activation.
Aclarubicin, an anthracycline anti-cancer drug, fluorescently contrasts mitochondria and reduces the oxygen consumption rate in living human cells.
Acoustically active perfluorocarbon nanoemulsions as drug delivery carriers for camptothecin: drug release and cytotoxicity against cancer cells.
Activation of a PGC-1-related Coactivator (PRC)-dependent Inflammatory Stress Program Linked to Apoptosis and Premature Senescence.
Activation of camptothecin derivatives by conjugation to triple helix-forming oligonucleotides.
Activation of caspases measured in situ by binding of fluorochrome-labeled inhibitors of caspases (FLICA): correlation with DNA fragmentation.
Activation of chymotrypsin-like serine protease(s) during apoptosis detected by affinity-labeling of the enzymatic center with fluoresceinated inhibitor.
Activation of programmed cell death by recombinant human tumor necrosis factor plus topoisomerase II-targeted drugs in L929 tumor cells.
Actively targeted low-dose camptothecin as a safe, long-acting, disease-modifying nanomedicine for rheumatoid arthritis.
Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Activity of intoplicine (RP60475), a new DNA topoisomerase I and II inhibitor, against human tumor colony-forming units in vitro.
Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro.
Acute presentation of rheumatoid arthritis following cancer chemotherapy using the topoisomerase I inhibitor irinotecan.
Addition of a topoisomerase I inhibitor to trimodality therapy [cis-diamminedichloroplatinum(II)/heat/radiation] in a murine tumor.
Adeno-associated virus mediated endostatin gene therapy in combination with topoisomerase inhibitor effectively controls liver tumor in mouse model.
Allosteric inhibition of topoisomerase I by pinostrobin: Molecular docking, spectroscopic and topoisomerase I activity studies.
Alpha, beta-unsaturated lactones 2-furanone and 2-pyrone induce cellular DNA damage, formation of topoisomerase I- and II-DNA complexes and cancer cell death.
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.
An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies.
An Insight into the Mechanism of Holamine- and Funtumine-Induced Cell Death in Cancer Cells.
An overview of topoisomerase I-targeting agents.
Analogues of distamycin--synthesis and biological evaluation of new aromatic oligopeptides, potential anticancer agents.
Analysis of bisdioxopiperazine dexrazoxane binding to human DNA topoisomerase II alpha: decreased binding as a mechanism of drug resistance.
Analysis of common gene expression patterns in four human tumor cell lines exposed to camptothecin using cDNA microarray: identification of topoisomerase-mediated DNA damage response pathways.
Analysis of plant-derived phytochemicals as anti-cancer agents targeting cyclin dependent kinase-2, human topoisomerase IIa and vascular endothelial growth factor receptor-2.
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Andrographolide potentiates the antitumor effect of topotecan in acute myeloid leukemia cells through an intrinsic apoptotic pathway.
Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host.
Anthracyclines.
Anti-cancer agents in Saudi Arabian herbals revealed by automated high-content imaging.
Anti-leukemic action of the novel agent MGI 114 (HMAF) and synergistic action with topotecan.
Anti-lung cancer activity and inhibitory mechanisms of a novel Calothrixin A derivative.
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Anti-tumor activity of CPT-11 in experimental human ovarian cancer and human soft-tissue sarcoma.
Antiangiogenesis response of endothelial cells to the antitumour drug 10-methoxy-9-nitrocamptothecin.
Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy.
Anticancer Activity of BIM-46174, a New Inhibitor of the Heterotrimeric G{alpha}/G{beta}{gamma} Protein Complex.
Anticancer Activity of Indeno[1,2-b]-Pyridinol Derivative as a New DNA Minor Groove Binding Catalytic Inhibitor of Topoisomerase II?.
Anticancer and Antiviral Properties of Cardiac Glycosides: A Review to Explore the Mechanism of Actions.
Anticancer and Cytotoxic activities of [Cu(C6H16N2O2)2][Ni(CN)4] and [Cu(C6H16N2O2)Pd(CN)4] Cyanidometallate Compounds on HT29, HeLa, C6 and Vero Cell Lines.
Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361.
Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Anticancer drug response and expression of molecular markers in early-passage xenotransplanted colon carcinomas.
Anticancer effects of CKD-602 (Camtobell(®)) via G2/M phase arrest in oral squamous cell carcinoma cell lines.
Anticancer Properties of Lamellarins.
Anticarcinogenic Effects of Dietary Phytoestrogens and Their Chemopreventive Mechanisms.
Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan.
Antiproliferative activity of O4-benzo[c]phenanthridine alkaloids against HCT-116 and HL-60 tumor cells.
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Antisense anti-MDM2 mixed-backbone oligonucleotides enhance therapeutic efficacy of topoisomerase I inhibitor irinotecan in nude mice bearing human cancer xenografts: In vivo activity and mechanisms.
Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
Antitumor activities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB.
Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Antitumor Activity of Asperphenin A, a Lipopeptidyl Benzophenone from Marine-Derived Aspergillus sp. Fungus, by Inhibiting Tubulin Polymerization in Colon Cancer Cells.
Antitumor activity of edotecarin in breast carcinoma models.
Antitumor activity of palmitic acid found as a selective cytotoxic substance in a marine red alga.
Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Antitumor activity of XR5944, a novel and potent topoisomerase poison.
Antitumor effect of irinotecan hydrochloride (CPT-11) on human renal tumors heterotransplanted in nude mice.
Antitumor potential of a novel camptothecin derivative, ZBH-ZM-06.
Antitumor triptycene analogs directly interact with isolated mitochondria to rapidly trigger markers of permeability transition.
Antitumor triptycene bisquinones induce a caspase-independent release of mitochondrial cytochrome c and a caspase-2-mediated activation of initiator caspase-8 and -9 in HL-60 cells by a mechanism which does not involve Fas signaling.
Antitumor triptycene bisquinones: a novel synthetic class of dual inhibitors of DNA topoisomerase I and II activities.
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Antitumour activity of DX-8951f: a new camptothecin derivative.
Antitumour drug design: DNA-binding ligands, which inhibit the topoisomerase I.
Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumors: preclinical in vitro/in vivo studies.
Apoptosis by genetic engineering.
Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Apoptosis is the most efficient death-pathway in tumor cells after topoisomerase II inhibition.
Apoptosis of S-phase HL-60 cells induced by DNA topoisomerase inhibitors: detection of DNA strand breaks by flow cytometry using the in situ nick translation assay.
Application of topoisomerase assays in the evaluation of natural products as antitumor agents.
ARC-111 inhibits hypoxia-mediated hypoxia-inducible factor-1alpha accumulation.
Assessing the interaction of irradiation with etoposide or idarubicin.
Assessment of topoisomerase II-alpha gene status by dual color chromogenic
Association of epigenetic inactivation of the WRN gene with anticancer drug sensitivity in cervical cancer cells.
Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.
Ataxia Telangiectasia-Mutated and Rad3-Related Inhibition and Topoisomerase I Trapping Create a Synthetic Lethality in Cancer Cells.
ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells.
ATR inhibitors VE-821 and VX-970 sensitize cancer cells to topoisomerase i inhibitors by disabling DNA replication initiation and fork elongation responses.
B-ring-aryl substituted luotonin A analogues with a new binding mode to the topoisomerase 1-DNA complex show enhanced cytotoxic activity.
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Barking up the wrong genome - we are not alone.
Basal-like subtype and BRCA1 dysfunction in breast cancers.
BCL-2, topoisomerase II?, microvessel density and prognosis of early advanced breast cancer patients after adjuvant anthracycline-based chemotherapy.
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
BD ProEx C: a sensitive and specific marker of HPV-associated squamous lesions of the cervix.
Benzoxazines as new human topoisomerase I inhibitors and potential poisons.
Beyond the unwinding: role of TOP1MT in mitochondrial translation.
Beyond topoisomerase inhibition: antitumor 1,4-naphthoquinones as potential inhibitors of human monoamine oxidase.
BID Preferentially Activates BAK while BIM Preferentially Activates BAX, Affecting Chemotherapy Response.
Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance.
Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology.
Biodistribution of NX211, liposomal lurtotecan, in tumor-bearing mice.
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Biological activity of the tryprostatins and their diastereomers on human carcinoma cell lines.
Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase II? inhibitors.
Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions.
Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development.
BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II.
Bone marrow and tumor cell colony-forming units and human tumor xenograft efficacy of noncamptothecin and camptothecin topoisomerase I inhibitors.
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Brostallicin: a new concept in minor groove DNA binder development.
Bufalin influences the repair of X-ray-induced DNA breaks in Chinese hamster cells.
Caffeic acid and quercitrin purified from Houttuynia cordata inhibit DNA topoisomerase I activity.
Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.
Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
Camptothecin analogs with bulky, hydrophobic substituents at the 7-position via a Grignard reaction.
Camptothecin and 9-nitrocamptothecin (9NC) as anti-cancer, anti-HIV and cell-differentiation agents. Development of resistance, enhancement of 9NC-induced activities and combination treatments in cell and animal models.
Camptothecin and taxol: historic achievements in natural products research.
Camptothecin antitumor agents.
Camptothecin conjugated with DNA minor-groove binder netropsin: enhanced lactone stability, inhibition of human DNA topoisomerase I and antiproliferative activity.
Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Camptothecin in sterically stabilized phospholipid nano-micelles: a novel solvent pH change solubilization method.
Camptothecin induces c-Myc- and Sp1-mediated hTERT expression in LNCaP cells: Involvement of reactive oxygen species and PI3K/Akt.
Camptothecin post-treatments inhibit the biochemical events linked to the tumor-promoting component of carcinogenesis in mouse epidermis in vivo.
Camptothecin promotes the production of nitric oxide that triggers subsequent S-nitrosoproteome-mediated signaling cascades in endothelial cells.
Camptothecin Resistance in Cancer: Insights into the Molecular Mechanisms of a DNA damaging Drug.
Camptothecin targets WRN protein: mechanism and relevance in clinical breast cancer.
Camptothecin's journey from discovery to WHO Essential Medicine: Fifty years of promise.
Camptothecins: a review of their chemotherapeutic potential.
Camptothecins: a review of their development and schedules of administration.
Cancer cell mitochondria are direct proapoptotic targets for the marine antitumor drug lamellarin d.
Cancer chemopreventive potential of aromathecins and phenazines, novel natural product derivatives.
Cancer Essential Genes Stratified Lung Adenocarcinoma Patients with Distinct Survival Outcomes and Identified a Subgroup from the Terminal Respiratory Unit Type with Different Proliferative Signatures in Multiple Cohorts.
Cancer Targeted Enzymatic Theranostic Prodrug: Precise Diagnosis and Chemotherapy.
Cancer-Stroma Targeting Therapy by Cytotoxic Immunoconjugate Bound to the Collagen 4 Network in the Tumor Tissue.
Carboxylesterases expressed in human colon tumor tissue and their role in CPT-11 hydrolysis.
Cardiac glycosides in cancer research and cancer therapy.
Catalytic inhibition of eukaryotic topoisomerases I and II by flavonol glycosides extracted from Vicia faba and Lotus edulis.
CD117, CK20, TTF-1, and DNA topoisomerase II-alpha antigen expression in small cell tumors.
Cell-based assays for profiling activity and safety properties of cancer drugs.
Cellular and molecular responses to topoisomerase I poisons. Exploiting synergy for improved radiotherapy.
Cellular bases of the antitumor activity of a 7-substituted camptothecin in hormone-refractory human prostate carcinoma models.
Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study.
Cellular resistance to topoisomerase-targeted drugs: from drug uptake to cell death.
Cellular stress triggers the human topoisomerase I damage response independently of DNA damage in a p53 controlled manner.
CES2, ABCG2, TS and Topo-I primary and synchronous metastasis expression and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI regimen.
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Characterization of a human small-cell lung cancer cell line resistant to a new water-soluble camptothecin derivative, DX-8951f.
Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.
Characterization of novel Checkpoint kinase 1 inhibitors by in vitro assays and in human cancer cells treated with topoisomerase inhibitors.
Characterization of protein kinase chk1 essential for the cell cycle checkpoint after exposure of human head and neck carcinoma A253 cells to a novel topoisomerase I inhibitor BNP1350.
Characterization of the 3' region of the human DNA topoisomerase I gene.
Characterization of the antitumor-promoting activity of camptothecin in SENCAR mouse skin.
Characterization of topotecan-mediated redistribution of DNA topoisomerase I by digital imaging microscopy.
Checkpoint inhibition of origin firing prevents DNA topological stress.
Chemopotentiation by PARP inhibitors in cancer therapy.
Chemosensitivity testing--present and future in Japan.
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo.
Chiral ruthenium(II) complexes with phenolic hydroxyl groups as dual poisons of topoisomerases I and II?.
Chitosan-Dextran sulfate coated doxorubicin loaded PLGA-PVA-nanoparticles caused apoptosis in doxorubicin resistance breast cancer cells through induction of DNA damage.
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Circadian regulation of mouse topoisomerase I gene expression by glucocorticoid hormones.
Circadian rhythm of irinotecan tolerability in mice.
Circumventing multidrug resistance in cancer by beta-galactoside binding protein, an antiproliferative cytokine.
Circumvention of atypical multidrug resistance with tumor necrosis factor.
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Cisplatin enhances the p53-independent apoptosis induced by a topoisomerase I inhibitor (CPT-11) in the lens epithelial tumors in transgenic mice.
CK2-mediated hyperphosphorylation of topoisomerase I targets serine 506, enhances topoisomerase I-DNA binding, and increases cellular camptothecin sensitivity.
Clinical advances with topoisomerase I inhibitors in gastrointestinal malignancies.
Clinical applications of the camptothecins.
Clinical pharmacokinetics of encapsulated oral 9-aminocamptothecin in plasma and saliva.
Clinical pharmacokinetics of irinotecan.
Clinical pharmacokinetics of topotecan.
Clinical phase II study and pharmacological evaluation of rubitecan in non-pretreated patients with metastatic colorectal cancer-significant effect of food intake on the bioavailability of the oral camptothecin analogue.
Clinical resistance to topoisomerase-targeted drugs.
Clinical status and optimal use of topotecan.
Cloning of Chinese hamster DNA topoisomerase I cDNA and identification of a single point mutation responsible for camptothecin resistance.
Co-amplification of erbB2, topoisomerase II alpha and retinoic acid receptor alpha genes in breast cancer and allelic loss at topoisomerase I on chromosome 20.
Co-expression of cancer testis antigens and topoisomerase 2-alpha in triple negative breast carcinomas.
Co-targeting cancer drug escape pathways confers clinical advantage for multi-target anticancer drugs.
Collateral sensitivity of natural products in drug-resistant cancer cells.
Combating liver cancer through GO-targeted biomaterials.
Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts.
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Combination Treatment of CI-994 With Etoposide Potentiates Anticancer Effects Through a Topoisomerase II-Dependent Mechanism in Atypical Teratoid/Rhabdoid Tumor (AT/RT).
Combinational effect of topotecan and octreotide on murine leukemia cells in vivo and in vitro.
Comparative drug screening in NUT midline carcinoma.
Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells.
Comprehensive evaluation of carboxylesterase-2 expression in normal human tissues using tissue array analysis.
Computational screening of chalcones acting against topoisomerase II? and their cytotoxicity towards cancer cell lines.
Computational Study of Anticancer Drug Resistance Caused by 10 Topisomerase I Mutations, Including 7 Camptothecin Analogs and Lucanthone.
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Concomitant exposure of ovarian cancer cells to docetaxel, CPT-11 or SN-38 and adenovirus-mediated p53 gene therapy.
Conjugation with polyamines enhances the antitumor activity of naphthoquinones against human glioblastoma cells.
Contribution of genotoxic anticancer treatments to the development of multiple primary tumours in the context of germline TP53 mutations.
Contribution of immunohistochemistry in prognostic assessment of epithelial ovarian carcinoma --review of the literature I.
Controlled release of 9-nitro-20(S)-camptothecin from methoxy poly(ethylene glycol)-poly(D,L-lactide) micelles.
Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex.
Coordinated regulation of mitochondrial topoisomerase IB with mitochondrial nuclear encoded genes and MYC.
Copper Complexes as Anticancer Agents Targeting Topoisomerases I and II.
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers.
Correction: Cytocidal Activities of Topoisomerase 1 Inhibitors and 5-Azacytidine against Pheochromocytoma/Paraganglioma Cells in Primary Human Tumor Cultures and Mouse Cell Lines.
Correction: The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.
Correspondence re: M. Provencio, et al. the topoisomerase IIa expression correlates with survival in patients with advanced Hodgkin's lymphoma. Clin. Cancer Res., 9: 1406-1411, 2003.
Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
CPT-11 converting carboxylesterase and topoisomerase activities in tumour and normal colon and liver tissues.
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.
CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype.
CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.
Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I alterations.
Cross-sensitivity to x-radiation and type-I and type-ii DNA topoisomerase inhibitors in a range of human and rodent cell-lines.
Crystal structure of the Geobacillus stearothermophilus carboxylesterase Est55 and its activation of prodrug CPT-11.
CTDSP1 inhibitor rabeprazole regulates DNA-PKcs dependent topoisomerase I degradation and irinotecan drug resistance in colorectal cancer.
Cucurbitane triterpenes from the fruiting bodies and cultivated mycelia of Leucopaxillus gentianeus.
Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.
Current status and perspectives in the development of camptothecins.
Current updates on microRNAs as regulators of chemoresistance.
Cyanobacterial Metabolite Calothrixins: Recent Advances in Synthesis and Biological Evaluation.
Cyclane-aminol 10-hydroxycamptothecin analogs as novel DNA topoisomerase I inhibitors induce apoptosis selectively in tumor cells.
Cyclometalated gold(iii) complexes with N-heterocyclic carbene ligands as topoisomerase I poisons.
Cyclooxygenase-2 inhibition with celecoxib enhances antitumor efficacy and reduces diarrhea side effect of CPT-11.
Cytochrome P450 3A-mediated metabolism of the topoisomerase I inhibitor 9-aminocamptothecin: impact on cancer therapy.
Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients.
Cytotoxic compounds from Annonaceus species as DNA topoisomerase I poisons.
Cytotoxic mechanism of flavonoid from Temu Kunci (Kaempferia pandurata) in cell culture of human mammary carcinoma.
Cytotoxic pyrroloiminoquinones from four new species of South African latrunculid sponges.
Cytotoxicity and preliminary mode of action studies of novel 2-aryl-4-thiopyrone-based organometallics.
Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel transplatinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells.
Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as determined by a monoclonal antibody.
Decreased serum levels of carboxylesterase-2 in patients with ovarian cancer.
Degradation of DNA topoisomerase I by a novel trypsin-like serine protease in proliferating human T lymphocytes.
Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.
Design and synthesis of a fluoroindolocarbazole series as selective topoisomerase I active agents. Discovery of water-soluble 3,9-difluoro-12,13-dihydro-13-[6-amino-beta-D-glucopyranosyl]-5H,13H-benzo[b]- thienyl[2,3-a]pyrrolo[3,4-c]carbazole- 5,7(6H)-dione (BMS-251873) with curative antitumor activity against prostate carcinoma xenograft tumor model.
Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents.
Design and synthesis of N-methylmaleimide indolocarbazole bearing modified 2-acetamino acid moieties as Topoisomerase I inhibitors.
Design and synthesis of novel 2,4-diaryl-5H-indeno[1,2-b]pyridine derivatives, and their evaluation of topoisomerase inhibitory activity and cytotoxicity.
Design of antineoplastic agents on the basis of the "2-phenylnaphthalene-type" structural pattern. 2. Synthesis and biological activity studies of benzo]b]naphtho[2,3-d]furan-6,11-dione derivatives.
Design of topoisomerase inhibitors to overcome MDR1-mediated drug resistance.
Design, synthesis and biological evaluation of 3-nitro-1,8-naphthalimides as potential antitumor agents.
Design, Synthesis and Cytotoxicity Evaluation of New 3, 5-Disubstituted-2-Thioxoimidazolidinones.
Design, synthesis and docking study of 5-amino substituted indeno[1,2-c]isoquinolines as novel topoisomerase I inhibitors.
Design, synthesis and topoisomerase II inhibition activity of 4'-demethylepipodophyllotoxin-lexitropsin conjugates.
Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
Design, synthesis, and biological evaluation of 1,3-diarylisoquinolines as novel topoisomerase I catalytic inhibitors.
Design, synthesis, and biological evaluation of cytotoxic 11-alkenylindenoisoquinoline topoisomerase I inhibitors and indenoisoquinoline-camptothecin hybrids.
Design, synthesis, and biological evaluation of indenoisoquinoline topoisomerase I inhibitors featuring polyamine side chains on the lactam nitrogen.
Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.
Design, synthesis, and evaluation of psorospermin/quinobenzoxazine hybrids as structurally novel antitumor agents.
Determinants of cellular sensitivity to topoisomerase-targeting antitumor drugs.
Determination of 9-nitrocamptothecin by precolumn derivatization and its metabolite 9-aminocamptothecin in a biological fluid using reversed-phase high-performance liquid chromatography with fluorescence detection.
Determination of synthetic lethal interactions in KRAS oncogene-dependent cancer cells reveals novel therapeutic targeting strategies.
Determination of the novel topoisomerase I inhibitor NU/ICRF 505 and its major metabolite in plasma, tissue and tumour by high-performance liquid chromatography.
Developing a Phosphospecific IHC Assay as a Predictive Biomarker for Topoisomerase I Inhibitors.
Development and characterization of five cell models for chemoresistance studies of human ovarian carcinoma.
Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues.
Development of a quantitative pharmacodynamic assay for apoptosis in fixed tumor tissue and its application in distinguishing cytotoxic drug-induced DNA double strand breaks from DNA double strand breaks associated with apoptosis.
Development of New ADC Technology with Topoisomerase I Inhibitor.
Dianhydrogalactitol synergizes with topoisomerase poisons to overcome DNA repair activity in tumor cells.
Diazoniapolycyclic ions inhibit the activity of topoisomerase I and the growth of certain tumor cell lines.
Dietary phytoestrogens.
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
Differences between normal and ras-transformed NIH-3T3 cells in expression of the 170kD and 180kD forms of topoisomerase II.
Differential activity of topotecan, irinotecan and SN-38 in fresh human tumour cells but not in cell lines.
Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug resistant sublines in vitro.
Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Differential effect of camptothecin treatment on topoisomerase II alpha expression in ML-1 and HL-60 leukemia cell lines.
Differential expression of DNA topoisomerase I gene between CPT-11 acquired- and native-resistant human pancreatic tumor cell lines: detected by RNA/PCR-based quantitation assay.
Differential expression of DNA topoisomerases in non-small cell lung cancer and normal lung.
Differential increase in topoisomerase II in simian virus 40-infected cells.
Differential regulation of p21waf-1/cip-1 and Mdm2 by etoposide: etoposide inhibits the p53-Mdm2 autoregulatory feedback loop.
Differential response of tumor cells and normal fibroblasts to fractionated combined treatment with topotecan and ionizing radiation.
Differentiated Human Colorectal Cancer Cells Protect Tumor-Initiating Cells from Irinotecan.
Differentiation-inducing activity of lupane triterpenes on a mouse melanoma cell line.
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype.
Dihydroxylated 2,4,6-triphenyl pyridines: Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study.
Dihydroxylated 2,6-diphenyl-4-chlorophenylpyridines: Topoisomerase I and II? dual inhibitors with DNA non-intercalative catalytic activity.
Dioscin, a natural steroid saponin, induces apoptosis and DNA damage through reactive oxygen species: A potential new drug for treatment of glioblastoma multiforme.
Discovery and Biological Evaluations of Halogenated 2,4-Diphenyl Indeno[1,2-b]pyridinol Derivatives as Potent Topoisomerase II?-Targeted Chemotherapeutic Agents for Breast Cancer.
Discovery of 5-(or 6)-benzoxazoles and oxazolo[4,5-b]pyridines as novel candidate antitumor agents targeting hTopo II?.
Discovery of Camptothecin based Topoisomerase I Inhibitors: Identification Using an Atom based 3D-QSAR, Pharmacophore Modeling, Virtual Screening and Molecular Docking Approach.
Discovery of cell-permeable inhibitors that target the BRCT domain of BRCA1 protein by using a small-molecule microarray.
Discovery of DNA Topoisomerase I Inhibitors with Low-Cytotoxicity Based on Virtual Screening from Natural Products.
Discovery of Novel Sultone Fused Berberine Derivatives as Promising Tdp1 Inhibitors.
Discovery of potent indenoisoquinoline topoisomerase I poisons lacking the 3-nitro toxicophore.
Dissecting the transcriptional functions of human DNA topoisomerase I by selective inhibitors: Implications for physiological and therapeutic modulation of enzyme activity.
Distinct requirements for the Rad32(Mre11) nuclease and Ctp1(CtIP) in the removal of covalently bound topoisomerase I and II from DNA.
Distribution bias and biochemical characterization of TOP1MT single nucleotide variants.
DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin.
DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH.
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
DNA damage persistence as determinant of tumor sensitivity to the combination of Topo I inhibitors and telomere-targeting agents.
DNA Polymerase theta (POLQ) is important for repair of DNA double-strand breaks caused by fork collapse.
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
DNA topoisomerase I and II in cancer chemotherapy: update and perspectives.
DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
DNA topoisomerase i as a transcription protein and a lethal cellular toxin.
DNA topoisomerase I as one of the cellular targets of certain tyrphostin derivatives.
DNA topoisomerase I in oncology: Dr Jekyll or Mr Hyde?
DNA topoisomerase I inhibitor, ergosterol peroxide from Penicillium oxalicum.
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
DNA topoisomerase I phosphorylation in murine fibroblasts treated with 12-O-tetradecanoylphorbol-13-acetate and in vitro by protein kinase.
DNA topoisomerase I-targeting drugs as radiation sensitizers.
DNA topoisomerase II as a potential factor in drug resistance of human malignancies.
DNA Topoisomerase II Enzymes as Molecular Targets for Cancer Chemotherapy.
DNA topoisomerase II mutations and resistance to anti-tumor drugs.
DNA Topoisomerase II-alpha as a marker of cell proliferation in endocrine and other neoplasms.
DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival.
DNA topoisomerase II-alpha immunoreactivity as a marker of tumor aggressiveness in invasive breast cancer.
DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides.
DNA topoisomerase II? and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.
DNA Topoisomerase III Alpha Regulates p53-Mediated Tumor Suppression.
DNA topoisomerase-targeting antitumor agents and drug resistance.
DNA topoisomerases and the DNA lesion in human genetic instability syndromes.
DNA topoisomerases as anticancer drug targets: from the laboratory to the clinic.
DNA topoisomerases in cancer chemotherapy: using enzymes to generate selective DNA damage.
DNA topoisomerases in therapy--tenth conference. 6-8 October 1999, Amsterdam, The Netherlands.
DNA Topology and Topoisomerases: Teaching a "Knotty" Subject.
DNA-interactive agents.
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Down-regulation of topoisomerase II by camptothecin does not prevent additive activity of the topoisomerase II inhibitor etoposide in vitro.
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins.
Drugging topoisomerases: lessons and challenges.
Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Dual topoisomerase I/II inhibitors in cancer therapy.
Dual-acting histone deacetylase-topoisomerase I inhibitors.
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
DX-8951f: summary of phase I clinical trials.
E-pharmacophore guided discovery of pyrazolo[1,5-c]quinazolines as dual inhibitors of topoisomerase-I and histone deacetylase.
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
ED-110, a novel indolocarbazole, prevents the growth of experimental tumors in mice.
Edotecarin.
Effect of chlorine substituent on cytotoxic activities: Design and synthesis of systematically modified 2,4-diphenyl-5H-indeno[1,2-b]pyridines.
Effect of Pterostilbene, a Natural Derivative of Resveratrol, in the Treatment of Colorectal Cancer through Top1/Tdp1-Mediated DNA Repair Pathway.
Effective conversion of irinotecan to SN-38 after intratumoral drug delivery to an intracranial murine glioma model in vivo.
Effects of albaconol from the basidiomycete Albatrellus confluens on DNA topoisomerase II-mediated DNA cleavage and relaxation.
Effects of camptothecin, an inhibitor of DNA topoisomerase I on ribosomal gene structure and function in TG cells.
Effects of cinobufacini injection on cell proliferation and the expression of topoisomerases in human HepG-2 hepatocellular carcinoma cells.
Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
Effects of inhibitors of topoisomerases-I and topoisomerases-ii on DNA methylation and DNA-synthesis in human colonic adenocarcinoma cells-invitro.
Effects of minor groove binding drugs on camptothecin-induced DNA lesions in L1210 nuclei.
Effects of plant phenolics and grape extracts from Greek varieties of Vitis vinifera on Mitomycin C and topoisomerase I-induced nicking of DNA.
Effects of resveratrol on topoisomerase II-? activity: induction of micronuclei and inhibition of chromosome segregation in CHO-K1 cells.
Effects of topoisomerases inhibitors protoberberine on Leishmania donovani growth, macrophage function, and infection.
Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional anticancer agents: retention of activity against various mdr phenotypes and unusual cytotoxicity against ERCC2 and ERCC3 DNA helicase-deficient cells.
Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors.
EGCG regulates the cross-talk between JWA and topoisomerase II? in non-small-cell lung cancer (NSCLC) cells.
Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy.
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Elevation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer chemotherapy.
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Elevations of DNA topoisomerase I in invasive carcinoma of the breast.
Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression.
Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.
Elucidation of Mechanisms of Topotecan-Induced Cell Death in Human Breast MCF-7 Cancer Cells by Gene Expression Analysis.
Emerging DNA topisomerase inhibitors as anticancer drugs.
Encapsulation of the topoisomerase I inhibitor GL147211C in pegylated (STEALTH) liposomes: pharmacokinetics and antitumor activity in HT29 colon tumor xenografts.
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.
Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.
Enhanced killing of cancer cells by poly(ADP-ribose) polymerase inhibitors and topoisomerase I inhibitors reflects poisoning of both enzymes.
Enhanced malignant transformation is accompanied by increased survival recovery after ionizing radiation in Chinese hamster embryo fibroblasts.
Enhanced Stability of the Pharmacologically Active Lactone Form of 10-Hydroxycamptothecin by Self-Microemulsifying Drug Delivery Systems.
Enhanced topoisomerase I activity and increased topoisomerase II alpha content in cisplatin-resistant cancer cell lines.
Enhanced tumor killing by Apo2L/TRAIL and CPT-11 co-treatment is associated with p21 cleavage and differential regulation of Apo2L/TRAIL ligand and its receptors.
Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents.
Entrapment of DNA topoisomerase-DNA complexes by nucleotide/nucleoside analogs.
Environment-Sensitive Polymeric Micelles Encapsulating SN-38 Potently Suppress Growth of Neuroblastoma Cells Exhibiting Intrinsic and Acquired Drug Resistance.
Enzymatic O-Glycosylation of Etoposide Aglycone by Exploration of the Substrate Promiscuity for Glycosyltransferases.
Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer.
Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer.
ERK3 regulates TDP2-mediated DNA damage response and chemoresistance in lung cancer cells.
Establishment and characterization of 18 human colorectal cancer cell lines.
Etirinotecan pegol for the treatment of breast cancer.
Etoposide induction of tumor immunity in Lewis lung cancer.
Etoposide, topoisomerase II and cancer.
Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes.
Evaluation of topoisomerase I catalytic activity as determinant of drug response in human cancer cell lines.
Evaluation of topoisomerase I/topoisomerase IIalpha status in esophageal cancer.
Evaluation of topotecan in resistant and relapsing multiple myeloma: a Southwest Oncology Group study.
Evodiamine and rutaecarpine alkaloids as highly selective transient receptor potential vanilloid 1 agonists.
Evolutionary trace analysis of eukaryotic DNA topoisomerase I superfamily: identification of novel antitumor drug binding site.
Ex vivo activity of XR5000 against solid tumors.
Ex vivo characterization of XR11576 (MLN576) against ovarian cancer and other solid tumors.
Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer.
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).
Exon array analyses across the NCI-60 reveal potential regulation of TOP1 by transcription pausing at guanosine quartets in the first intron.
Experience with irinotecan for the treatment of malignant glioma.
Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice.
Exploration of acridine scaffold as a potentially interesting scaffold for discovering novel multi-target VEGFR-2 and Src kinase inhibitors.
Exploring DNA topoisomerase I ligand space in search of novel anticancer agents.
Exploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.
Exploring the DNA binding/cleavage, cellular accumulation and topoisomerase inhibition of 2-hydroxy-3-(aminomethyl)-1,4-naphthoquinone Mannich bases and their platinum(II) complexes.
Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon.
Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival.
Expression of DNA topoisomerase I, DNA topoisomerase II-alpha, and p53 in metastatic malignant melanoma.
Expression of DNA topoisomerase IIalpha in oligodendroglioma.
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Expression of growth-related genes and drug-resistance genes in HTLV-I-positive and HTLV-I-negative post-thymic T-cell malignancies.
Expression of meiotic genes in the germline progenitors of Drosophila embryos.
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
Expression of multidrug resistance-related genes (mdrl, MRP, GST-pi and DNA topoisomerase II) in urothelial cancers.
Expression of p53 and selected proliferative markers (Ki-67, MCM3, PCNA, and topoisomerase II?) in borderline ovarian tumors: Correlation with clinicopathological features.
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
Expression of Topoisomerase 1 and carboxylesterase 2 correlates with irinotecan treatment response in metastatic colorectal cancer.
Expression of Topoisomerase II-? protein in salivary gland tumors.
Expression of topoisomerase IIIalpha in normal and neoplastic tissues determined by immunohistochemistry using a novel monoclonal antibody.
Expression profiles analysis identifies the values of carcinogenesis and the prognostic prediction of three genes in adrenocortical carcinoma.
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
Extraskeletal Myxoid Chondrosarcoma of the Vulva With PLAG1 Gene Activation: Molecular Genetic Characterization of 2 Cases.
Extravascular transport of the DNA intercalator and topoisomerase poison N-[2-(Dimethylamino)ethyl]acridine-4-carboxamide (DACA): diffusion and metabolism in multicellular layers of tumor cells.
Features of potentially predictive biomarkers of chemotherapeutic efficacy in small cell lung cancer.
Fine-Tuning the Activation Mode of an 1,3-Indandione-Based Ruthenium(II)-Cymene Half-Sandwich Complex by Variation of Its Leaving Group.
Fish oil supplementation enhanced CPT-11 (irinotecan) efficacy against MCF7 breast carcinoma xenografts and ameliorated intestinal side-effects.
Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR-associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIalpha) in 57 newly diagnosed acute myeloid leukaemias. Swiss Group for Clinical Cancer Research (SAKK).
Formulation of injectable glycyrrhizic acid-hydroxycamptothecin micelles as new generation of DNA topoisomerase I inhibitor for enhanced antitumor activity.
FPDHP, a novel anticancer agent, induces cell detachment and caspase-dependent apoptosis in Caki cells.
Functional expression of human DNA topoisomerase I and its subcellular localization in HeLa cells.
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.
Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.
Geminin deficiency enhances survival in a murine medulloblastoma model by inducing apoptosis of preneoplastic granule neuron precursors.
Gene expression of DNA topoisomerases I, II alpha and II beta and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Gene expression profiling of adrenal cortical tumors by cDNA macroarray analysis. Results of a preliminary study.
Gene mutation analysis and quantitation of DNA topoisomerase I in previously untreated non-small cell lung carcinomas.
Genetic toxicity of cytokines.
Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan.
Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients.
Genotoxic effects of topoisomerase poisoning and PARP inhibition on zebrafish embryos.
Genz-644282, a Novel Non-Camptothecin Topoisomerase I Inhibitor for Cancer Treatment.
Gimatecan, a novel camptothecin with a promising preclinical profile.
Gli1 protein regulates the S-phase checkpoint in tumor cells via Bid protein, and its inhibition sensitizes to DNA topoisomerase 1 inhibitors.
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Gold(III) complexes of pyridyl- and isoquinolylamido ligands: structural, spectroscopic, and biological studies of a new class of dual topoisomerase I and II inhibitors.
Green tea constituent (--)-epigallocatechin-3-gallate inhibits topoisomerase I activity in human colon carcinoma cells.
Green tea constituents (-)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I- and topoisomerase II-DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide.
Growth-inhibitory properties of novel anthracyclines in human leukemic cell lines expressing either Pgp-MDR or at-MDR.
H1 histone sub-type distribution and DNA topoisomerase activity in skeletal muscle of tumour-bearing rats.
Harnessing Solute Carrier Transporters for Precision Oncology.
Has-miR-30a regulates autophagic activity in cervical cancer upon hydroxycamptothecin exposure.
HER-2/neu and topoisomerase IIalpha--simultaneous drug targets in cancer.
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
High antineoplastic activity of new heterocyclic compounds in cancer cells with resistance against classical DNA topoisomerase II-targeting drugs.
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.
Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks.
Homocamptothecin, an E-ring-modified camptothecin, exerts more potent antiproliferative activity than other topoisomerase I inhibitors in human colon cancers obtained from surgery and maintained in vitro under histotypical culture conditions.
Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
hsa-miR-9-3p and hsa-miR-9-5p as Post-Transcriptional Modulators of DNA Topoisomerase II? in Human Leukemia K562 Cells with Acquired Resistance to Etoposide.
HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
HU-331 is a catalytic inhibitor of topoisomerase II?.
Human deoxyribonucleic acid topoisomerases: molecular targets of anticancer drugs.
Human DNA topoisomerase I poisoning activity of bis-1-aminomethylnaphtalenes. A correlation with their cytotoxic activity.
Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Human DNA topoisomerase II-alpha expression in laparoscopically treated renal cell carcinoma.
Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
Human DNA topoisomerase-IIalpha expression as a prognostic factor for transitional cell carcinoma of the urinary bladder.
Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Human neural stem cells overexpressing a carboxylesterase inhibit bladder tumor growth.
Human topoisomerase inhibition and DNA/BSA binding of Ru(II)-SCAR complexes as potential anticancer candidates for oral application.
Human xeroderma pigmentosum group A protein interacts with human replication protein A and inhibits DNA replication.
Hydrophilic camptothecin analogs that form extremely stable cleavable complexes with DNA and topoisomerase I.
Hydroxylated 2,4-diphenyl indenopyridine derivatives as a selective non-intercalative topoisomerase II? catalytic inhibitor.
ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors.
Identification and characterization of the sulfate precipitate in GI147211C IV formulation.
Identification of a caspase-2 isoform that behaves as an endogenous inhibitor of the caspase cascade.
Identification of a ligand binding hot spot and structural motifs replicating aspects of tyrosyl-DNA phosphodiesterase I (TDP1) phosphoryl recognition by crystallographic fragment cocktail screening.
Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and cell-based assays.
Identification of a small topoisomerase I-binding peptide that has synergistic antitumor activity with 9-aminocamptothecin.
Identification of cyclohexanone derivatives that act as catalytic inhibitors of topoisomerase I: effects on tamoxifen-resistant MCF-7 cancer cells.
Identification of early gene expression changes in primary cultured neurons treated with topoisomerase I poisons.
Identification of functional nuclear export sequences in human topoisomerase IIalpha and beta.
Identification of gene polymorphisms of human DNA topoisomerase I in the National Cancer Institute panel of human tumour cell lines.
Identification of novel inhibitors for the tyrosyl-DNA-phosphodiesterase 1 (Tdp1) mutant SCAN1 using virtual screening.
Identification of sumoylated targets in proliferating mouse spermatogonia and human testicular seminomas.
Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase I poisons.
Imatinib-induced apoptosis: a possible link to topoisomerase enzyme inhibition.
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas.
Immunohistochemical study of DNA topoisomerase I, p53, and Ki-67 in uterine carcinosarcomas.
Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.
Impact of p53 knockout and topotecan treatment on gene expression profiles in human colon carcinoma cells: a pharmacogenomic study.
Importance of PIKKs in NF-?B activation by genotoxic stress.
In vitro action of flavonoids in the canine malignant histiocytic cell line DH82.
In Vitro and In Vivo Anticancer Activity of Gimatecan against Hepatocellular Carcinoma
In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin.
In vitro cytotoxicity against different human cancer cell lines of laticifer proteins of Calotropis procera (Ait.) R. Br.
In vitro pharmacodynamics of CKD-602 in HT-29 cells.
In vitro sensitivity of fresh ovarian carcinoma specimens to CPT-11 (irinotecan).
In Vitro Synergistic Interaction between DTA0100 and Radiation in Human Cancer Cell Lines.
In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues.
In vivo metabolism of a new anticancer agent, 6-N-formylamino-12, 13-dihydro-1,11-dihydroxy-13-(beta-D-glucopyranosil)5H-indolo [2,3-a]pyrrolo [3,4-c]carbazole-5,7(6H)-dione (NB-506) in rats and dogs: pharmacokinetics, isolation, identification, and quantification of metabolites.
In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1? target genes and decreases tumor angiogenesis.
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Indenocinnoline derivatives as G-quadruplex binders, topoisomerase II? inhibitors and antiproliferative agents.
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
Indolocarbazole poisons of human topoisomerase I: regioisomeric analogues of ED-110.
Induction of apoptosis in 9-nitrocamptothecin-treated DU145 human prostate carcinoma cells correlates with de novo synthesis of CD95 and CD95 ligand and down-regulation of c-FLIP(short).
Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
Induction of tumor necrosis factor by a camptothecin derivative, irinotecan, in mice and human mononuclear cells.
Influence of irinotecan and SN-38 on the irradiation response of WHO3 human oesophageal tumour cells under hypoxic conditions.
Influence of MLH1 on colon cancer sensitivity to poly(ADP-ribose) polymerase inhibitor combined with irinotecan.
Inhibition of acetylcholinesterase by the anticancer prodrug CPT-11.
Inhibition of cis-diamminedichloroplatinum (II)-induced DNA interstrand cross-link removal by 7-ethyl-10-hydroxy-camptothecin in HST-1 human squamous-carcinoma cells.
Inhibition of DNA topoisomerase I activity and induction of apoptosis by thiazacridine derivatives.
Inhibition of DNA topoisomerase I activity by heparan sulfate and modulation by basic fibroblast growth factor.
Inhibition of DNA topoisomerase I and growth inhibition of human cancer cell lines by an oleanane from Junellia aspera (Verbenaceae).
Inhibition of DNA topoisomerases I and II and growth inhibition of HL-60 cells by novel acridine-based compounds.
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Inhibition of human DNA topoisomerase IB by a cyclometalated gold III compound: analysis on the different steps of the enzyme catalytic cycle.
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Inhibition of potentially lethal DNA damage repair in human tumor cells by beta-lapachone, an activator of topoisomerase I.
Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy.
Inhibition of topoisomerase I activity and efflux drug transporters' expression by xanthohumol. from hops.
Inhibition of topoisomerase I shapes antitumor immunity through the induction of monocyte-derived dendritic cells.
Inhibition of Vascular Calcification.
Inhibitory effect of conjugated eicosapentaenoic acid on mammalian DNA polymerase and topoisomerase activities and human cancer cell proliferation.
Inhibitory effects of ?-mangostin on mammalian DNA polymerase, topoisomerase, and human cancer cell proliferation.
Inhibitory effects of cholesterol derivatives on DNA polymerase and topoisomerase activities, and human cancer cell growth.
Inhibitory effects of diacylglyceride phospholipids on DNA polymerase and topoisomerase activities, and human cancer cell growth.
Inhibitory effects of docosyl p-coumarate on DNA topoisomerase activity and human cancer cell growth.
Inhibitory effects of low molecular weight polyphenolics from Inonotus obliquus on human DNA topoisomerase activity and cancer cell proliferation.
Inhibitory effects of myricetin on mammalian DNA polymerase, topoisomerase and human cancer cell proliferation.
Initial testing of topotecan by the pediatric preclinical testing program.
Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5.
Interaction of anticancer drug mitoxantrone with DNA hexamer sequence d-(CTCGAG)2 by absorption, fluorescence and circular dichroism spectroscopy.
Interaction of ionizing radiation with topotecan in two human tumor cell lines.
Internalization of Foldamer-Based DNA Mimics through a Site-Specific Antibody Conjugate to Target HER2-Positive Cancer Cells.
Intrinsic curvature in duplex DNA inhibits Human Topoisomerase I.
Invasive growth and topoisomerase-switch induced by tumorous extracellular matrix in osteosarcoma cell culture.
Investigation of Isoindolo[2,1-a]quinoxaline-6-imines as Topoisomerase I Inhibitors With Molecular Modeling Methods.
Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures.
Investigation of the Structure-Activity Relationships of Aza-A-Ring Indenoisoquinoline Topoisomerase I Poisons.
Involvement of hydrogen peroxide in topoisomerase inhibitor beta-lapachone-induced apoptosis and differentiation in human leukemia cells.
Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
Involvement of transcriptional repressor ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis.
Ionizing radiation damage repair: a role for topoisomerases?
Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells.
Iridoids as DNA topoisomerase I poisons.
Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Irinotecan and radiation in vitro and in vivo.
Irinotecan combined with co-stimulatory molecule blockade prolongs survival of cardiac allografts in alloantigen-primed mice.
Irinotecan hydrochloride: drug profile and nursing implications of a topoisomerase I inhibitor in patients with advanced colorectal cancer.
Irinotecan in combination with radiation therapy for small-cell and non-small-cell lung cancer.
Irinotecan in combined-modality therapy for locally advanced non-small-cell lung cancer.
Irinotecan in the treatment of colorectal cancer: clinical overview.
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
Irinotecan resistance is accompanied by upregulation of EGFR and Src signaling in human cancer models.
Irinotecan-Associated Dysarthria in Patients with Pancreatic Cancer: A Single Site Experience.
Irinotecan-based combinations for the adjuvant treatment of stage III colon cancer.
Irinotecan-induced apoptosis is inhibited by increased P-glycoprotein expression and decreased p53 in human hepatocellular carcinoma cells.
Irinotecan-induced colitis.
Irinotecan-induced mucositis is associated with changes in intestinal mucins.
Irinotecan: 25 years of cancer treatment.
Iron chelators with topoisomerase-inhibitory activity and their anticancer applications.
Is there a role for base excision repair in estrogen/estrogen receptor-driven breast cancers?
Isoeugenol is a selective potentiator of camptothecin cytotoxicity in vertebrate cells lacking TDP1.
Isolated tumor cells in the bone marrow (ITC-BM) of breast cancer patients before and after anthracyclin based therapy: influenced by the HER2- and Topoisomerase IIalpha-status of the primary tumor?
Isolation and biochemical characterization of a new topoisomerase I inhibitor from Ocotea leucoxylon.
It's about time: scheduling alters effect of histone deacetylase inhibitors on camptothecin-treated cells.
Kinetic studies of human tyrosyl-DNA phosphodiesterase, an enzyme in the topoisomerase I DNA repair pathway.
Kosinostatin, a quinocycline antibiotic with antitumor activity from Micromonospora sp. TP-A0468.
Ku70 and Rad51 vary in their importance for the repair of doxorubicin- versus etoposide-induced DNA damage.
Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Lanostanoids from Fungi: A Group of Potential Anticancer Compounds.
Levels of E2F-1 expression are higher in lung metastasis of colon cancer as compared with hepatic metastasis and correlate with levels of thymidylate synthase.
Limited sampling models for simultaneous estimation of the pharmacokinetics of irinotecan and its active metabolite SN-38.
Lipid-complexed camptothecin: formulation and initial biodistribution and antitumor activity studies.
Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
Loss of one allele of the p53 gene in the lens epithelial tumor in transgenic mice suppresses apoptosis induced by a topoisomerase I inhibitor (CPT-11).
Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives.
Markers of drug resistance in relapsing colon cancer.
Mechanism of Generation of Therapy Related Leukemia in Response to Anti-Topoisomerase II Agents.
Mechanisms of cancer prevention by tea constituents.
Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors.
Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs.
Methylation profile of the promoter CpG islands of 14 "drug-resistance" genes in hepatocellular carcinoma.
Methylenedioxy- and Ethylenedioxy-Fused Indolocarbazoles. Potent Human Topoisomerase I Inhibitors and Antitumor Agents.
Metnase/SETMAR: a domesticated primate transposase that enhances DNA repair, replication, and decatenation.
Microvessel Density and Status of p53 Protein as Potential Prognostic Factors for Adjuvant Anthracycline Chemotherapy in Retrospective Analysis of Early Breast Cancer Patients Group.
Microwave synthesis of novel halogenated ?-enaminonitriles linked 9-bromo-1H-benzo[f]chromene moieties: Induces cell cycle arrest and apoptosis in human cancer cells via dual inhibition of topoisomerase I and II.
Mining topoisomerase isoforms in gastric cancer.
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Mitomycin as a modulator of irinotecan anticancer activity.
MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo.
Mode of action of DNA-competitive small molecule inhibitors of tyrosyl DNA phosphodiesterase 2.
Modified 2,4-diaryl-5H-indeno[1,2-b]pyridines with hydroxyl and chlorine moiety: Synthesis, anticancer activity, and structure-activity relationship study.
Modulation of radiation response by inhibiting topoisomerase II catalytic activity.
Modulation of topoisomerase activities by tumor necrosis factor.
Moguntinones--new selective inhibitors for the treatment of human colorectal cancer.
Molecular design, synthesis and docking study of benz[b]oxepines and 12-oxobenzo[c]phenanthridinones as topoisomerase 1 inhibitors.
Molecular Docking based analysis to elucidate the DNA Topoisomerase II? as the potential target for the Ganoderic acid, A natural therapeutic agent in cancer therapy.
Molecular drug design, synthesis and structure elucidation of a new specific target peptide based metallo drug for cancer chemotherapy as topoisomerase I inhibitor.
Molecular, cellular, and clinical aspects of the pharmacology of 20(S)camptothecin and its derivatives.
MRE11 function in response to topoisomerase poisons is independent of its function in double-strand break repair in Saccharomyces cerevisiae.
MTA (LY231514) in combination treatment regimens using human tumor xenografts and the EMT-6 murine mammary carcinoma.
Multifactorial Approach to Predicting Resistance to Anthracyclines.
Multilevel therapeutic targeting by topoisomerase inhibitors.
Multiple functions of human single-stranded-DNA binding protein in simian virus 40 DNA replication: single-strand stabilization and stimulation of DNA polymerases alpha and delta.
Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression.
Mutagenic activity of topoisomerase I inhibitors
Mutational analysis of simian virus 40 T-antigen primosome activities in viral DNA replication.
Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.
Mycoplasma fermentans Inhibits the Activity of Cellular DNA Topoisomerase I by Activation of PARP1 and Alters the Efficacy of Its Anti-Cancer Inhibitor.
Myosin VI is differentially regulated by DNA damage in p53- and cell type-dependent manners.
Namitecan: a hydrophilic camptothecin with a promising preclinical profile.
Nanosponge-encapsulated camptothecin exerts anti-tumor activity in human prostate cancer cells.
Nascent DNA Proteomics Reveals a Chromatin Remodeler Required for Topoisomerase I Loading at Replication Forks.
Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases.
Natural Trienoic Acids as Anticancer Agents: First Stereoselective Synthesis, Cell Cycle Analysis, Induction of Apoptosis, Cell Signaling and Mitochondrial Targeting Studies.
Necroptosis Induced by Ruthenium(II) Complexes as Dual Catalytic Inhibitors of Topoisomerase I/II.
Neoamphimedine circumvents metnase-enhanced DNA topoisomerase II? activity through ATP-competitive inhibition.
Neurotoxic activity of a Topoisomerase-I inhibitor, camptothecin, in cultured cerebellar granule neurons.
New advances in fatty acids as antimalarial, antimycobacterial and antifungal agents.
New advances in lung cancer chemotherapy: topotecan and the role of topoisomerase I inhibitors.
New agents for colon and breast cancer.
New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties.
New camptothecin derivatives for generalized oncological chemotherapy: Synthesis, stereochemistry and biology.
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
New drugs for patients with pancreatic cancer.
New heterobimetallic Cu(II)-Sn(2)(IV) complex as potential topoisomerase I inhibitor: In vitro DNA binding, cleavage and cytotoxicity against human cancer cell lines.
New Insights Into DNA Helicases as Druggable Targets for Cancer Therapy.
New propylamine oligopyrrole carboxamides linked to a heterocyclic or anthraquinone system: synthesis, DNA binding, topoisomerase I inhibition and cytotoxicity.
New pyrazoles incorporating pyrazolylpyrazole moiety: synthesis, anti-HCV and antitumor activity.
New synthetic analogues of natural 5Z,9Z-dienoic acids: Stereoselective synthesis and study of the anticancer activity.
NF-kappaB activation by double-strand breaks.
Nitric Oxide Down-Regulates Topoisomerase I and Induces Camptothecin Resistance in Human Breast MCF-7 Tumor Cells.
Nitric oxide inhibits ATPase activity and induces resistance to topoisomerase II-poisons in human MCF-7 breast tumor cells.
Nitric oxide inhibits topoisomerase II activity and induces resistance to topoisomerase II-poisons in human tumor cells.
No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer.
Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy.
Nonclinical pharmacokinetics and activity of etirinotecan pegol (NKTR-102), a long-acting topoisomerase 1 inhibitor, in multiple cancer models.
Nonhomologous end joining is essential for cellular resistance to the novel antitumor agent, beta-lapachone.
Nonproductive rearrangement of DNA topoisomerase I and II genes: correlation with resistance to topoisomerase inhibitors.
Novel 2-aryl-4-(4'-hydroxyphenyl)-5H-indeno[1,2-b]pyridines as potent DNA non-intercalative topoisomerase catalytic inhibitors.
Novel 4-(4-substituted amidobenzyl)furan-2(5H)-one derivatives as topoisomerase I inhibitors.
Novel 4-quinoline-thiosemicarbazone derivatives: Synthesis, antiproliferative activity, in vitro and in silico biomacromolecule interaction studies and topoisomerase inhibition.
Novel 9-(2-(1-arylethylidene)hydrazinyl)acridine derivatives: Target Topoisomerase 1 and growth inhibition of HeLa cancer cells.
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis.
Novel and Highly Potent ATR Inhibitor M4344 Kills Cancer Cells With Replication Stress, and Enhances the Chemotherapeutic Activity of Widely Used DNA Damaging Agents.
Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11- dihydroxy-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo[3,4- c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity.
Novel autoxidative cleavage reaction of 9-fluoredenes discovered during synthesis of a potential DNA-threading indenoisoquinoline.
Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Novel Hybrid Molecules on the Basis of Steroids and (5Z,9Z)-Tetradeca-5,9-dienoic Acid: Synthesis, Anti-Cancer Studies and Human Topoisomerase I Inhibitory Activity.
Novel indolo-sophoridinic scaffold as Topo I inhibitors: Design, synthesis and biological evaluation as anticancer agents.
Novel insights into the apoptosis mechanism of DNA topoisomerase I inhibitor isoliquiritigenin on HCC tumor cell.
Novel phosphine sulphide gold(i) complexes: topoisomerase I inhibitors and antiproliferative agents.
Novel polypyridyl ruthenium complexes acting as high affinity DNA intercalators, potent transcription inhibitors and antitumor reagents.
Novel securinine derivatives as topoisomerase I based antitumor agents.
Novel treatment strategies for soft tissue sarcoma.
Novel tyrosyl-DNA phosphodiesterase 1 inhibitors enhance the therapeutic impact of topote?an on in vivo tumor models.
NSC606985 induces apoptosis, exerts synergistic effects with cisplatin, and inhibits hypoxia-stabilized HIF-1alpha protein in human ovarian cancer cells.
NSC606985, a novel camptothecin analog, induces apoptosis and growth arrest in prostate tumor cells.
Nuclear export of proteins and drug resistance in cancer.
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
Nucleic acids therapeutics using PolyPurine Reverse Hoogsteen hairpins.
Nucleo-cytoplasmic transport as a therapeutic target of cancer.
O6-benzylguanine-mediated enhancement of chemotherapy.
Octa-substituted anionic porphyrins: topoisomerase I inhibition and tumor cell apoptosis induction.
Oligosaccharide-camptothecin conjugates as potential antineoplastic drugs: Design, synthesis and biological evaluation.
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents.
Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Optimization of the lactam side chain of 7-azaindenoisoquinoline topoisomerase I inhibitors and mechanism of action studies in cancer cells.
Over-expression of TOP2A as a prognostic biomarker in patients with glioma.
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Overview of studies on experimental radioimmunotherapy.
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
p53 stimulates human topoisomerase I activity by modulating its DNA binding.
Palladium(ii) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors.
Paradoxical effects of ethoxidine, a topoisomerase I inhibitor, in the cellular processes leading to angiogenesis on endothelial cells.
PARP inhibitors for cancer therapy.
Partial characterization of human leukemia U-937 cell sublines resistant to 9-nitrocamptothecin.
Pathobiologic characteristics of hereditary breast cancer.
Pathway Engineering of Anthracyclines: Blazing Trails in Natural Product Glycodiversification.
Pediatric phase I trial and pharmacokinetic study of topotecan administered as a 24-hour continuous infusion.
Peptidyl Prolyl Isomerase, Pin1 is a Potential Target for Enhancing the Therapeutic Efficacy of Etoposide.
Personalized Drug Efficacy Monitoring Chip.
PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy.
pH-dependent regulation of camptothecin-induced cytotoxicity and cleavable complex formation by the antimalarial agent chloroquine.
Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
Pharmacogenetics of irinotecan.
Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin.
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan.
Pharmacometabolomics Reveals Irinotecan Mechanism of Action in Cancer Patients.
Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.
Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response.
Phase I and pharmacokinetic study of DE-310 in patients with advanced solid tumors.
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia.
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Phase I and pharmacokinetic study of mitomycin C and celecoxib as potential modulators of tumor resistance to irinotecan in patients with solid malignancies.
Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.
Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.
Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function.
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors.
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.
Phase I and pharmacologic study of sequential topotecan, carboplatin, and etoposide.
Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Phase I and pharmacology study of intoplicine (RP 60475; NSC 645008), novel topoisomerase I and II inhibitor, in cancer patients.
Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies.
Phase I evaluation of sequential topoisomerase targeting with irinotecan/cisplatin followed by etoposide in patients with advanced malignancy.
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Phase I Study of ATR Inhibitor M6620 in Combination With Topotecan in Patients With Advanced Solid Tumors.
Phase I study of capecitabine in combination with cisplatin and irinotecan in patients with advanced solid malignancies.
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
Phase I study of docetaxel and topotecan in patients with solid tumors.
Phase I Study of PARP Inhibitor ABT-888 in Combination with Topotecan in Adults with Refractory Solid Tumors and Lymphomas.
Phase I trial of intoplicine (RP 60475) administered as a 72 h infusion every 3 weeks in patients with solid tumors.
Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker.
Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion.
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies.
Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Phase II study of sequentially administered low-dose mitomycin-C (MMC) and irinotecan (CPT-11) in women with metastatic breast cancer (MBC).
Phase II study of topotecan in patients with recurrent malignant glioma. National Clinical Institute of Canada Clinical Trials Group.
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
Phase II trial of irinotecan (CPT-11) in relapsed or refractory non-Hodgkin's lymphomas.
Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
Phase II trial of topotecan in advanced breast cancer: a Cancer and Leukemia Group B study.
Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer.
Phenoxodiol (2H-1-benzopyran-7-0,1,3-(4-hydroxyphenyl)), a novel isoflavone derivative, inhibits DNA topoisomerase II by stabilizing the cleavable complex.
Phosphate ester derivatives of homocamptothecin: synthesis, solution stabilities and antitumor activities.
Phospholipid Fatty Acid Composition and Diamine Oxidase Activity of Intestinal Mucosa From Rats Treated With Irinotecan Hydrochloride (CPT-11) under Vegetable Oil-Enriched Diets: Comparison Between Perilla Oil and Corn Oil.
Phosphorylation of DNA topoisomerase I is increased during the response of mammalian cells to mitogenic stimuli.
Phosphorylation of human topoisomerase I by protein kinase C in vitro and in phorbol 12-myristate 13-acetate-activated HL-60 promyelocytic leukaemia cells.
Photochemical properties of camptothecin in the presence of copper(II) ions: the role of radicals as prospective species in photodynamic therapy.
Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates.
Poly(D,L-lactic-co-glycolic acid) microspheres for sustained delivery and stabilization of camptothecin.
Potent and sustained inhibition of HIF-1? and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects.
Potent cytotoxic arylnaphthalene lignan lactones from Phyllanthus poilanei.
Potent topoisomerase I inhibition by novel silatecans eliminates glioma proliferation in vitro and in vivo.
Potential use of Pichia pastoris strain SMD1168H expressing DNA topoisomerase I in the screening of potential anti?breast cancer agents.
Potentiation of CD95L-induced apoptosis of human malignant glioma cells by topotecan involves inhibition of RNA synthesis but not changes in CD95 or CD95L protein expression.
Potentiation of radioimmunotherapy by inhibition of topoisomerase I.
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Potentiation of topoisomerase inhibitor-induced DNA strand breakage and cytotoxicity by tumor necrosis factor: enhancement of topoisomerase activity as a mechanism of potentiation.
Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer.
Preclinical Evaluation of Combined Topoisomerase and Proteasome Inhibition Against Pediatric Malignancies.
Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase.
Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance.
Pro-Angiogenic Effects of Low Dose Ethoxidine in a Murine Model of Ischemic Hindlimb: Correlation between Ethoxidine Levels and Increased Activation of the Nitric Oxide Pathway.
Prognostic significance of DNA topoisomerase II-alpha (Ki-S1) immunoexpression in endometrial carcinoma.
Prognostic Significance of p27, Ki-67, and Topoisomerase lla Expression in Clinically Nonfunctioning Pancreatic Endocrine Tumors.
Programmed activation of cancer cell apoptosis: A tumor-targeted phototherapeutic topoisomerase I inhibitor.
Proliferative markers in diagnosis of thyroid tumors: a comparative study of MIB-1 and topoisomerase II-a immunostaining.
Promising new developments in cancer chemotherapy.
Prostaglandins Isolated from the Octocoral Plexaura homomalla: In Silico and In Vitro Studies Against Different Enzymes of Cancer.
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs.
Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
Protein Expression Profiles Indicative for Drug Resistance of Kidney Carcinoma.
Protein kinase C phosphorylates DNA topoisomerase I.
Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines.
Protein-linked DNA strand breaks induced by NSC 314622, a novel noncamptothecin topoisomerase I poison.
Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor.
Proteomic Analysis of Nuclei Isolated from Cancer Cell Lines Treated with Indenoisoquinoline NSC 724998, a Novel Topoisomerase I Inhibitor.
Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma.
Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents.
Pyranicin, a non-classical annonaceous acetogenin, is a potent inhibitor of DNA polymerase, topoisomerase and human cancer cell growth.
Pyrrolo[2,3-?]carbazole derivatives as topoisomerase I inhibitors that affect viability of glioma and endothelial cells in vitro and angiogenesis in vivo.
QSAR and docking studies on xanthone derivatives for anticancer activity targeting DNA topoisomerase II?.
QSAR modeling on benzo[c]phenanthridine analogues as topoisomerase I inhibitors and anti-cancer agents.
Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
Quantitative microscopy of human DNA topoisomerase II-alpha expression in transitional cell carcinoma of the bladder.
Quantitative structure-antitumor activity relationships of camptothecin analogues: cluster analysis and genetic algorithm-based studies.
Quinazolinecarboline alkaloid evodiamine as scaffold for targeting topoisomerase I and sirtuins.
Quinolino[3,4-b]quinoxalines and pyridazino[4,3-c]quinoline derivatives: Synthesis, inhibition of topoisomerase II?, G-quadruplex binding and cytotoxic properties.
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
Radiological and Pathological Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer: A Brief Literature Review.
Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.
Radiosensitization of noradrenaline transporter-expressing tumour cells by proteasome inhibitors and the role of reactive oxygen species.
Radiosynthesis of carbon-11-labeled camptothecin derivatives as potential positron emission tomography tracers for imaging of topoisomerase I in cancers.
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Rational design, synthesis, and evaluation of novel 2,4-Chloro- and Hydroxy-Substituted diphenyl Benzofuro[3,2-b]Pyridines: Non-intercalative catalytic topoisomerase I and II dual inhibitor.
Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies.
Real-time investigation of human topoisomerase I reaction kinetics using an optical sensor: a fast method for drug screening and determination of active enzyme concentrations.
Rearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase II.
Recapitulation of Werner syndrome sensitivity to camptothecin by limited knockdown of the WRN helicase/exonuclease.
Recent Advances in Use of Topoisomerase Inhibitors in Combination Cancer Therapy.
Recent Development in Nano-sized Dosage Forms of Plant Alkaloid Camptothecin-Derived Drugs.
Recent developments in mushrooms as anti-cancer therapeutics: a review.
Recent Developments in Oxazole Derivatives as Anticancer Agents: Review on Synthetic Strategies, Mechanism of Action and SAR studies.
Recent developments in topoisomerase-targeted cancer chemotherapy.
Recent Developments on Thiourea Based Anticancer Chemotherapeutics.
Recifin A, Initial Example of the Tyr-Lock Peptide Structural Family, Is a Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I.
RecQ helicases and topoisomerase III in cancer and aging.
Recurrent Glioblastomas Exhibit Higher Expression of Biomarkers with Stem-like Properties.
Redox responsive 7-ethyl-10-hydroxycamptothecin (SN38) lysophospholipid conjugate: synthesis, assembly and anticancer evaluation.
Regulation of p14ARF through subnuclear compartmentalization.
Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts.
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Relationship of DNA damage signaling to DNA replication following treatment with DNA topoisomerase inhibitors camptothecin/topotecan, mitoxantrone, or etoposide.
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Replication-dependent and transcription-dependent mechanisms of DNA double-strand break induction by the topoisomerase 2-targeting drug etoposide.
Resistance of human leukemic and normal lymphocytes to drug-induced DNA cleavage and low levels of DNA topoisomerase II.
Resistance-associated signatures in breast cancer.
Resveratrol acts as a topoisomerase II poison in human glioma cells.
Resveratrol-3-O-glucuronide and resveratrol-4'-O-glucuronide reduce DNA strand breakage but not apoptosis in Jurkat T cells treated with camptothecin.
Reversal of etoposide resistance in non-P-glycoprotein expressing multidrug resistant tumor cell lines by novobiocin.
Ring fusion strategy for the synthesis of anthra[2,3-d]oxazole-2-thione-5,10-dione homologues as DNA topoisomerase inhibitors and as antitumor agents.
Robustadial A and B from Eucalyptus globulus Labill. and their anticancer activity as selective tyrosyl-DNA phosphodiesterase 2 inhibitors.
Role of an inverted CCAAT element in human topoisomerase IIalpha gene expression in ICRF-187-sensitive and -resistant CEM leukemic cells.
Role of cytokines (TNF-alpha, IL-1beta and KC) in the pathogenesis of CPT-11-induced intestinal mucositis in mice: effect of pentoxifylline and thalidomide.
Role of folylpolygutamate synthetase (FPGS) in antifolate chemotherapy; a biochemical and clinical update.
Role of human topoisomerase IB on ionizing radiation induced damage.
Role of Indole Scaffolds as Pharmacophores in the Development of Anti-Lung Cancer Agents.
Role of nucleotide excision repair proteins in response to DNA damage induced by topoisomerase II inhibitors.
Role of the protein in the DNA sequence specificity of the cleavage site stabilized by the camptothecin topoisomerase IB inhibitor: a metadynamics study.
Role of topoisomerase I and thymidylate synthase expression in sporadic colorectal cancer: associations with clinicopathological and molecular features.
Role of tyrosyl-DNA phosphodiesterase 1 and inter-players in regulation of tumor cell sensitivity to topoisomerase I inhibition.
Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.
Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Ruthenium(II) Diphosphine Complexes with Mercapto Ligands That Inhibit Topoisomerase IB and Suppress Tumor Growth In Vivo.
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Sacituzumab Govitecan: First Approval.
Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Sarcoma chemotherapy.
Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan.
Screening of mammalian DNA polymerase and topoisomerase inhibitors from Garcinia mangostana L. and analysis of human cancer cell proliferation and apoptosis.
Segregation of RNA and separate packaging of DNA and RNA in apoptotic bodies during apoptosis.
Selected novel flavones inhibit the DNA binding or the DNA religation step of eukaryotic topoisomerase I.
Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy.
Selective killing of G2 decatenation checkpoint defective colon cancer cells by catalytic topoisomerase II inhibitor.
Selenite induces topoisomerase I and II-DNA complexes in K562 leukemia cells.
Self-resistance guided genome mining uncovers new topoisomerase inhibitors from myxobacteria.
Semi-quantitative analysis of DNA topoisomerase-I mRNA level using reverse transcription-polymerase chain reaction in cancer cell lines: its relation to cytotoxicity against camptothecin derivative.
Sensitivity and acquired resistance of BRCA1;p53-deficient mouse mammary tumors to the topoisomerase I inhibitor topotecan.
Sensitivity of gastric cancer cells to chemotherapy drugs in elderly patients and its correlation with cyclooxygenase-2 expression.
Sensitivity to topoisomerase I inhibitors and cisplatin is associated with epidermal growth factor receptor expression in human cervical squamous carcinoma ME180 sublines.
Sensitization of Cancer Cells to Radiation and Topoisomerase I Inhibitor Camptothecin Using Inhibitors of PARP and Other Signaling Molecules.
Sequence effect of irinotecan (CPT-11) and topoisomerase II inhibitors in vivo.
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence.
Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells.
Serine phosphorylation-dependent coregulation of topoisomerase I by the p14ARF tumor suppressor.
Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizer.
Silicon-containing analogs of camptothecin as anticancer agents.
Silver Nanoparticles Potentiates Cytotoxicity and Apoptotic Potential of Camptothecin in Human Cervical Cancer Cells.
Simian virus 40 (SV40) DNA replication: SV40 large T antigen unwinds DNA containing the SV40 origin of replication.
SLFN11 Is a Transcriptional Target of EWS-FLI1 and a Determinant of Drug Response in Ewing Sarcoma.
SLFN11: Achilles' Heel or Troublemaker.
SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy.
Special Issue "Anticancer Drugs".
Spindle Assembly Checkpoint Inhibition Can Resensitize p53-Null Stem Cells to Cancer Chemotherapy.
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
STEALTH liposomal CKD-602, a topoisomerase II inhibitor, improves the therapeutic index in human tumor xenograft models.
Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Structural and mechanistic bases of the anticancer activity of natural aporphinoid alkaloids.
Structural modification of 3-arylisoquinolines to isoindolo[2,1-b]isoquinolinones for the development of novel topoisomerase 1 inhibitors with molecular docking study.
Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.
Structural Recognition and Binding Pattern Analysis of Human Topoisomerase II Alpha with Steroidal Drugs: In Silico Study to Switchover the Cancer Treatment.
Structure and function of DNA-binding proteins.
Structure-based discovery of cytotoxic dimeric tetrahydroxanthones as potential topoisomerase I inhibitors from a marine-derived fungus.
Structure-guided optimization of 4,6-substituted-1,3,5-triazin-2(1H)-ones as catalytic inhibitors of human DNA topoisomerase II?.
Studies on the initiation and elongation reactions in the simian virus 40 DNA replication system.
Studies on the initiation of simian virus 40 replication in vitro: RNA primer synthesis and its elongation.
Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype.
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.
Substituted dibenzo[c,h]cinnolines: topoisomerase I-targeting anticancer agents.
Successful local regional therapy with topotecan of intraperitoneally growing human ovarian carcinoma xenografts.
Suppression of Reserve MCM Complexes Chemosensitizes to Gemcitabine and 5-Fluorouracil.
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Suzuki coupling based synthesis and in vitro cytotoxic evaluation of 7-heteroaryl-substituted camptothecin analogs.
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.
Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity.
Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864).
Synergistic cytotoxicity of topoisomerase I inhibitors with alkylating agents and etoposide in human brain tumor cell lines.
Synergistic enhancement of topotecan-induced cell death by ascorbic acid in human breast MCF-7 tumor cells.
Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Synergistic interactions between tumor necrosis factor and inhibitors of DNA topoisomerase I and II.
Synergy between the herpes simplex virus tk/ganciclovir prodrug suicide system and the topoisomerase I inhibitor topotecan.
Syntheses and antiproliferative activities of 7-azarebeccamycin analogues bearing one 7-azaindole moiety.
Syntheses, molecular targets and antitumor activities of novel triptycene bisquinones and 1,4-anthracenedione analogs.
Synthesis and Anticancer Activity Evaluation of Novel Phenanthridine Derivatives.
Synthesis and anticancer activity of simplified indenoisoquinoline topoisomerase I inhibitors lacking substituents on the aromatic rings.
Synthesis and antiproliferative evaluation of certain indeno[1,2-c]quinoline derivatives. Part 2.
Synthesis and antiproliferative evaluation of certain indolo[3,2-c]quinoline derivatives.
Synthesis and antitumor activity of novel 10-substituted camptothecin analogues.
Synthesis and antitumor activity of some indeno[1,2-b]quinoline-based bis carboxamides.
Synthesis and antitumor characterization of pyrazolic analogues of the marine pyrroloquinoline alkaloids: wakayin and tsitsikammamines.
Synthesis and bioevaluation of 22-hydroxyacuminatine analogs.
Synthesis and biological activity of 2,4-di-p-phenolyl-6-2-furanyl-pyridine as a potent topoisomerase II poison.
Synthesis and biological activity of ferrocenyl indeno[1,2-c]isoquinolines as topoisomerase II inhibitors.
Synthesis and biological evaluation of 14-(aminoalkyl-aminomethyl)aromathecins as topoisomerase I inhibitors: investigating the hypothesis of shared structure-activity relationships.
Synthesis and biological evaluation of 2-phenol-4-chlorophenyl-6-aryl pyridines as topoisomerase II inhibitors and cytotoxic agents.
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Synthesis and characterization of Cu(II)-based anticancer chemotherapeutic agent targeting topoisomerase I?: in vitro DNA binding, pBR322 cleavage, molecular docking studies and cytotoxicity against human cancer cell lines.
Synthesis and crystal structure determination of copper(II)-complex: In vitro DNA and HSA binding, pBR322 plasmid cleavage, cell imaging and cytotoxic studies.
SYNTHESIS AND CYTOTOXIC ACTIVITY OF NEW 5H-INDOLO[2,3-B]QUINOLINE O-AMINOGLYCOSIDES.
Synthesis and cytotoxic activity of substituted 7-aryliminomethyl derivatives of camptothecin.
Synthesis and evaluation of ether-linked demethylepipodophyllotoxin dimers.
Synthesis and Evaluation of New Naphthalene and Naphthoquinone Derivatives as Anticancer Agents.
Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Synthesis and mechanism of action studies of a series of norindenoisoquinoline topoisomerase I poisons reveal an inhibitor with a flipped orientation in the ternary DNA-enzyme-inhibitor complex as determined by X-ray crystallographic analysis.
Synthesis and SAR study of new hydroxy and chloro-substituted 2,4-diphenyl 5H-chromeno[4,3-b]pyridines as selective topoisomerase II?-targeting anticancer agents.
Synthesis and structure-activity relationship study of potent cytotoxic analogues of the marine alkaloid Lamellarin D.
Synthesis of 2,4-diaryl chromenopyridines and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Synthesis of 2-(thienyl-2-yl or -3-yl)-4-furyl-6-aryl pyridine derivatives and evaluation of their topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship.
Synthesis of a DNA-targeting nickel (II) complex with testosterone thiosemicarbazone which exhibits selective cytotoxicity towards human prostate cancer cells (LNCaP).
Synthesis of cytotoxic indenoisoquinoline topoisomerase I poisons.
Synthesis of Methoxy-, Methylenedioxy-, Hydroxy-, and Halo-Substituted Benzophenanthridinone Derivatives as DNA Topoisomerase IB (TOP1) and Tyrosyl-DNA Phosphodiesterase 1 (TDP1) Inhibitors and Their Biological Activity for Drug-Resistant Cancer.
Synthesis of new dihydroindeno[1,2-c]isoquinoline and indenoisoquinolinium chloride topoisomerase I inhibitors having high in vivo anticancer activity in the hollow fiber animal model.
Synthesis of new indeno[1,2-c]isoquinolines: cytotoxic non-camptothecin topoisomerase I inhibitors.
Synthesis of novel C5-curcuminoid-fatty acid conjugates and mechanistic investigation of their anticancer activity.
Synthesis of podophyllotoxin congeners as potential DNA topoisomerase II inhibitors.
Synthesis, antitumor activity, and structure-activity relationship study of trihydroxylated 2,4,6-triphenyl pyridines as potent and selective topoisomerase II inhibitors.
Synthesis, cytotoxicity and topoisomerase II inhibitory activity of lomefloxacin derivatives.
Synthesis, cytotoxicity and topoisomerase inhibition properties of multifarious aminoalkylated indeno[1,2-c]isoquinolin-5,11-diones.
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of 2-phenyl- or hydroxylated 2-phenyl-4-aryl-5H-indeno[1,2-b]pyridines.
Synthesis, topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of hydroxylated 2,4-diphenyl-6-aryl pyridines.
Synthesis, topoisomerase I inhibition and antitumor cytotoxicity of 2,2':6',2"-, 2,2':6',3"- and 2,2':6',4"-terpyridine derivatives.
Synthetic Cytotoxicity: Digenic Interactions with TEL1/ATM Mutations Reveal Sensitivity to Low Doses of Camptothecin.
Tacrine-Coumarin Derivatives as Topoisomerase Inhibitors with Antitumor Effects on A549 Human Lung Carcinoma Cancer Cell Lines.
Tailored immunoconjugate therapy depending on a quantity of tumor stroma.
Targeted radiosensitization with DNA topoisomerase I drugs.
Targeting cell cycle by ?-carboline alkaloids in vitro: Novel therapeutic prospects for the treatment of cancer.
Targeting dePARylation selectively suppresses DNA repair-defective and PARP inhibitor-resistant malignancies.
Targeting DNA Topoisomerase I with Non-Camptothecin Poisons.
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Targeting topoisomerase I cleavage to specific sequences of DNA by triple helix-forming oligonucleotide conjugates. A comparison between a rebeccamycin derivative and camptothecin.
Targeting topoisomerase I to inhibit hypoxia inducible factor 1.
Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors.
Targeting Topoisomerase II Activity in NSCLC with 9-Aminoacridine Derivatives.
TBCRC 018: phase II study of iniparib in combination with irinotecan to treat progressive triple negative breast cancer brain metastases.
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Tdp1 processes chromate-induced single-strand DNA breaks that collapse replication forks.
Template supercoiling during ATP-dependent DNA helix tracking: studies with simian virus 40 large tumor antigen.
Terbenzimidazoles: influence of 2"-, 4-, and 5-substituents on cytotoxicity and relative potency as topoisomerase I poisons.
Thapsigargin enhances camptothecin-induced apoptosis in cardiomyocytes.
The accumulation of topotecan in 9L glioma and in brain parenchyma with and without dexamethasone administration.
The anticancer thiosemicarbazones Dp44mT and triapine lack inhibitory effects as catalytic inhibitors or poisons of DNA topoisomerase II?.
The antileukemia activity of natural product HQ17(3) is possibly associated with downregulation of miR-17-92 cluster.
The antitumor and antimetastatic effects of N-trimethyl chitosan-encapsulated camptothecin on ovarian cancer with minimal side effects.
The Association Between HSP90/topoisomerase I Immunophenotype and the Clinical Features of Colorectal Cancers in Respect to KRAS Gene Status.
The association between the p53/topoisomerase I and p53/ topoisomerase IIalpha immunophenotypes and the progression of ovarian carcinomas.
The bioavailability of oral GI147211 (GG211), a new topoisomerase I inhibitor.
The broken genome: genetic and pharmacologic approaches to breaking DNA.
The chemosensitivity profile of retinoblastoma.
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
The collective nuclear migration of p53 and phosphorylated S473 of Akt during ellipticine-mediated apoptosis in human lung epithelial cancer cells.
The combination of A-966492 and Topotecan for effective radiosensitization on glioblastoma spheroids.
The crystal structure of the complex between a disaccharide anthracycline and the DNA hexamer d(CGATCG) reveals two different binding sites involving two DNA duplexes.
The curative efficacy of namitecan (ST1968) in preclinical models of pediatric sarcoma is associated with antiangiogenic effects.
The cyclin-dependent kinase inhibitor flavopiridol potentiates the effects of topoisomerase I poisons by suppressing Rad51 expression in a p53-dependent manner.
The development of camptothecin analogs in childhood cancers.
The dietary flavonoids myricetin and fisetin act as dual inhibitors of DNA topoisomerases I and II in cells.
The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth.
The dual-acting chemotherapeutic agent Alchemix induces cell death independently of ATM and p53.
The effect of quercetin on topotecan cytotoxicity in MCF-7 and MDA-MB 231 human breast cancer cells.
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy.
The effect of whole-body hyperthermia combined with 'metronomic' chemotherapy on rat mammary adenocarcinoma metastases.
The effects of camptothecin on RNA polymerase II transcription: roles of DNA topoisomerase I.
The effects of T-DXd on the expression of HLA class I and chemokines CXCL9/10/11 in HER2-overexpressing gastric cancer cells.
The expression and significance of MRP1, LRP, TOPOII?, and BCL2 in tongue squamous cell carcinoma.
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
The genetic consequences of ablating helicase activity and the Top3 interaction domain of Sgs1.
The glycolytic inhibitor 2-deoxy-D-glucose enhances the efficacy of etoposide in ehrlich ascites tumor-bearing mice.
The Human Tyrosyl-DNA Phosphodiesterase 1 (hTdp1) Inhibitor NSC120686 as an Exploratory Tool to Investigate Plant Tdp1 Genes.
The impact of tumor physiology on camptothecin-based drug development.
The Indenoisoquinoline LMP517: A Novel Antitumor Agent Targeting both TOP1 and TOP2.
The indenoisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives.
The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
The inhibition of acetylcholinesterase by irinotecan and related camptothecins: key structural properties and experimental variables.
The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase.
The interaction between CtIP and BRCA1 is not essential for resection-mediated DNA repair or tumor suppression.
The mitochondrial type IB topoisomerase drives mitochondrial translation and carcinogenesis.
The natural inhibitor of DNA topoisomerase I, camptothecin, modulates HIF-1? activity by changing miR expression patterns in human cancer cells.
The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.
The potential of topoisomerase I inhibitors in the treatment of CNS malignancies: report of a synergistic effect between topotecan and radiation.
The predictive and prognostic significance of pre- and post-treatment topoisomerase II? in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer.
The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase II?.
The relationship between the molecular structure of natural acetogenins and their inhibitory activities which affect DNA polymerase, DNA topoisomerase and human cancer cell growth.
The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
The Role of the MAPK Signaling, Topoisomerase and Dietary Bioactives in Controlling Cancer Incidence.
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
The role of topoisomerase II? in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures.
The significance of the sequence of administration of topotecan and etoposide.
The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA Cleavage.
The superior prognostic value of humoral factors compared with molecular proliferation markers in renal cell carcinoma.
The topoisomerase I inhibitor topotecan increases the sensitivity of prostate tumor cells to TRAIL/Apo-2L-induced apoptosis.
The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor.
The topoisomerase II-inhibitor NC-190 reduces the level of thymidine kinase mRNA in murine tumor cells.
The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro.
The use of olaparib (AZD2281) potentiates SN-38 cytotoxicity in colon cancer cells by indirect inhibition of Rad51-mediated repair of DNA double-strand breaks.
The use of topoisomerase I inhibitors in multiple myeloma.
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl) -5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts.
Therapeutic applications of PARP inhibitors: Anticancer therapy and beyond.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against pediatric and adult central nervous system tumor xenografts.
Therapeutic potential and molecular mechanism of a novel sulfonamide anticancer drug, indisulam (E7070) in combination with CPT-11 for cancer treatment.
Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies.
Therapeutic targets in subependymoma.
Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.
Therapy-related acute myeloid leukemia following HIV-associated lymphoma.
Therapy-related acute promyelocytic leukaemia.
Therapy-related acute promyelocytic leukemia.
Thromboxane A2, released by the anti-tumour drug irinotecan, is a novel stimulator of Cl- secretion in isolated rat colon.
Thymoquinone-chemotherapeutic combinations: new regimen to combat cancer and cancer stem cells.
TIMP-1 Increases Expression and Phosphorylation of Proteins Associated with Drug Resistance in Breast Cancer Cells.
TOP2? Is Essential for Ovarian Follicles That Are Hypersensitive to Chemotherapeutic Drugs.
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
TOP2A Promotes Lung Adenocarcinoma Cells' Malignant Progression and Predicts Poor Prognosis in Lung Adenocarcinoma.
TopBP1 contributes to the chemoresistance in non-small cell lung cancer through upregulation of p53.
TopBP1 promotes malignant progression and correlates with poor prognosis in osteosarcoma.
TOPBP1 regulates RAD51 phosphorylation and chromatin loading and determines PARP inhibitor sensitivity.
Topo II? gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
Topoisomerase 1 inhibition reversibly impairs synaptic function.
Topoisomerase 1 inhibitors and cancer therapy.
Topoisomerase 1B poisons: Over a half-century of drug leads, clinical candidates, and serendipitous discoveries.
Topoisomerase 2? and thymidylate synthase expression in adrenocortical cancer.
Topoisomerase 2alpha plays a pivotal role in the tumor biology of stage IV thymic neoplasia.
Topoisomerase activity associated with polyoma virus large tumor antigen.
Topoisomerase activity associated with SV40 large tumor antigen.
Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.
Topoisomerase enzymes as therapeutic targets for cancer chemotherapy.
Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
Topoisomerase expression in cancer cell lines and clinical samples.
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Topoisomerase I activity in squamous cell carcinoma of the head and neck.
Topoisomerase I amplification in melanoma is associated with more advanced tumours and poor prognosis.
Topoisomerase I and II activity in human breast, cervix, lung and colon cancer.
Topoisomerase I and II inhibitory activity, cytotoxicity, and structure-activity relationship study of dihydroxylated 2,6-diphenyl-4-aryl pyridines.
Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.
Topoisomerase I deregulation in laryngeal squamous cell carcinomas based on tissue microarray analysis.
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Topoisomerase I expression in tumors as a biological marker for CPT-11 chemosensitivity in patients with colorectal cancer.
Topoisomerase I expression is associated with prognosis in postoperative non-small cell lung cancer patients.
Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types.
Topoisomerase I inactivation by reticulol and its in vivo cytotoxicity against B16F10 melanoma.
Topoisomerase I inhibition and cytotoxicity of licochalcones A and E from Glycyrrhiza inflata.
Topoisomerase I inhibition by the camptothecin analog Gl147211C. From the laboratory to the clinic.
Topoisomerase I inhibition in colorectal cancer: biomarkers and therapeutic targets.
Topoisomerase I inhibition with topotecan: pharmacologic and clinical issues.
Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Topoisomerase I inhibitors in the combined modality therapy of lung cancer.
Topoisomerase I inhibitors in the treatment of gastrointestinal cancer: from intravenous to oral administration.
Topoisomerase I Inhibitors in the Treatment of Primary CNS Malignancies: An Update on Recent Trends.
Topoisomerase I inhibitors in the treatment of primary CNS malignancies: an update on recent trends.
Topoisomerase I Inhibitors.
Topoisomerase I interactive drugs in children with cancer.
Topoisomerase I involvement in schedule-dependent interaction between 5-fluoro-uracil and irinotecan in the treatment of colorectal cancer.
Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity.
Topoisomerase I poisoning results in PARP-mediated replication fork reversal.
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy.
Topoisomerase I targeting agents in small-cell lung cancer.
Topoisomerase I, II{alpha} and II{beta} mRNA expression in peripheral blood mononuclear cells of patients with solid tumor: preliminary results.
Topoisomerase I-DNA covalent complexes in human colorectal cancer xenografts with different p53 and microsatellite instability status: relation with their sensitivity to CTP-11.
Topoisomerase I-mediated DNA cleavage as a guide to the development of antitumor agents derived from the marine alkaloid lamellarin D: triester derivatives incorporating amino acid residues.
Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Institute anticancer screen.
Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity.
Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by fluorescence spectroscopy.
Topoisomerase II is required for mitoxantrone to signal nuclear factor kappa B activation in HL60 cells.
Topoisomerase II-alpha (topoII) and HER2 amplification in breast cancers and response to preoperative doxorubicin chemotherapy.
Topoisomerase II-alpha as a predictive factor of response to therapy with anthracyclines in locally advanced breast cancer.
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
Topoisomerase II-mediated DNA damage of episomes in tumor-bearing mice.
Topoisomerase II? immunoreactivity (IR) co-localizes with neuronal marker-IR but not glial fibrillary acidic protein-IR in GLI3-positive medulloblastomas: an immunohistochemical analysis of 124 medulloblastomas from the Japan Children's Cancer Group.
Topoisomerase II? in chromosome instability and personalized cancer therapy.
Topoisomerase II? promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation.
Topoisomerase IIalpha-positive and BRCA1-negative phenotype: association with favorable response to epirubicin-based regimens for human breast cancers.
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Topoisomerase inhibitor coralyne photosensitizes DNA, leading to elicitation of Chk2-dependent S-phase checkpoint and p53-independent apoptosis in cancer cells.
Topoisomerase Inhibitors and Targeted Delivery in Cancer Therapy.
Topoisomerase Inhibitors Conference, University of Maryland Cancer Center. Proceedings. Monterey, California, 27-30 October 1993.
Topoisomerase inhibitors enhance the cytocidal effect of AAV-HSVtk/ganciclovir on head and neck cancer cells.
Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells.
Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Topoisomerase inhibitors. A review of their therapeutic potential in cancer.
Topoisomerase inhibitors: Pharmacology and emerging nanoscale delivery systems.
Topoisomerase levels determine chemotherapy response in vitro and in vivo.
Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
Topoisomerase-I inhibitors in gynaecologic tumours.
Topoisomerase-I inhibitors in gynecologic tumors.
Topoisomerase-I PS506 as a Dual Function Cancer Biomarker.
Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients.
Topoisomerase-targeting antitumor drugs.
Topoisomerases in the treatment of metastatic or recurrent squamous carcinoma of the head and neck.
topors, a p53 and topoisomerase I-binding RING finger protein, is a coactivator of p53 in growth suppression induced by DNA damage.
Topotecan in combination chemotherapy.
Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group phase II study.
Topotecan in the treatment of non-small cell lung cancer.
Topotecan increases topoisomerase IIalpha levels and sensitivity to treatment with etoposide in schedule-dependent process.
Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
Topotecan triggers apoptosis in p53-deficient cells by forcing degradation of XIAP and survivin thereby activating caspase-3 mediated Bid cleavage.
Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study.
Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Topotecan-triggered degradation of topoisomerase I is p53-dependent and impacts cell survival.
Topotecan. A review of its potential in advanced ovarian cancer.
Topotecan: Incorporating It Into the Treatment of Solid Tumors.
Toxicity of the topoisomerase I inhibitors.
Transcription-associated DNA breaks and cancer: A matter of DNA topology.
Transcription-dependent activation of ataxia telangiectasia-mutated prevents DNA-dependent protein kinase-mediated cell death in response to topoisomerase I poison.
Transcription-dependent DNA double-strand breaks and human disease.
Transport of SN-38 by the wild type of human ABC transporter ABCG2 and its inhibition by quercetin, a natural flavonoid.
Trastuzumab Deruxtecan: First Approval.
Treating hematological malignancies with drugs inhibiting ribosome biogenesis: when and why.
Trifluoromethyl-promoted homocamptothecins: Synthesis and biological activity.
Triggering of Suicidal Erythrocyte Death by Topotecan.
Triple helix-forming oligonucleotides conjugated to indolocarbazole poisons direct topoisomerase I-mediated DNA cleavage to a specific site.
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Tumor Physiology and Charge Dynamics of Anticancer Drugs: Implications for Camptothecin-based Drug Development.
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
Tumor- and stromal cell-specific expression of topoisomerase II? and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity.
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent.
Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene.
Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors.
Tyrosyl-DNA phosphodiesterase 1 targeting for modulation of camptothecin-based treatment.
Ubiquitin/26S proteasome-mediated degradation of topoisomerase I as a resistance mechanism to camptothecin in tumor cells.
Ubiquitous Nature of Fluoroquinolones: The Oscillation between Antibacterial and Anticancer Activities.
Unexpected hepatotoxicities in patients with non-Hodgkin's lymphoma treated with irinotecan (CPT-11) and etoposide.
Unique Polyhalogenated Peptides from the Marine Sponge Ircinia sp.
Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
Update on the treatment of cervical and uterine carcinoma: focus on topotecan.
Updates on Receptors Targeted by Heterocyclic Scaffolds: New Horizon in Anticancer Drug Development.
Uptake Transporters of the SLC21, SLC22A, and SLC15A Families in Anticancer Therapy-Modulators of Cellular Entry or Pharmacokinetics?
Variation in topoisomerase I gene copy number as a mechanism for intrinsic drug sensitivity.
VIRTUAL SCREENING FOR THE DEVELOPMENT OF DUAL-INHIBITORS TARGETING TOPOISOMERASE IB AND TYROSYL-DNA PHOSPHODIESTERASE 1.
Vitamin D Enhances the Efficacy of Irinotecan through miR-627-Mediated Inhibition of Intratumoral Drug Metabolism.
Voreloxin is an anticancer quinolone derivative that intercalates DNA and poisons topoisomerase II.
Werner Syndrome Protein Expression in Breast Cancer.
When hypoxia signalling meets the ubiquitin-proteasomal pathway, new targets for cancer therapy.
WRN protects against topo I but not topo II inhibitors by preventing DNA break formation.
Xanthocidin derivatives as topoisomerase II? enzymatic inhibitors.
Y-box binding protein 1 enhances DNA topoisomerase 1 activity and sensitivity to camptothecin via direct interaction.
ZD9331 in combination with topotecan: phase I and II experience.
[Activity of topoisomerase I and endonucleases in cells transfected by a ras oncogene]
[Advance on study in anti-tumor mechamism of bererine (Ber)]
[Combination cancer chemotherapy using a DNA topoisomerase inhibitor CPT-11, as a core agent--the in vitro evaluation]
[DNA topoisomerase inhibitor]
[DNA topoisomerases targeting anticancer agents and mechanism for acquirement of drug resistance]
[Drug resistance mediated by ABC transporters]
[Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo]
[Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823]
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
[Expression and significance of MRP, GST-pi, Topo IIalpha, and LRP in gastric carcinoma]
[Expression of topoisomerase III alpha in epithelial ovarian tumors of different types and relation between the expression of topoisomerase III alpha and the clinical pathology of tumor]
[fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification.
[Immunohistochemical evaluation of topoisomerase IIalpha as proliferation factor in gastric lymphoma]
[Inhibition of mixture of lucid garoderma and lucid garoderma spore on tumor cell in vitro and in vivo]
[Inhibitors of DNA topoisomerases]
[Inhibitory effect of galangin on DNA topoisomerases in lung cancer cells].
[Late sequelae of oncologic treatment in children]
[Mechanisms of acquired resistance to DNA topoisomerase I inhibitors]
[Multidrug resistance]
[New cytotoxics in the treatment of bronchial cancers]
[Pharmacology of camptothecin and its derivatives]
[Preclinical trials from the standpoint of clinical trials]
[Preliminary study of apoptosis of human hepatocarcinoma cell line HepG2 induced by topotecan]
[Preliminary study of lyophilized 10-hydroxycamptothecin in advanced or recurrent malignancies]
[Principles of drug therapy of malignant tumors: determinants of the efficacy of cytostatic agents]
[Recent trend on the development of new anticancer drugs]
[Response of metastatic colorectal cancers to treatment with CPT11 (irinotecan): implications of the mismatched base repair system]
[Synthesis of camptothecin glycosides by phase transfer-catalysis and its inhibitory activity against topo I]
[Taxotere (docetaxel) and CPT 11 (irinotecan): phase I trials]
[The activity of nuclear endonucleases and topoisomerases in the liver of rats and in diethylnitrosamine-induced tumors]
[The synergistic antitumor effects of berberine alpha-hydroxy-beta-decanoylethyl sulfonate with hydroxycamptothecine and its effect on topoisomerase].
[Topotecan for pediatric patients with resistant and recurrent solid tumors]
[Treatment of small-cell lung cancer].
Neoplasms, Germ Cell and Embryonal
A phase II single institution single arm prospective study with paclitaxel, ifosfamide and cisplatin (TIP) as first-line chemotherapy in high-risk germ cell tumor patients with more than ten years follow-up and retrospective correlation with ERCC1, Topoisomerase 1, 2A, p53 and HER-2 expression.
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Neoplasms, Second Primary
Childhood cancer: improved prospects for survival but is prevention possible?
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Neoplasms, Squamous Cell
A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent.
CPT-11 may provide therapeutic efficacy for esophageal squamous cell cancer and the effects correlate with the level of DNA topoisomerase I protein.
The expressions of p21 and pRB may be good indicators for the sensitivity of esophageal squamous cell cancers to CPT-11: Cell proliferation activity correlates with the effect of CPT-11.
Neoplastic Cells, Circulating
Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Nephritis, Hereditary
Topoisomerase I and II consensus sequences in a 17-kb deletion junction of the COL4A5 and COL4A6 genes and immunohistochemical analysis of esophageal leiomyomatosis associated with Alport syndrome.
Nerve Sheath Neoplasms
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Nervous System Diseases
Gold nanoparticles - an optical biosensor for RNA quantification for cancer and neurologic disorders diagnosis.
Transcription-dependent DNA double-strand breaks and human disease.
Nervous System Neoplasms
Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor.
Neuroblastoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
A proteomic investigation into etoposide chemo-resistance of neuroblastoma cell lines.
Antibody-drug conjugate efficacy in neuroblastoma - role of payload, resistance mechanisms, target density, and antibody internalization.
BACPTDP: a water-soluble camptothecin pro-drug with enhanced activity in hypoxic/acidic tumors.
Calcium-regulatory proteins as modulators of chemotherapy in human neuroblastoma.
Chromatin remodelling at the topoisomerase II-beta promoter is associated with enhanced sensitivity to etoposide in human neuroblastoma cell lines.
Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines.
DNA damage promotes herpes simplex virus-1 protein expression in a neuroblastoma cell line.
DNA-topoisomerase I, a new target for the treatment of neuroblastoma.
Dual inhibition of MAGL and type II topoisomerase by N-phenylmaleimides as a potential strategy to reduce neuroblastoma cell growth.
Effects of CPT-11 (a unique DNA topoisomerase I inhibitor) on a highly malignant xeno-transplanted neuroblastoma.
Efficacy of oral irinotecan against neuroblastoma xenografts.
Efficacy of systemic administration of irinotecan against neuroblastoma xenografts.
Experimental treatment of neuroblastoma using [131I]meta-iodobenzylguanidine and topotecan in combination.
Expression profiling identifies epoxy anthraquinone derivative as a DNA topoisomerase inhibitor.
In vivo treatment with CPT-11 leads to differentiation of neuroblastoma xenografts and topoisomerase I alterations.
No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan.
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Suppressive effect of topoisomerase inhibitors on JC polyomavirus propagation in human neuroblastoma cells.
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Topotecan inhibits vascular endothelial growth factor production and angiogenic activity induced by hypoxia in human neuroblastoma by targeting hypoxia-inducible factor-1alpha and -2alpha.
Tumor regression and curability of preclinical neuroblastoma models by PEGylated SN38 (EZN-2208), a novel topoisomerase I inhibitor.
[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
Neurodegenerative Diseases
A human 5'-tyrosyl DNA phosphodiesterase that repairs topoisomerase-mediated DNA damage.
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability.
Excision repair of topoisomerase DNA-protein crosslinks (TOP-DPC).
Neuroectodermal Tumors, Primitive, Peripheral
Therapeutic activity of CPT-11, a DNA-topoisomerase I inhibitor, against peripheral primitive neuroectodermal tumour and neuroblastoma xenografts.
Neurofibroma
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection.
Neurofibrosarcoma
Mechanisms underlying synergy between DNA topoisomerase I-targeted drugs and mTOR kinase inhibitors in NF1-associated malignant peripheral nerve sheath tumors.
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours - A prognostic test after surgical resection.
Neutropenia
Circadian rhythm of irinotecan tolerability in mice.
Complete remission of unresectable hepatocellular carcinoma on healthy liver by the combination of aggressive surgery and high-dose-intensity chemotherapy by CPT-11.
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer.
Population pharmacokinetic-pharmacodynamic modelling and simulation of neutropenia induced by TP300, a novel topoisomerase I inhibitor.
Recent Advances in the Development of Dual Topoisomerase I and II Inhibitors as Anticancer Drugs.
[Topoisomerase I inhibitors. Review of phase II trials with irinotecan (CPT-11) and topotecan]
Nevus
Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Nevus, Pigmented
Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Oligodendroglioma
The prognostic significance of DNA topoisomerase II-alpha (Ki-S1), p21/Cip-1, and p27/Kip-1 protein immunoexpression in oligodendrogliomas.
Oligospermia
Decrease of topoisomerase I activity in the testes of infertile men with varicocele.
Onychomycosis
Evaluation of PCR for the diagnosis of dermatophytes in nail specimens from patients with suspected onychomycosis.
Opportunistic Infections
Topoisomerase inhibitor camptothecin sensitizes mouse hepatocytes in vitro and in vivo to TNF-mediated apoptosis.
Osteosarcoma
Anti-neoplastic effects of topoisomerase inhibitors in canine mammary carcinoma, melanoma, and osteosarcoma cell lines.
Different types of DNA cleavage involved in osteosarcoma cell death.
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Parathyroid hormone regulates the expression of rat osteoblast and osteosarcoma nuclear matrix proteins.
pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.
Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.
Ovarian Neoplasms
A dose-escalating study of weekly bolus topotecan in previously treated ovarian cancer patients.
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
A phase II study of liposomal lurtotecan (OSI-211) in patients with topotecan resistant ovarian cancer.
A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.
Accumulation of anthracenyl-amino acid topoisomerase I and II inhibitors in drug-sensitive and drug-resistant human ovarian cancer cell lines determined by high-performance liquid chromatography.
Altered expression of gamma-glutamylcysteine synthetase, metallothionein and topoisomerase I or II during acquisition of drug resistance to cisplatin in human ovarian cancer cells.
Altered phosphorylation of topoisomerase I following overexpression in an ovarian cancer cell line.
Characterization of therapy-related acute leukemia in hereditary breast-ovarian carcinoma patients: role of BRCA1 mutation and topoisomerase II-directed therapy.
Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
Chemotherapy with irinotecan (CPT-11), a topoisomerase-I inhibitor, for refractory and relapsed non-Hodgkin's lymphoma.
Circumvention of atypical multidrug resistance with tumor necrosis factor.
Clinical applications of the camptothecins.
Clinical pharmacokinetics of topotecan.
Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Cytoprotective activity of amifostine on cultured human lymphocytes exposed to irinotecan.
Daurinol, a catalytic inhibitor of topoisomerase II?, suppresses SNU-840 ovarian cancer cell proliferation through cell cycle arrest in S phase.
Development of anthracenyl-amino acid conjugates as topoisomerase I and II inhibitors that circumvent drug resistance.
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology Group.
DNA topoisomerase I-targeting drugs as radiation sensitizers.
DNA-topoisomerase I activity and content in epithelial ovarian cancer.
Drug conjugation to hyaluronan widens therapeutic indications for ovarian cancer.
EBNA1 may prolong G(2)/M phase and sensitize HER2/neu-overexpressing ovarian cancer cells to both topoisomerase II-targeting and paclitaxel drugs.
Efficacy and Toxicity of Belotecan With and Without Cisplatin in Patients With Recurrent Ovarian Cancer.
Etirinotecan pegol in women with recurrent platinum-resistant or refractory ovarian cancer.
Evolution in medicinal chemistry of E-ring-modified Camptothecin analogs as anticancer agents.
Ex vivo activity of XR5000 against solid tumors.
Glucose-regulated stresses induce resistance to camptothecin in human cancer cells.
Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas.
Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.
Inhibition of Poly(ADP-Ribose) Polymerase Enhances Radiochemosensitivity in Cancers Proficient in DNA Double-Strand Break Repair.
Irinotecan in epithelial ovarian cancer.
Key role of topoisomerase I inhibitors in the treatment of recurrent and refractory epithelial ovarian carcinoma.
New non-cytotoxic approaches to ovarian cancer.
New options for the treatment of advanced ovarian cancer.
Ovarian cancer, from the laboratory to the clinic: challenges for the future.
Overexpression of PTEN increases sensitivity to SN-38, an active metabolite of the topoisomerase I inhibitor irinotecan, in ovarian cancer cells.
Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line.
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
Phase II evaluation of CKD-602, a camptothecin analog, administered on a 5-day schedule to patients with platinum-sensitive or -resistant ovarian cancer.
Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer.
Potentiation of topoisomerase I and II inhibitors cell killing by tumor necrosis factor: relationship to DNA strand breakage formation.
Quantitative and qualitative aspects of topoisomerase I and II alpha and beta in untreated and platinum/cyclophosphamide treated malignant ovarian tumors.
Randomized study of sequential cisplatin-topotecan/carboplatin-paclitaxel versus carboplatin-paclitaxel: effects on quality of life.
Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line.
Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer.
Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
Synergism of AZD6738, an ATR Inhibitor, in Combination with Belotecan, a Camptothecin Analogue, in Chemotherapy-Resistant Ovarian Cancer.
Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer.
The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.
The role of topoisomerase I inhibitor in cisplatin-resistant ovarian cancer.
The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Topoisomerase 1 inhibitors and cancer therapy.
Topoisomerase 1A, HER/2neu and Ki67 expression in paired primary and relapse ovarian cancer tissue samples.
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Topoisomerase-I activity and response to second-line chemotherapy consisting of camptothecin-11 and cisplatin in patients with ovarian cancer.
Topotecan in the treatment of gynecologic cancer.
Transcriptome analysis of stem wood of Nothapodytes nimmoniana (Graham) Mabb. identifies genes associated with biosynthesis of camptothecin, an anti-carcinogenic molecule.
Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors.
Tumor- and stromal cell-specific expression of topoisomerase II? and HER-2/neu in primary and recurrent ovarian cancer: Results of a prospective study.
[DNA topoisomerase I inhibitor in the treatment of ovarian neoplasm]
[Promising new drugs for gynecological cancer]
[Topotecan: prospects for using it in combination therapy for ovarian carcinoma]
[Treatment of recurrent ovarian cancer]
Pancreatic Neoplasms
First-Line Treatment for Advanced Pancreatic Cancer. Highlights from the "2011 ASCO Gastrointestinal Cancers Symposium". San Francisco, CA, USA. January 20-22, 2011.
Gemcitabine plus irinotecan as first-line weekly therapy in locally advanced and/or metastatic pancreatic cancer.
Irinotecan: 25 years of cancer treatment.
Multicohort Retrospective Validation of a Predictive Biomarker for Topoisomerase I Inhibitors.
Phase II data on paclitaxel and docetaxel in gastrointestinal malignancies.
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature.
Real-World Dosing Patterns and Outcomes of Patients With Metastatic Pancreatic Cancer Treated With a Liposomal Irinotecan Regimen in the United States.
Synergistic activity of Hsp90 inhibitors and anticancer agents in pancreatic cancer cell cultures.
The hydroxyquinoline analog YUM70 inhibits GRP78 to induce ER stress-mediated apoptosis in pancreatic cancer.
Translating landmark trial-based evidence to the front lines of care for pancreatic cancer: the evolving trial-based and guideline-supported role for nanoliposomal topoisomerase inhibitors in metastatic pancreatic adenocarcinoma.
Pancreatitis
Altered phospholipid transfer protein gene expression and serum lipid profile by topotecan.
Papilloma
Human topoisomerase II-alpha is highly expressed in sinonasal-inverted papilloma, but not in inflammatory polyp.
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Paralysis
DNA topoisomerase I inhibitors ameliorate seizure-like behaviors and paralysis in a Drosophila model of epilepsy.
Parasitic Diseases
Characterizing the bi-subunit type IB DNA topoisomerase of Leishmania parasites; a novel scenario for drug intervention in trypanosomatids.
Parkinson Disease
Down regulation of DNA topoisomerase II? exerts neurodegeneration like effect through Rho GTPases in cellular model of Parkinson's disease by Down regulating tyrosine hydroxylase.
Peptic Ulcer
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
Peripheral Nerve Injuries
Topoisomerase I inhibition and peripheral nerve injury induce DNA breaks and ATF3-associated axon regeneration in sensory neurons.
Peritoneal Neoplasms
Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis.
Pharyngitis
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Pheochromocytoma
Inhibitory effect of the non-camptothecin topoisomerase I inhibitor LMP-400 on female mice models and human pheochromocytoma cells.
Low Doses of Camptothecin Induced Hormetic and Neuroprotective Effects in PC12 Cells.
Plasma membrane phospholipid asymmetry precedes DNA fragmentation in different apoptotic cell models.
Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Pituitary Neoplasms
The relation of pituitary adenomas invasiveness and the proliferative index measured by immunoexpression of topoisomerase II?.
Topoisomerase II? as a prognostic factor in pituitary tumors.
Plasmacytoma
Eukaryotic DNA topoisomerase I reaction is topology dependent.
Pneumococcal Infections
Antibacterial activity of a DNA topoisomerase I inhibitor versus fluoroquinolones in Streptococcus pneumoniae.
Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.
Seconeolitsine, the Novel Inhibitor of DNA Topoisomerase I, Protects against Invasive Pneumococcal Disease Caused by Fluoroquinolone-Resistant Strains.
Pneumonia
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Polycystic Kidney Diseases
Altered gene expression pattern in cultured human breast cancer cells treated with hepatocyte growth factor/scatter factor in the setting of DNA damage.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Activity of CoII-Quinalizarin: A Novel Analogue of Anthracycline-Based Anticancer Agents Targets Human DNA Topoisomerase, Whereas Quinalizarin Itself Acts via Formation of Semiquinone on Acute Lymphoblastic Leukemia MOLT-4 and HCT 116 Cells.
Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I.
Expression of functional markers in acute lymphoblastic leukemia.
Impact of Topoisomerase II alpha and spermine on the clinical outcome of children with acute lymphoblastic leukemia.
In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells.
Isolation of a mitochondrial DNA topoisomerase from human leukemia cells.
Modification of topoisomerase genes copy number in newly diagnosed childhood acute lymphoblastic leukemia.
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
Prostatic Hyperplasia
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Prostatic Neoplasms
9-Aminocamptothecin: a topoisomerase I inhibitor with preclinical activity in prostate cancer.
A comparative study of protein profiling by proteomic analysis in camptothecin-resistant PC3 and camptothecin-sensitive LNCaP human prostate cancer cells.
A novel 1-((3-(2-toluyl)-4,5-dihydroisoxazol-5-yl)methyl)-4-(trifluoromethyl)pyrimidin-2(1H)-one activates intrinsic mitochondria-dependent pathway and decreases angiogenesis in PC-3 cells.
A novel epoxypropoxy flavonoid derivative and topoisomerase II inhibitor, MHY336, induces apoptosis in prostate cancer cells.
A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Adrenomedullin prevents apoptosis in prostate cancer cells.
beta-lapachone induces cell cycle arrest and apoptosis in human colon cancer cells.
Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response.
Betulinic acid, a catalytic inhibitor of topoisomerase I, inhibits reactive oxygen species-mediated apoptotic topoisomerase I-DNA cleavable complex formation in prostate cancer cells but does not affect the process of cell death.
Calpain-mediated androgen receptor breakdown in apoptotic prostate cancer cells.
Camptothecin disrupts androgen receptor signaling and suppresses prostate cancer cell growth.
Characterization of a novel topoisomerase I mutation from a camptothecin-resistant human prostate cancer cell line.
Chemosensitivity of prostate cancer cell lines and expression of multidrug resistance-related proteins.
Differences between latent and clinical prostate carcinomas: lower cell proliferation activity in latent cases.
DUPA conjugation of a cytotoxic indenoisoquinoline topoisomerase I inhibitor for selective prostate cancer cell targeting.
Dynamic Regulation of Rad51 by E2F1 and p53 in Prostate Cancer Cells upon DrugInduced DNA Damage under Hypoxia.
Ethonafide-induced cytotoxicity is mediated by topoisomerase II inhibition in prostate cancer cells.
Etoposide and topoisomerase II inhibition for aggressive prostate cancer: Data from a translational study.
Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Expression of multidrug resistance related proteins and proliferative activity is increased in advanced clinical prostate cancer.
HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2',5'-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand.
Induction of DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II inhibitor, promotes apoptosis in prostate cancer cells.
Inhibition of prostate cancer growth by 9-aminocamptothecin and estramustine.
Ligand-dependent enhancer activation regulated by topoisomerase-I activity.
NKX3.1 contributes to S phase entry and regulates DNA damage response (DDR) in prostate cancer cell lines.
NKX3.1 homeodomain protein binds to topoisomerase I and enhances its activity.
Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2? expression to TMPRSS2-ERG fusion status in prostate cancer.
Replication-deficient adenovirus induces host topoisomerase I activity: implications for adenovirus-mediated gene expression.
Retinoblastoma tumor suppressor status is a critical determinant of therapeutic response in prostate cancer cells.
Rottlerin potentiates camptothecin-induced cytotoxicity in human hormone refractory prostate cancers through increased formation and stabilization of topoisomerase I-DNA cleavage complexes in a PKC?-independent pathway.
SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex.
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.
Suramin inhibits DNA damage in human prostate cancer cells treated with topoisomerase inhibitors in vitro.
Topoisomerase II-alpha expression increases with increasing Gleason score and with hormone insensitivity in prostate carcinoma.
Topoisomerase II-binding protein 1 promotes the progression of prostate cancer via ATR-CHK1 signaling pathway.
Transcription-independent and -dependent p53-mediated apoptosis in response to genotoxic and non-genotoxic stress.
Protein Deficiency
[Mechanisms of pandrug-resistance of Pseudomonas aeruginosa]
Proteinuria
Reversal of established lupus nephritis and prolonged survival of New Zealand black x New Zealand white mice treated with the topoisomerase I inhibitor irinotecan.
The Topoisomerase I Inhibitor Irinotecan and the Tyrosyl-DNA Phosphodiesterase 1 Inhibitor Furamidine Synergistically Suppress Murine Lupus Nephritis.
Pseudorabies
Stimulation of type I DNA topoisomerase gene expression by pseudorabies virus.
Psoriasis
Experimental studies on topoisomerase inhibitor camptothecin as an antipsoriatic agent.
Synthesis and identification of quinoline derivatives as topoisomerase I inhibitors with potent antipsoriasis activity in an animal model.
Topical treatment of psoriasis with the topoisomerase inhibitors novobiocin and nalidixic acid: a pilot study.
Pulmonary Disease, Chronic Obstructive
Dissociation between airway and systemic autoantibody responses in chronic obstructive pulmonary disease.
Pulmonary Fibrosis
Association of human leukocyte antigen class II genes with autoantibody profiles, but not with disease susceptibility in Japanese patients with systemic sclerosis.
B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.
Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
Leflunomide prevents ROS-induced systemic fibrosis in mice.
Massive pericardial effusion in scleroderma: a review of five cases.
Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model.
Targeting ADAM-17/notch signaling abrogates the development of systemic sclerosis in a murine model.
Rectal Neoplasms
New developments in cancer treatment with the novel thymidylate synthase inhibitor raltitrexed ('Tomudex').
Topoisomerase I expression correlates to response to neoadjuvant irinotecan-based chemoradiation in rectal cancer.
Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases.
Renal Insufficiency, Chronic
Transcriptomic signatures of exacerbated progression in leptospirosis subclinical chronic kidney disease with secondary nephrotoxic injury.
Reoviridae Infections
Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Respiratory Insufficiency
[Interstitial lung disease in patients with connective tissue diseases]
Retinitis Pigmentosa
Mutations in the TOPORS gene cause 1% of autosomal dominant retinitis pigmentosa.
Mutations in TOPORS Cause Autosomal Dominant Retinitis Pigmentosa with Perivascular Retinal Pigment Epithelium Atrophy.
Retinoblastoma
Caspase-dependent activation of calpain during drug-induced apoptosis.
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
Induction of apoptosis in human retinoblastoma cells by topoisomerase inhibitors.
Nodular lesions of monocytic component in myelodysplastic syndrome.
Nuclear export of proteins and drug resistance in cancer.
pRb suppresses camptothecin-induced apoptosis in human osteosarcoma Saos-2 cells by inhibiting c-Jun N-terminal kinase.
Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
Sodium phenylbutyrate induces apoptosis in human retinoblastoma Y79 cells: the effect of combined treatment with the topoisomerase I-inhibitor topotecan.
Synergistic cytotoxic interactions between sodium butyrate, MG132 and camptothecin in human retinoblastoma Y79 cells.
The retinoblastoma tumor suppressor protein is required for efficient processing and repair of trapped topoisomerase II-DNA-cleavable complexes.
Topoisomerase alpha II, retinoblastoma gene product, and p53: potential relationships with aggressive behavior and malignant transformation in recurrent respiratory papillomatosis.
Topotecan hydrochloride effects on retinal vessels in newborn rats.
Rhabdomyosarcoma
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin against xenografts derived from adult and childhood solid tumors.
Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Functional interaction between human topoisomerase IIalpha and retinoblastoma protein.
In vitro assessment of novel transcription inhibitors and topoisomerase poisons in rhabdomyosarcoma cell lines.
Pooled analysis of phase II window studies in children with contemporary high-risk metastatic rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts.
Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
UCHL3 Regulates Topoisomerase-Induced Chromosomal Break Repair by Controlling TDP1 Proteostasis.
Rhabdomyosarcoma, Alveolar
Progress in the diagnosis and treatment of rhabdomyosarcoma and related soft tissue sarcomas.
Rheumatic Diseases
Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain.
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases.
Sarcoidosis
Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.
Sarcoma
CPT-11 Chemotherapy Rescued A Patient with Atypical Sclerosing Epithelioid Fibrosarcoma from Emergent Condition.
Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies.
Exatecan in pretreated adult patients with advanced soft tissue sarcoma: results of a phase II--study of the EORTC Soft Tissue and Bone Sarcoma Group.
Human DNA topoisomerase I: An anticancer drug target present in human sarcomas.
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas.
SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA damaging agents.
STA-8666, a novel HSP90 inhibitor/SN-38 drug conjugate, causes complete tumor regression in preclinical mouse models of pediatric sarcoma.
Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas.
Sarcoma, Avian
DNA topoisomerase activity associated with Rous sarcoma virus.
Virus- and cell-encoded tyrosine protein kinases inactivate DNA topoisomerases in vitro.
Sarcoma, Ewing
A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study.
E1A sensitizes HER2/neu-overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs.
Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study.
Sarcoma, Synovial
Oncoproteins and proliferation markers in synovial sarcomas: a clinicopathologic study of 19 cases.
Scleroderma, Diffuse
A casein kinase type II (CKII)-like nuclear protein kinase associates with, phosphorylates, and activates topoisomerase I.
Antibody specificities of Thai and Australian scleroderma sera with topoisomerase I recombinant fusion proteins.
Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.
IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts.
IgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients.
Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype.
Involvement of lysosomal cathepsins in the cleavage of DNA topoisomerase I during necrotic cell death.
Specificity of anti-Scl-70 antibodies in scleroderma: increased sensitivity of detection using purified DNA topoisomerase I from calf thymus.
The expression and localization of Scl-70/DNA topoisomerase I vary throughout the cell cycle.
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
Scleroderma, Localized
Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma.
Scleroderma, Systemic
A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.
An immunodominant epitope on DNA topoisomerase I is conformational in nature: heterogeneity in its recognition by systemic sclerosis sera.
Analysis of an immunodominant epitope of topoisomerase I in patients with systemic sclerosis.
Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.
Anti-Scl-70 (topo-I) antibodies in SLE: Myth or reality?
Anti-topoisomerase-I and clinical findings in systemic sclerosis (scleroderma).
Are ACA and Scl 70 antibodies mutually exclusive?
Association between centromere and topoisomerase specific immune responses and the degree of microangiopathy in Systemic Sclerosis.
Autoantibodies against topoisomerase I detected with the natural enzyme and overlapping recombinant peptides.
Autoantibodies in the diagnosis of systemic rheumatic diseases.
Autoantigenic epitopes on DNA topoisomerase I. Clinical and immunogenetic associations in systemic sclerosis.
Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis.
B-Cell epitope mapping of DNA topoisomerase I defines epitopes strongly associated with pulmonary fibrosis in systemic sclerosis.
Chromosome studies in systemic sclerosis with consideration of antibodies to topoisomerase I.
Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis.
Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.
Contribution of Soluble Forms of Programmed Death 1 and Programmed Death Ligand 2 to Disease Severity and Progression in Systemic Sclerosis.
Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis.
Detection of anti-topoisomerase I antibodies using a full length human topoisomerase I recombinant protein purified from a baculovirus expression system.
Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis.
Development of systemic sclerosis in a patient with systemic lupus erythematosus and topoisomerase I antibody.
Different distribution of HLA class II alleles in anti-topoisomerase I autoantibody responders between silicosis and systemic sclerosis patients, with a common distinct amino acid sequence in the HLA-DQB1 domain.
Direct binding of anti-DNA topoisomerase I autoantibodies to the cell surface of fibroblasts in patients with systemic sclerosis.
Distinct autoreactive T cell responses to native and fragmented DNA topoisomerase I: influence of APC type and IL-2.
DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients.
Does Sc1-70 modulate collagen production in systemic sclerosis?
Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases.
Heparin inhibits the interaction of DNA topoisomerase I (topo-I)/anti-topo-I immune complexes with heparan sulfate on dermal fibroblasts.
Highly restricted TCR-alpha beta usage by autoreactive human T cell clones specific for DNA topoisomerase I: recognition of an immunodominant epitope.
IgM, IgG, and IgA anti-DNA topoisomerase I antibodies in systemic sclerosis.
Immunization with DNA topoisomerase I and complete Freund's adjuvant induces skin and lung fibrosis and autoimmunity via interleukin-6 signaling.
Immunization with DNA topoisomerase I induces autoimmune responses but not scleroderma-like pathologies in mice.
Implications for the use of topoisomerase I inhibitors in treatment of patients with systemic sclerosis.
Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody.
Interactions of HLA-DR and Topoisomerase I Epitope Modulated Genetic Risk for Systemic Sclerosis.
Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis.
Mapping of the immunodominant T cell epitopes of the protein topoisomerase I.
MHC class II associations with autoantibody and T cell immune responses to the scleroderma autoantigen topoisomerase I.
Molecular recognition patterns of anti-topoisomerase I-antibodies in patients with systemic sclerosis before and after autologous stem cell transplantation.
Molecular recognition patterns of serum anti-DNA topoisomerase I antibody in systemic sclerosis.
Naturally occurring and disease-associated auto-antibodies against topoisomerase I: a fine epitope mapping study in systemic sclerosis and systemic lupus erythematosus.
Progressive appearance of overlap syndrome together with autoantibodies in a patient with fatal thrombotic microangiopathy.
Relationship between natural and infection -induced antibodies in systemic autoimmune diseases (SAD); SLE, SSc and RA.
Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse.
Specificity of antinuclear antibodies in scleroderma-like chronic graft-versus-host disease: clinical correlation and histocompatibility locus antigen association.
T and B cell collaboration is essential for the autoantibody response to DNA topoisomerase I in systemic sclerosis.
T cell lines from systemic sclerosis patients and healthy controls recognize multiple epitopes on DNA topoisomerase I.
T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.
The autoantigen DNA topoisomerase I interacts with chemokine receptor 7 and exerts cytokine-like effects on dermal fibroblasts.
The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).
The inhibitory effects of camptothecin, a topoisomerase I inhibitor, on collagen synthesis in fibroblasts from patients with systemic sclerosis.
The level of anti-topoisomerase I antibodies highly correlates with metacarpophalangeal and proximal interphalangeal joints flexion contractures in patients with systemic sclerosis.
Topoisomerase I peptide-loaded dendritic cells induce autoantibody response as well as skin and lung fibrosis.
[The clinical significance of detecting the inhibition of topoisomerase I by the sera of patients with systemic scleroderma]
Seizures
From bench to drug: human seizure modeling using Drosophila.
Seizure suppression by top1 mutations in Drosophila.
Seminoma
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas.
Sepsis
The AI-discovered aetiology of COVID-19 and rationale of the irinotecan+ etoposide combination therapy for critically ill COVID-19 patients.
Topotecan Alleviates Lipopolysaccharide-Mediated Acute Lung Injury Via the NF-?B Signaling Pathway.
Sjogren's Syndrome
Antitopoisomerase I antibody in patients with systemic lupus erythematosus/sicca syndrome without a concomitant scleroderma: two case reports.
Skin Neoplasms
Coralyne, a protoberberine alkaloid, causes robust photosenstization of cancer cells through ATR-p38 MAPK-BAX and JAK2-STAT1-BAX pathways.
Cryptolepine, a Plant Alkaloid, Inhibits the Growth of Non-Melanoma Skin Cancer Cells through Inhibition of Topoisomerase and Induction of DNA Damage.
Small Cell Lung Carcinoma
A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
A phase I clinical trial of topotecan given every 2 weeks in patients with refractory solid tumors.
A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer.
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
Clinical pharmacokinetics of topotecan.
Combination effects of TAS-103, a novel dual topoisomerase I and II inhibitor, with other anticancer agents on human small cell lung cancer cells.
Combination of HDAC and topoisomerase inhibitors in small cell lung cancer.
Combined MET Inhibition and Topoisomerase I Inhibition Block Cell Growth of Small Cell Lung Cancer.
DNA topoisomerase I is a cofactor for c-Jun in the regulation of epidermal growth factor receptor expression and cancer cell proliferation.
ERCC1 and topoisomerase I expression in small cell lung cancer: Prognostic and predictive implications.
Expressions of Topoisomerase II? and BCRP in Metastatic Cells are Associated with Overall Survival in Small Cell Lung Cancer Patients.
Intracellular uptake study of radiolabeled anticancer drug and impedimetric detection of its interaction with DNA.
Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: a phase II trial of West Japan Thoracic Oncology Group.
Low-dose irinotecan as a second-line chemotherapy for recurrent small cell lung cancer.
Modulation of c-Kit/SCF pathway leads to alterations in topoisomerase-I activity in small cell lung cancer.
Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Phase II study of sequential triplet chemotherapy, irinotecan and cisplatin followed by amrubicin, in patients with extensive-stage small cell lung cancer: West Japan Thoracic Oncology Group Study 0301.
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer.
Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOP?-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide.
Real-Time Positron Emission Tomography Evaluation of Topotecan Brain Kinetics after Ultrasound-Mediated Blood-Brain Barrier Permeability.
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
Synergistic effects of topoisomerase I inhibitor, 7-ethyl-10-hydroxycamptothecin, and irradiation in a cisplatin-resistant human small cell lung cancer cell line.
The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells.
Therapeutic targeting of ATR yields durable regressions in small cell lung cancers with high replication stress.
Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
Topotecan: An evolving option in the treatment of relapsed small cell lung cancer.
Update on the role of topotecan in the treatment of non-small cell lung cancer.
[Cytotoxic effect of topoisomerase II inhibitors against adriamycin- and etoposide-resistant small cell lung cancer sublines]
[Expression and significance of DNA topoisomerase I (topo I) in small cell lung cancer]
Smallpox
Kinetic Study of DNA Topoisomerases by Supercoiling-Dependent Fluorescence Quenching.
Microheterogeneity of Topoisomerase IA/IB and Their DNA-Bound States.
Regulation of catalysis by the smallpox virus topoisomerase.
Structural basis for specificity in the poxvirus topoisomerase.
Unraveling the structure of the variola topoisomerase IB-DNA complex: a possible new twist on smallpox therapy.
Variola type IB DNA topoisomerase: DNA binding and supercoil unwinding using engineered DNA minicircles.
Variola virus topoisomerase: DNA cleavage specificity and distribution of sites in Poxvirus genomes.
Smith-Magenis Syndrome
Gene for topoisomerase III maps within the Smith-Magenis syndrome critical region: analysis of cell-cycle distribution and radiation sensitivity.
Spinocerebellar Ataxias
Mutation of TDP1, encoding a topoisomerase I-dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy.
TDP1 serine 81 promotes interaction with DNA ligase IIIalpha and facilitates cell survival following DNA damage.
Spinocerebellar Degenerations
Hereditary ataxia SCAN1 cells are defective for the repair of transcription-dependent topoisomerase I cleavage complexes.
TDP1 deficiency sensitizes human cells to base damage via distinct topoisomerase I and PARP mechanisms with potential applications for cancer therapy.
Squamous Cell Carcinoma of Head and Neck
Analysis of type of cell death induced by topoisomerase inhibitor SN-38 in human oral squamous cell carcinoma cell lines.
Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts.
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Expression of drug resistance-related genes in head and neck squamous cell carcinomas and normal mucosa.
Expression of human DNA Topoisomerase II-alpha in squamous cell carcinoma of the larynx and its correlation with clinicopathologic variables.
High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma.
Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas.
The influence of hyaluronan-CD44 interaction on topoisomerase II activity and etoposide cytotoxicity in head and neck cancer.
Topoisomerase expression in oral squamous cell carcinoma: relationship with cancer stem cells profiles and lymph node metastasis.
Staphylococcal Infections
New aminocoumarin antibiotics as gyrase inhibitors.
Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
Starvation
Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs.
Topoisomerase mutants and physiological conditions control supercoiling and Z-DNA formation in vivo.
Stomach Neoplasms
(S)-Erypoegin K, an isoflavone isolated from Erythrina poeppigiana, is a novel inhibitor of topoisomerase II?: Induction of G2 phase arrest in human gastric cancer cells.
A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma.
A-62176, a potent topoisomerase inhibitor, inhibits the expression of human epidermal growth factor receptor 2.
Cisplatin and irinotecan in upper gastrointestinal malignancies.
Combating liver cancer through GO-targeted biomaterials.
DS-8201a, a new HER2-targeting antibody-drug conjugate incorporating a novel DNA topoisomerase I inhibitor, overcomes HER2-positive gastric cancer T-DM1 resistance.
Effects of quercetin combined with anticancer drugs on metastasis-associated factors of gastric cancer cells: in vitro and in vivo studies.
Expression and relationship between topoisomerase I and II alpha genes in tumor and normal tissues in esophageal, gastric and colon cancers.
Expression of a molecular marker panel as a prognostic tool in gastric cancer patients treated postoperatively with docetaxel and irinotecan. A study of the Hellenic Cooperative Oncology Group.
Gimatecan exerts potent antitumor activity against gastric cancer in vitro and in vivo via AKT and MAPK signaling pathways.
High glucose promotes gastric cancer chemoresistance in vivo and in vitro.
Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Inhibition of Topoisomerase II? and Induction of Apoptosis in Gastric Cancer Cells by 19-Triisopropyl Andrographolide
MHY440, a Novel Topoisomerase ? Inhibitor, Induces Cell Cycle Arrest and Apoptosis via a ROS-Dependent DNA Damage Signaling Pathway in AGS Human Gastric Cancer Cells.
Mining topoisomerase isoforms in gastric cancer.
Mitochondrial topoisomerase I absence enhances aerobic glycolysis in cancer.
Precursor-Directed Generation of Indolocarbazoles with Topoisomerase II? Inhibitory Activity.
Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes.
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
Tissue microarray analysis of topoisomerase IIalpha protein in gastric adenocarcinomas: histogenetic and prognostic implications.
Topoisomerase I inhibitor (camptothecin)-induced apoptosis in human gastric cancer cells and the role of wild-type p53 in the enhancement of its cytotoxicity.
Topotecan induces apoptosis via ASCT2 mediated oxidative stress in gastric cancer.
Transcriptomic profiling and quantitative high-throughput (qHTS) drug screening of CDH1 deficient hereditary diffuse gastric cancer (HDGC) cells identify treatment leads for familial gastric cancer.
Trastuzumab Deruxtecan: First Approval.
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
[Effects of hydroxycamptothecin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823]
Telangiectasis
Structural and functional interactions of the prostate cancer suppressor protein NKX3.1 with topoisomerase I.
Teratocarcinoma
[Effect of inhibitors of topoisomerases and poly(ADP-ribosylation) on homologous and non-homologous integration of exogenous DNA in genes of mammalian somatic cells]
Teratoma
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Method for selective ablation of undifferentiated human pluripotent stem cell populations for cell-based therapies.
Testicular Neoplasms
A study of topoisomerase activity in human testicular cancers.
DNA topoisomerase I and II expression in drug resistant germ cell tumours.
Thrombocytopenia
Phase I and pharmacological study of the new topoisomerase I inhibitor GI147211, using a daily x 5 intravenous administration.
Thymus Neoplasms
Endogenous topoisomerase II-mediated DNA breaks drive thymic cancer predisposition linked to ATM deficiency.
Thyroid Cancer, Papillary
RET rearrangements in radiation-induced papillary thyroid carcinomas: high prevalence of topoisomerase I sites at breakpoints and microhomology-mediated end joining in ELE1 and RET chimeric genes.
Thyroid Neoplasms
Prognostic Value and Significant Pathway Exploration Associated with TOP2A Involved in Papillary Thyroid Cancer.
Triple Negative Breast Neoplasms
BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.
Enhanced Killing of Triple-Negative Breast Cancer Cells by Reassortant Reovirus and Topoisomerase Inhibitors.
Expression of Topoisomerase II-? in Triple Negative Breast Cancer.
Impact of Topoisomerase II?, PTEN, ABCC1/MRP1, and KI67 on triple-negative breast cancer patients treated with neoadjuvant chemotherapy.
Loss of O?-methylguanine-DNA methyltransferase confers collateral sensitivity to carmustine in topoisomerase II-mediated doxorubicin resistant triple negative breast cancer cells.
New Dibenzoquinoxalines Inhibit Triple-Negative Breast Cancer Growth by Dual Targeting of Topoisomerase 1 and the c-MYC G-Quadruplex.
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy.
Significance of Tumor-Infiltrating Lymphocytes and the Expression of Topoisomerase II? in the Prediction of the Clinical Outcome of Patients with Triple-Negative Breast Cancer after Taxane-Anthracycline-Based Neoadjuvant Chemotherapy.
The selective effect of glycyrrhizin and glycyrrhetinic acid on topoisomerase II? and apoptosis in combination with etoposide on triple negative breast cancer MDA-MB-231 cells.
Triple-negative breast cancer exhibits a favorable response to neoadjuvant chemotherapy independent of the expression of topoisomerase II?.
[Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Trypanosomiasis, African
Newly identified antibacterial compounds are topoisomerase poisons in African trypanosomes.
Tuberculosis
Amsacrine Derivatives Selectively Inhibit Mycobacterial Topoisomerase I (TopA), Impair M. smegmatis Growth and Disturb Chromosome Replication.
Analysis of DNA relaxation and cleavage activities of recombinant Mycobacterium tuberculosis DNA topoisomerase I from a new expression and purification protocol.
Antimicrobial Susceptibility and SOS-Dependent Increase in Mutation Frequency Are Impacted by Escherichia coli Topoisomerase I C-Terminal Point Mutation.
Autoregulation of topoisomerase I expression by supercoiling sensitive transcription.
Bimodal Actions of a Naphthyridone/Aminopiperidine-Based Antibacterial That Targets Gyrase and Topoisomerase IV.
Boldine-Derived Alkaloids Inhibit the Activity of DNA Topoisomerase I and Growth of Mycobacterium tuberculosis.
Characterization of an interplay between a Mycobacterium tuberculosis MazF homolog, Rv1495 and its sole DNA topoisomerase I.
Characterization of DNA topoisomerase I from Mycobacterium tuberculosis: DNA cleavage and religation properties and inhibition of its activity.
Characterization of new, efficient Mycobacterium tuberculosis topoisomerase-I inhibitors and their interaction with human ABC multidrug transporters.
Cloning, expression, purification and characterization of DNA topoisomerase I of Mycobacterium tuberculosis.
Conditional silencing of topoisomerase I gene of Mycobacterium tuberculosis validates its essentiality for cell survival.
Determination of the recognition sequence of Mycobacterium smegmatis topoisomerase I on mycobacterial genomic sequences.
Direct regulation of topoisomerase activity by a nucleoid-associated protein.
Discovery of novel bacterial topoisomerase I inhibitors by use of in silico docking and in vitro assays.
Distinct Mechanism Evolved for Mycobacterial RNA Polymerase and Topoisomerase I Protein-Protein Interaction.
DNA topoisomerase I and DNA gyrase as targets for TB therapy.
DNA topoisomerase I from Mycobacterium smegmatis. An enzyme with distinct features.
First functional characterization of a singly expressed bacterial type II topoisomerase: the enzyme from Mycobacterium tuberculosis.
Galeon: A Biologically Active Molecule with In Silico Metabolite Prediction, In Vitro Metabolic Profiling in Rat Liver Microsomes, and In Silico Binding Mechanisms with CYP450 Isoforms.
Genetic and chemical validation identifies Mycobacterium tuberculosis topoisomerase I as an attractive anti-tubercular target.
Identification of potential Mycobacterium tuberculosis topoisomerase I inhibitors: A study against active, dormant and resistant tuberculosis.
Inhibition of Mycobacterium tuberculosis topoisomerase I by m-AMSA, a eukaryotic type II topoisomerase poison.
Inhibition of Zn(II) binding type IA topoisomerases by organomercury compounds and Hg(II).
Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold.
Investigating mycobacterial topoisomerase I mechanism from the analysis of metal and DNA substrate interactions at the active site.
Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
Mechanism and resistance for antimycobacterial activity of a fluoroquinophenoxazine compound.
Mycobacterium tuberculosis DNA gyrase as a target for drug discovery.
Mycobacterium tuberculosis Gyrase Inhibitors as a New Class of Antitubercular Drugs.
Physical and functional interaction between d-ribokinase and topoisomerase I has opposite effects on their respective activity in Mycobacterium smegmatis and Mycobacterium tuberculosis.
Physical and functional interactions between 3-methyladenine DNA glycosylase and topoisomerase I in mycobacteria.
Replacement of cardiotoxic aminopiperidine linker with piperazine moiety reduces cardiotoxicity? Mycobacterium tuberculosis novel bacterial topoisomerase inhibitors.
Small-Molecule Inhibitors Targeting Topoisomerase I as Novel Antituberculosis Agents.
Targeting Mycobacterium tuberculosis Topoisomerase I by Small-Molecule Inhibitors.
The DNA relaxation activity and covalent complex accumulation of Mycobacterium tuberculosis topoisomerase I can be assayed in Escherichia coli: application for identification of potential FRET-dye labeling sites.
Transcription facilitated genome-wide recruitment of topoisomerase I and DNA gyrase.
Type IA topoisomerase inhibition by clamp closure.
Xer recombinase and genome integrity in Helicobacter pylori, a pathogen without topoisomerase IV.
Tuberculosis, Multidrug-Resistant
Insights from the Structure of Mycobacterium tuberculosis Topoisomerase I with a Novel Protein Fold.
Tumor Lysis Syndrome
Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin.
Tumor Virus Infections
Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus.
Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.
SFV topoisomerase: sequence specificity in a genetically mapped interval.
Shope fibroma virus DNA topoisomerase catalyses holliday junction resolution and hairpin formation in vitro.
Urinary Bladder Neoplasms
DNA topoisomerase II? and RAD21 cohesin complex component are predicted as potential therapeutic targets in bladder cancer.
Genistein sensitizes bladder cancer cells to HCPT treatment in vitro and in vivo via ATM/NF-?B/IKK pathway-induced apoptosis.
Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
[Detecting multi-drug resistance of bladder cancer for the intravesical chemotherapy]
Urinary Tract Infections
The disposition of gemifloxacin, a new fluoroquinolone antibiotic, in rats and dogs.
The frequency of DNA gyrase and topoisomerase IV mutations, and plasmid-mediated quinolone resistance genes among Escherichia coli and Klebsiella pneumoniae isolated from urinary tract infections in Azerbaijan, Iran.
Uterine Cervical Neoplasms
Biological activity and molecular docking studies of some new quinolines as potent anticancer agents.
Chemotherapeutic Drugs Inhibiting Topoisomerase 1 Activity Impede Cytokine-Induced and NF-?B p65-Regulated Gene Expression.
CKD-602, a topoisomerase I inhibitor, induces apoptosis and cell-cycle arrest and inhibits invasion in cervical cancer.
Elevated topoisomerase I activity in cervical cancer as a target for chemoradiation therapy.
Factors affecting topotecan-induced programmed cell death: adhesion protects cells from apoptosis and impairs cleavage of poly(ADP-ribose)polymerase.
Irinotecan for the treatment of cervical cancer.
Irinotecan in cervical cancer.
Latex of Euphorbia antiquorum-induced S-phase arrest via active ATM kinase and MAPK pathways in human cervical cancer HeLa cells.
Panobinostat induces apoptosis via production of reactive oxygen species and synergizes with topoisomerase inhibitors in cervical cancer cells.
Predicting high-risk human papillomavirus infection, progression of cervical intraepithelial neoplasia, and prognosis of cervical cancer with a panel of 13 biomarkers tested in multivariate modeling.
Synergistic anticancer effect of panobinostat and topoisomerase inhibitors through ROS generation and intrinsic apoptotic pathway induction in cervical cancer cells.
Synthesis and biological evaluation of N-(carbobenzyloxy)-l-phenylalanine and N-(carbobenzyloxy)-l-aspartic acid-?-benzyl ester derivatives as potent topoisomerase II? inhibitors.
The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme.
Topoisomerase I deficiency results in chromosomal alterations in cervical cancer cells.
[Promising new drugs for gynecological cancer]
Uveitis
Lymphocyte proliferation induced by high-affinity peptides for HLA-B*51:01 in Behçet's uveitis.
Vaccinia
19F NMR studies of vaccinia type IB topoisomerase. Conformational dynamics of the bound DNA substrate.
3'-modified oligonucleotides by reverse DNA synthesis.
5'OH DNA breaks in apoptosis and their labeling by topoisomerase-based approach.
A catalytic domain of eukaryotic DNA topoisomerase I.
A DNA nicking-closing enzyme encapsidated in vaccinia virus: partial purification and properties.
A functional type I topoisomerase from Pseudomonas aeruginosa.
A poxvirus-like type IB topoisomerase family in bacteria.
A universal cloning vector using vaccinia topoisomerase I.
An Alternative Method to Facilitate cDNA Cloning for Expression Studies in Mammalian Cells by Introducing Positive Blue White Selection in Vaccinia Topoisomerase I-Mediated Recombination.
An engineered mutant of vaccinia virus DNA topoisomerase I is sensitive to the anti-cancer drug camptothecin.
Analogues of vaccinia virus DNA topoisomerase I modified at the active site tyrosine.
Application of DNA topoisomerase-activated adapters to riboprobe synthesis.
Atomic force microscopy shows that vaccinia topoisomerase IB generates filaments on DNA in a cooperative fashion.
ATP independent type IB topoisomerase of Leishmania donovani is stimulated by ATP: an insight into the functional mechanism.
Benzo[a]pyrene-dG adduct interference illuminates the interface of vaccinia topoisomerase with the DNA minor groove.
Benzo[c]phenanthrene adducts and nogalamycin inhibit DNA transesterification by vaccinia topoisomerase.
Biochemical analysis of mutant alleles of the vaccinia virus topoisomerase I carrying targeted substitutions in a highly conserved domain.
Catalytic phosphoryl interactions of topoisomerase IB.
Characterization of a DNA topoisomerase encoded by Amsacta moore entomopoxvirus.
Characterization of DNA Binding by the Isolated N-Terminal Domain of Vaccinia Virus DNA Topoisomerase IB.
Characterization of vaccinia virus DNA topoisomerase I expressed in Escherichia coli.
Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry.
Chemical mutagenesis of vaccinia DNA topoisomerase lysine 167 provides insights to the catalysis of DNA transesterification.
Conditional growth of Escherichia coli caused by expression of vaccinia virus DNA topoisomerase I.
Conservation of structure and mechanism between eukaryotic topoisomerase I and site-specific recombinases.
Covalent and noncovalent DNA binding by mutants of vaccinia DNA topoisomerase I.
Covalent DNA binding by vaccinia topoisomerase results in unpairing of the thymine base 5' of the scissile bond.
Crystal Structure of a Bacterial Type IB DNA Topoisomerase Reveals a Preassembled Active Site in the Absence of DNA.
Crystal structure of the amino-terminal fragment of vaccinia virus DNA topoisomerase I at 1.6 A resolution.
Deletions at the carboxyl terminus of vaccinia DNA topoisomerase affect DNA binding and enhance distributivity in DNA relaxation.
Diverse Energetic Effects of Charge Reversal Mutations of Poxvirus Topoisomerase IB.
DNA strand transfer catalyzed by vaccinia topoisomerase: ligation of DNAs containing a 3' mononucleotide overhang.
DNA strand transfer catalyzed by vaccinia topoisomerase: peroxidolysis and hydroxylaminolysis of the covalent protein-DNA intermediate.
DNA strand transfer reactions catalyzed by vaccinia topoisomerase I.
DNA strand transfer reactions catalyzed by vaccinia topoisomerase: hydrolysis and glycerololysis of the covalent protein-DNA intermediate.
Effect of 2'-5' phosphodiesters on DNA transesterification by vaccinia topoisomerase.
Effects of ATP and inhibitory factors on the activity of vaccinia virus type I topoisomerase.
Exploring DNA topoisomerases as targets of novel therapeutic agents in the treatment of infectious diseases.
Expression and Purification of Vaccinia Virus DNA Topoisomerase IB Produced in the Silkworm-Baculovirus Expression System.
Fluorescence spectroscopy studies of vaccinia type IB DNA topoisomerase. Closing of the enzyme clamp is faster than DNA cleavage.
Fluoroquinolone-dependent DNA supercoiling by Vaccinia topoisomerase I.
Generation of linear expression constructs by one-step PCR with vaccinia DNA topoisomerase I.
Genome-scale cloning and expression of individual open reading frames using topoisomerase I-mediated ligation.
High-throughput backbone resonance assignment of small 13C,15N-labeled proteins by a triple-resonance experiment with four sequential connectivity pathways using chemical shift-dependent, apparent 1J(1H,13C): HNCACBcodedHAHB.
Histidine 265 is important for covalent catalysis by vaccinia topoisomerase and is conserved in all eukaryotic type I enzymes.
Identification and DNA sequence of the Shope fibroma virus DNA topoisomerase gene.
Identification of a vaccinia virus gene encoding a type I DNA topoisomerase.
Identification of contacts between topoisomerase I and its target DNA by site-specific photocrosslinking.
In vitro assembly of semi-artificial molecular machine and its use for detection of DNA damage.
Individual nucleotide bases, not base pairs, are critical for triggering site-specific DNA cleavage by vaccinia topoisomerase.
Insertional mutagenesis of the vaccinia virus gene encoding a type I DNA topoisomerase: evidence that the gene is essential for virus growth.
Intercalating polycyclic aromatic hydrocarbon-DNA adducts poison DNA religation by Vaccinia topoisomerase and act as roadblocks to digestion by exonuclease III.
Intramolecular synapsis of duplex DNA by vaccinia topoisomerase.
Kinetic analysis of DNA and RNA strand transfer reactions catalyzed by vaccinia topoisomerase.
Major groove interactions of vaccinia Topo I provide specificity by optimally positioning the covalent phosphotyrosine linkage.
Mapping the active-site tyrosine of vaccinia virus DNA topoisomerase I.
Mechanism and specificity of DNA strand exchange catalyzed by vaccinia DNA topoisomerase type I.
Mechanism of DNA transesterification by vaccinia topoisomerase: catalytic contributions of essential residues Arg-130, Gly-132, Tyr-136 and Lys-167.
Mechanism of inhibition of vaccinia DNA topoisomerase by novobiocin and coumermycin.
Mechanisms for the processing of a frozen topoisomerase-DNA conjugate by human cell-free extracts.
Melanoplus sanguinipes entomopoxvirus DNA topoisomerase: site-specific DNA transesterification and effects of 5'-bridging phosphorothiolates.
Molluscum contagiosum virus topoisomerase: purification, activities, and response to inhibitors.
Mutational analysis of 26 residues of vaccinia DNA topoisomerase identifies Ser-204 as important for DNA binding and cleavage.
Mutational analysis of 39 residues of vaccinia DNA topoisomerase identifies Lys-220, Arg-223, and Asn-228 as important for covalent catalysis.
Mutational analysis of vaccinia DNA topoisomerase defines amino acid residues essential for covalent catalysis.
Mutational analysis of vaccinia virus topoisomerase identifies residues involved in DNA binding.
Mutations of vaccinia virus DNA topoisomerase I that stabilize the cleavage complex.
Mutations within a conserved region of vaccinia topoisomerase affect the DNA cleavage-religation equilibrium.
Nanoblinker: Brownian motion powered bio-nanomachine for FRET detection of phagocytic phase of apoptosis.
New peptide inhibitors of type IB topoisomerases: similarities and differences vis-a-vis inhibitors of tyrosine recombinases.
Nonpolar nucleobase analogs illuminate requirements for site-specific DNA cleavage by vaccinia topoisomerase.
Novel and specific inhibitors of a poxvirus type I topoisomerase.
Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase.
On the simultaneous binding of eukaryotic DNA topoisomerase II to a pair of double-stranded DNA helices.
Oscillating probe for dual detection of 5'PO4 and 5'OH DNA breaks in tissue sections.
p-Thiophenylalanine-induced DNA cleavage and religation activity of a modified vaccinia topoisomerase IB.
Peptide inhibitors of DNA cleavage by tyrosine recombinases and topoisomerases.
Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.
Phenotypic selection and characterization of mutant alleles of a eukaryotic DNA topoisomerase I.
Polynucleotide ligase activity of eukaryotic topoisomerase I.
Poxvirus DNA topoisomerase knockout mutant exhibits decreased infectivity associated with reduced early transcription.
Protein footprinting by the combined use of reversible and irreversible lysine modifications.
Proteolytic footprinting of vaccinia topoisomerase bound to DNA.
Proton relay mechanism of general acid catalysis by DNA topoisomerase IB.
Reactions of Cre with methylphosphonate DNA: similarities and contrasts with Flp and vaccinia topoisomerase.
Recombination mediated by vaccinia virus DNA topoisomerase I in Escherichia coli is sequence specific.
Recombinogenic flap ligation mediated by human topoisomerase I.
Recombinogenic flap ligation pathway for intrinsic repair of topoisomerase IB-induced double-strand breaks.
Remote phosphate contacts trigger assembly of the active site of DNA topoisomerase IB.
Replacement of the active site tyrosine of vaccinia DNA topoisomerase by glutamate, cysteine or histidine converts the enzyme into a site-specific endonuclease.
Requirements for noncovalent binding of vaccinia topoisomerase I to duplex DNA.
Resolution of a Holliday junction by vaccinia topoisomerase requires a spacer DNA segment 3' of the CCCTT/ cleavage sites.
Resolution of Holliday junctions by eukaryotic DNA topoisomerase I.
Resolution of undistorted symmetric immobile DNA junctions by vaccinia topoisomerase I.
Ribonuclease activity of vaccinia DNA topoisomerase IB: kinetic and high-throughput inhibition studies using a robust continuous fluorescence assay.
Selective transport of cationized fluorescent topoisomerase into nuclei of live cells for DNA damage studies.
Self-cleaving purification tags re-engineered for rapid Topo® cloning.
SFV topoisomerase: sequence specificity in a genetically mapped interval.
Site-specific DNA cleavage by vaccinia virus DNA topoisomerase I. Role of nucleotide sequence and DNA secondary structure.
Site-specific DNA transesterification by vaccinia topoisomerase: effects of benzo[alpha]pyrene-dA, 8-oxoguanine, 8-oxoadenine and 2-aminopurine modifications.
Site-specific DNA transesterification by vaccinia topoisomerase: role of specific phosphates and nucleosides.
Site-specific interaction of vaccinia virus topoisomerase I with base and sugar moieties in duplex DNA.
Site-specific interaction of vaccinia virus topoisomerase I with duplex DNA. Minimal DNA substrate for strand cleavage in vitro.
Site-specific ribonuclease activity of eukaryotic DNA topoisomerase I.
Specific DNA cleavage and binding by vaccinia virus DNA topoisomerase I.
Stereochemical outcome and kinetic effects of Rp- and Sp-phosphorothioate substitutions at the cleavage site of vaccinia type I DNA topoisomerase.
Stimulation of vaccinia topoisomerase I by nucleoside triphosphates.
Structural insights into the function of type IB topoisomerases.
The domain organization of human topoisomerase I.
The role of lysine 532 in the catalytic mechanism of human topoisomerase I.
Two classes of DNA end-joining reactions catalyzed by vaccinia topoisomerase I.
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
Unmasking Anticooperative DNA-binding interactions of vaccinia DNA topoisomerase I.
Vaccinia DNA topoisomerase I promotes illegitimate recombination in Escherichia coli.
Vaccinia DNA topoisomerase I: evidence supporting a free rotation mechanism for DNA supercoil relaxation.
Vaccinia DNA topoisomerase I: kinetic evidence for general acid-base catalysis and a conformational step.
Vaccinia DNA topoisomerase I: single-turnover and steady-state kinetic analysis of the DNA strand cleavage and ligation reactions.
Vaccinia topoisomerase and Cre recombinase catalyze direct ligation of activated DNA substrates containing a 3'-para-nitrophenyl phosphate ester.
Vaccinia topoisomerase binds circumferentially to DNA.
Vaccinia topoisomerase mutants illuminate conformational changes during closure of the protein clamp and assembly of a functional active site.
Vaccinia topoisomerase mutants illuminate roles for Phe59, Gly73, Gln69 and Phe215.
Vaccinia virus DNA topoisomerase I preferentially removes positive supercoils from DNA.
Vaccinia virus DNA topoisomerase: a model eukaryotic type IB enzyme.
Vaccinia virus encapsidates a novel topoisomerase with the properties of a eucaryotic type I enzyme.
Varicocele
Decrease of topoisomerase I activity in the testes of infertile men with varicocele.
Virus Diseases
Biochemical analysis of mutant alleles of the vaccinia virus topoisomerase I carrying targeted substitutions in a highly conserved domain.
Prognostic markers of low-grade squamous intraepithelial lesions: the role of topoisomerase IIalpha and active caspase-3.
Stimulation of type I DNA topoisomerase gene expression by pseudorabies virus.
Topological DNA damage, telomere attrition and T cell senescence during chronic viral infections.
Type I topoisomerase activity after infection of enucleated, synchronized mouse L cells by vaccinia virus.
Vitreoretinopathy, Proliferative
The topoisomerase I inhibitors, camptothecin and beta-lapachone, induce apoptosis of human retinal pigment epithelial cells.
Waldenstrom Macroglobulinemia
XK469, a topo IIbeta inhibitor, induces apoptosis in Waldenstrom's macroglobulinemia through multiple pathways.
Werner Syndrome
A deletion within the murine Werner syndrome helicase induces sensitivity to inhibitors of topoisomerase and loss of cellular proliferative capacity.
DNA damage modulates nucleolar interaction of the Werner protein with the AAA ATPase p97/VCP.
Mammalian DNA topoisomerase IIIalpha is essential in early embryogenesis.
Overexpression of a truncated human topoisomerase III partially corrects multiple aspects of the ataxia-telangiectasia phenotype.
The Werner syndrome gene product co-purifies with the DNA replication complex and interacts with PCNA and topoisomerase I.
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
Topoisomerase III is essential for accurate nuclear division in Schizosaccharomyces pombe.
WRN helicase defective in the premature aging disorder Werner syndrome genetically interacts with topoisomerase 3 and restores the top3 slow growth phenotype of sgs1 top3.
Whooping Cough
Inhibition of endothelin-mediated topoisomerase I activation by pertussis toxin.
Stimulation of intracellular topoisomerase I activity by vasopressin and thrombin. Differential regulation by pertussis toxin.
Wilms Tumor
Expression of resistance-related proteins in nephroblastoma after chemotherapy.
Xeroderma Pigmentosum
Enhanced sensitivity to camptothecin in ataxia-telangiectasia cells and its relationship with the expression of DNA topoisomerase I.
Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan.
Ultraviolet-induced DNA damage stimulates topoisomerase I-DNA complex formation in vivo: possible relationship with DNA repair.
Yellow Fever
Topoisomerase III-? is required for efficient replication of positive-sense RNA viruses.
Topoisomerase III-ß is required for efficient replication of positive-sense RNA viruses.